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Abstract 
Pax3 is a gene that encodes for a transcription factor involved in embryogenesis. Pax3 
heterozygote mutants in mice (Splotch) and humans (Waardenburg Syndrome) exhibit 
pigmentary disturbances. AIso, neural tube defects (spina bifida) develop in homozygous 
splotch mice. Pax3 has 2 DNA binding domains, a paired Domain (PD), and a paired-type 
homeodomain (HD). We have used site-specific modification of single Cys Pax3 mutants (in 
a Cys-Iess backbone) to probe structure: function relationships. N-Ethyl maleimide (NEM) 
modification of a single Cys in the PD (C82) abrogates DNA binding by the PD but al~o by 
the HD. Likewise, NEM modification of V263C in the HD abrogates DNA binding by both 
the HD and the PD. These results demonstrate that the PD and HD do not function as 
independent ONA binding modules in Pax3, but are functionally interdependent. Pax3 was 
also modified by insertion of Factor Xa protease sites in either the PD (XalOO) or the HD 
(Xa216). The effect of ONA binding by the PD and HD on conformational changes in the 
other domain was monitored by accessibility of the Factor Xa site. Binding by the PD causes 
a structural change not only in the PD but also in the HD; similarly, DNA binding by the HD 
causes a conformational change in the PD. These results provide a structural basis for the 
funetional interdependenee of the PD and HD in Pax3. Site-specific modification of single 
Cys mutants was further used to identify a cluster of solvent exposed residues in the ~-hairpin 
structure and in the first 2 helices ofthe PD, which when modified (with NEM) impair DNA 
binding by the HO. Three-dimensional modeling shows that the se residues form a 
hydrophobie poeket possibly defining the site of interaction of the HD. Pax3 double eysteine 
mutants were also generated and used with bifunctional cysteine specific reagents to monitor 
proximity relationships in Pax3. We have observed that cysteines placed in the N-terminal 
portion ofthe HO can be crosslinked with cysteines placed in the putative HD interaction 
pocket in the PD, suggesting proximity of the two segments. Taken together, these results 
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suggest that residues in or close to the PD helix 2 and those in or close to the N-terminal arm 
of the RD undergo direct physical interaction, which we postulate is responsible of the 
functional interdependence we observe between the PD and RD ofPax3. 
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Résumé 
Pax3 est un facteur transcriptionel impliqué dans le développement embryonnaire. De 
manière hétérozygote, la mutation de Pax3 provoque une désorganisation pigmentaire et est 
reliée à l'appellation "Splotch" chez la souris et "Syndrôme de Waardenburg" chez l'humain. 
Dans sa forme homozygote, la mutation de Pax3 cause des anomalies du tube neural (Spina 
bifida) chez la souris. Pax3 possède deux domaines de liaisons à l'ADN: un domaine paired 
(PD) et un homéodomaine (RD). Nous avons utilisé une technique de modification chimique 
ciblant l'unique cysteine d'une série de formes mutantes de Pax3 construites à partir d'un Pax3 
modifié, à l'intérieur duquel tous les résidues de cysteine indigènes avaient préalablement été 
remplacées. Permettant l'analyse de sites spécifiques, cette technique fut utilisée afin d'étudier 
la relation entre la structure et le fonctionnement du facteur Pax3. La modification au N-Ethyl 
Maleimide (NEM) d'une cysteine unique à l'intérieur du PD (C82) provoque l'inhibition de 
l'affinité à lier l'ADN par le PD aussi bien que par le RD. De manière similaire, la 
modification au NEM de V263C à l'intérieur du HD se transcrit aussi par la perte de l'habilité 
à lier l'ADN par le HD aussi bien que par le PD. Ces résultats nous démontrent que le PD et le 
HO ne fonctionnent pas simplement de façon indépendante, mais bien par interdépendance 
pour permettre à Pax3 de se lier à l'ADN (Apuzzo et al., 2002). Pax3 fut aussi modifié par 
l'insertion de sites de facteur de protéase Xa en son PD (XaIOO) ou en son RD (Xa216). Les 
effets de la liaison à l'ADN par le PD et par le HO sur les changements de conformation dans 
l'un et l'autre domaine furent examiné par accessibilité au site du facteur Xa. La liaison du PD 
produit un changement structurel non seulement dans le PD, mais aussi dans le RD, et la 
liaison du HD produit également un effet similaire dans le PD ainsi que dans le HD. Ces 
résultats amènent une explication moléculaire à l'interdépendance fonctionnelle entre le PD et 
le HO à l'intérieur de Pax3 (Apuzzo et al., 2004). La modification de mutants à cysteine 
unique positionnée à des sites spécifiques fut utilisée de nouveau pour identifier un cluster de 
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résidus exposés au solvant dans la structure de l'épingle à cheveux beta et dans les deux 
premières hélices du domain PD. La modification au NEM de ces résidus correspond à une 
perte de la capacité à lier l'ADN par le RD et la modélisation 3-D de ces mêmes résidus du 
PD les démontre comme faisant partie d'une portion hydrophobe du site d'interaction avec le 
RD (Apuzzo et al., 2006). Enfin, des résidus de cysteines furent insérées aux mêmes sites que 
pour les mutants de Pax3 à cysteine unique, et ce, en differentes combinaisons de deux' 
cysteines par mutants (mutants double-Cys), afin d'y combiner des reactifs bifonctionnels 
specifiques aux cysteines pour y détailler les différentes relations de proximité à l'intérieur de 
Pax3 par pontage. Nous avons observé que des cysteines placées dans la portion amino-
terminale du RD pouvaient être pontées à des cysteines placées dans une portion du PD 
putative comme site d'interaction avec le RD, ce qui suggère une proximité entre ces deux 
segments (Apuzzo et al., 2006). En conclusion, ces résultats semblent démontrer que des 
résidus près de ou à l'intérieur même de la seconde hélice du PD ainsi que certains résidus 
près de ou à l'intérieur même du segment amino-terminal du RD sont impliqués dans une 
intéraction physique directe, ce que nous proposons être responsable de l'interdépendance 
fonctionnelle observée entre le PD et le RD du facteur Pax3. 
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Objectives of the presented work 
Pax3 is a member ofa family of transcription factors aIl ofwhich are aIl involved in 
development (Dahl et al., 1997). Members of the Pax family are defined by the presence of a 
128 amino acid DNA binding domain known as the paired domain (PD) (Walther et al., 
1991). Sorne members of the Pax family, which includes Pax3, also contain a second DNA 
binding domain, the paired-type homeodomain (HD) (Stuart et al., 1994). Many studies have 
shown that for members of the Pax family that contain both domains the PD and the HD may 
be structurally independent and show a functional interdependence ofDNA binding; that is 
the two domains each consist of their own primary and secondary structures but their ability 
to bind DNA involves sorne sort of communication between the domains. The objective of the 
work presented is to determine the mechanism underlying this observed interdependence. 
These studies will contribute to understanding the different modes in which Pax proteins bind 
DNA and regulate transcriptional expression oftarget genes during embryogenesis. 
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Chapter 1 
Literature Review 
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1.1 Historical perspective 
Many genes involved in the development of Drosophila melanogaster were discovered 
via large scale genetic screening (Nusslein-Volhard and Wieschaus, 1980). Many genes 
responsible for mammalian development have been discovered by sequence homology with 
known developmental genes of the fly. These genes include the mammalian family of Pax 
genes (Burri et al., 1989; Deutsch et al., 1988; Dressler et al., 1990; Stapleton et al., 1993; 
Walther et al., 1991; Wallin et al., 1993; Walther and Gruss, 1991). Pax family members are 
detined by the presence of the paired box, which encodes a DNA binding domain known as 
the PD. The paired box sequence was identified in flies as a region ofhomology between the 
Drosophila Prd gene and two linked genes present at the gooseberry locus (Bopp et al., 1986). 
The Prd gene of Drosophila was discovered during large genetic screens and is classified as a 
pair-ru le segmentation gene (Nusslein- Vollard and Wiechaus, 1980). Mammalian Pax genes 
were tirst identified by homology with the paired box sequence present in the Paired (Prd) 
Drosophila gene. This led to the discovery of the Paxl protein followed by the other members 
ofthe Pax family. 
Sequence analysis of the Prd gene identified a homeobox, which codes for the DNA 
binding domain known as the HD (Frigerio et al., 1986). The possible function of the PD as a 
DNA binding domain was suggested by the discovery ofa DNA binding activity of the Prd 
protein that was not mediated by the HD (Treisman et al., 1989). Extensive studies ofboth the 
Drosophila Prd and the mammalian Pax-l proteins revealed that the PD is a sequence specifie 
DNA binding domain (Chalepakis et al, 1991; Treisman et al., 1991). Analysis ofnaturally 
occurring and engineered mutations in Pax genes confirmed their important roles in various 
stages of embryogenesis. The first part ofthis literature review will provide an overview of 
the mammalian Pax gene family, starting with a brief outline of the classification of Pax genes 
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into subfamilies, followed by an exploration ofthe genetic disorders that are caused by loss-
of-function mutations in individual Pax genes. Subsequently, the biochemical properties as 
weIl as known physiological targets of Pax proteins will be discussed. 
1.2 Classification of Pax genes into subfamilies 
The Pax family consists ofnine members, Paxl to Pax9. The family is defined by the 
presence a paired domain (PD) at the N-terminus (Figure 1). Pax3 Pax4, Pax6 and Pax7, like 
Prd, also encode for a second DNA binding domain, the paired-type homeodomain (HD) 
(Frigerio et al., 1986). Pax2, Pax5 and Pax8 proteins only contain a portion of the HD and 
Paxl and Pax9 do not have any HD (reviewed in Dahl et al., 1997; Mansouri et al., 1996; 
Stuart and Gruss, 1995; Stuart et al., 1994). With the exception ofPax4 and Pax6, aIl Pax 
members also contain a conserved octapeptide motifpositioned between the PD and the HD. 
AIl Pax proteins contain a transactivation domain at their C-termini. 
This classification scheme is supported by the observation that within the same 
subfamily Pax genes share a high degree of sequence identity within their and outside oftheir 
PD, show similar genomic organizations and have similar temporal and spatial expression 
patterns (Dahl et al., 1997; Mansouri et al., 1996; Stuart and Gruss, 1995; Walther et al., 
1991 ). 
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Figure 1 
Schematic representations of the structural features of members of the Pax family. AlI 
members contain the 128 amino acid PD (large black box) at the N-terminus. A subset.ofPax 
proteins also contain a conserved octapeptide motif (small black box) and/or a complete or 
partial HO (hatched box). Pax proteins are classified into subfamilies based on the presence or 
absence of these 3 structural features. 
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1.2.1 The PaxlIPax9 subfamily 
Paxl and Pax9 are members of the same subfamily and contain PDs with 98% 
sequence identity as weil as the conserved octapeptide, but do not have a HD (Chalepakis et 
al., 1991; Deutsch et al., 1988; Neubuser et al., 1995; Stapleton et al., 1993; Wallin et al., 
1993). Both members share very similar, but not identical, temporal and spatial expression 
patterns in the Iimb buds, the developing vertebral column, and in adult and embryonic 
thymus (Deutsch et al., 1988; Neubuser et al., 1995). The developing vertebral column arises 
from PaxlIPax9 expressing sclerotome cells located in the ventral somites. Interestingly, only 
Pax9 is expressed in mesenchyme involved in tooth development (Neubuser et al., 1997). In 
agreement with their expression patterns, Paxl and Pax9 mutants develop abnormalities ofthe 
thymus as weIl as certain skeletal elements. The Un (Undulated) mouse Paxl mutant aile le 
contains a glycine-to-serine mutation in the PD and results in vertebral (Balling et al., 1988; 
Wright, 1947) and thymus dysgenesis (Dietrich and Gruss, 1995; Timmons et al., 1994; 
Wallin et al., 1996). A less severe phenotype is observed in Paxl heterozygotes thereby 
demonstrating that Un Paxl mutation is not recessive but semi-dominant, a characteristic 
common to several Pax genes (Dietrich and Gruss, 1995; Wilm et al. 1998). Pax9 mutants, 
generated by homologous recombination, have no phenotype in the heterozygote but 
homozygotes are devoid ofteeth. No defects are seen in the skeletal system of homozygotes 
suggesting that Pax 1 compensates for the lack of Pax9 activity during skeletogenesis (Peters 
et al., 1998). Human PAX9 heterozygotes suffer from autosomal dominant oligodentia and 
experience the agenesis of six or more permanent teeth (Stockton et al., 2000). Paxl and Pax9 
double knock out mice have more severe vertebral dysgenesis than Paxl-/- or Pax9-/- knock 
out mice and reveal a gene dosage effect in vertebral column development (Peters et al., 
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1999). Therefore Paxl and Pax 9 have unique roles during embryogenesis but cooperate or 
have redundant functions during the development of the skeletal system. 
1.2.2 The Pax2lPax5lPax8 subfamily 
Members ofthis subfamily contain a PD as weIl as an octapeptide and a partial HD, 
which contains only the first 23 amino acids of the 60 amino acid domain (Adams et al., 1992; 
Asano and Gruss, 1992; Dressler et al., 1990; Plachov et al., 1990). AlI members of this 
subfamily are expressed in the developing central nervous system, more specifically, in the 
midbrain-hindbrain boundary (Adams et al., 1992; Asano and Gruss, 1992; Nomes et al., 
1990; Plachov et al., 1990). Pax2 and Pax8 are both expressed in the developing kidney and 
are both downregulated once terminal differentiation ofkidney epithelial structures occurs 
(Dressler and Douglas, 1992; Plachov et al., 1990; Poleev et al., 1992). Pax2 and Pax8 
expression is observed in kidney epithelium in the Wilm's tumor renal malignancy where 
embryonically-derived tissues are unable to complete the mesenchymal-epithelial transition 
(Dressler and Douglas, 1992; Eccles et al., 1995; Poleev et al., 1992; Tagge et al., 1994). 
Pax2, Pax5 and Pax8 also have distinct expression domains. Pax2 is expressed in the 
developing inner ear and in the developing eye (optic cup and optic stalk), while Pax5 
expression is found in B-Iymphoid tissues and lineages involved in early B-cell 
differentiation. Pax8 is found expressed in the developing and adult thyroid gland (Nomes et 
al., 1990; Torres et al., 1996; Adams et al., 1992; Plachov et al., 1990; Zannini et al., 1992). 
Autosomal dominant human PAX2 mutations give ri se to renal-coloboma syndrome, 
which is characterized by optic nerve colobomas, renal hypoplasia (e.g. fewer nephrons) as 
weil as auditory and central nervous system defects (Eccles and Schimmenti, 1999; 
Schimmenti et al., 1997). Optic nerve coloboma results from lack of closure of the optic 
fissure (Favor et al., 1996; Torres et al., 1996). The Krd (kidney and retinal gefects) mouse is 
a heterozygous mutant ofPax2 and displays retinal and renal defects. In accordance with the 
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semi-dominant nature ofPax2 mutations, both the mouse and human, Pax2 mutant 
homozygotes experience kidney agenesis and embryonic death (Eccles and Schimmenti, 
1999; Keller et al., 1994). Induced overexpression ofPax2 is also detrimental to proper 
development and results in severe kidney abnormalities. The nature of these abnormalities 
suggests that persistent expression of Pax2 inhibits terminal differentiation of glomerular and 
tubular epithelia (Torres et al., 1995). Pax5 mutants display aberrant midbrainlhindbrain 
formation as weIl as a complete lack of functional B cells since B cell differentiation is halted 
at an early pre-B-cell stage (Urbanek et al., 1994). Mouse Pax8 homozygous mutants 
experience thyroid dysgenesis, more specitically, they develop smaller thyroid glands 
(Mansouri et al., 1998). AIso, PAX8 mutations in humans results in hypothyroidism (Macchia 
et al., 1998). 
1.2.3 The Pax3IPax7 subfamily 
Members ofthis subfamily conta in aIl three structural features: a PD, octapeptide and 
the HD. Both Pax3 and Pax7 have an additional isoform that results from alternative splicing 
and that differs from the original sequence by the addition of a glutamine residue in the linker 
between the two subdomains within the PD (Vogan et al., 1996). 
Both genes are expressed during neurogenesis with overlapping but not identical 
spatial and temporal expression domains. During early embryogenesis both genes are . 
expressed in the dorsal neural tube (Goulding et al., 1991; Jostes et al., 1990; Stoykova and 
Gruss, 1994). Pax3 and Pax7 expression requirement in neurogenesis is supported by the 
observation that diffusible factors Wntl, 3a, 4 and 6 are required to maintain Pax3 and Pax7 
expression in the neural tube (Otto et al., 2006). One difference of note is that Pax3 
expression precedes the cIosure of the neural tube (Pax3 expression is tirst detected in the tips 
ofthe neural folds) whereas Pax7 expression begins soon after cIosure. Pax3 and Pax7 
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expression is also evident in neural crest ceIls, a population of cells derived from the dorsal 
neural tube following closure that have the capacity to migrate to various areas of the embryo 
to give ri se to several unrelated structures (Conway et al., 1997; Goulding et al., 1991; 
Mansouri et al., 1996). Neural crest cells contribute to the formation of melanocytes, the 
peripheral nervous system (e.g. dorsal root ganglia) and the heart, among other structures. 
Pax3 and expression can also be found in somitic mesoderm that gives rise to 
myoblasts and then muscle tissues (Goulding et al., 1994; Jostes et al., 1990). A portion of 
Pax3 expressing cells in the somite have the ability to migrate into the limb to form limb 
musculature, but this expression is suppressed once in the limb and the activation of myogenic 
markers occurs. Pax7 expression is seen in proliferating myoblasts, in satellite cells as weIl as 
adult skeletal muscles (Goulding et al., 1994; Jostes et al., 1990; Seale et al., 2000; Williams; 
Ordahl, 1994 and Oustanina et al., 2004). Satellite cells are quiescent myogenic precursor 
cells located between the basal membrane and the sarcolemma of myofibers and they are 
characterized by Pax7 expression (Kawiak et al., 2006). OveraIl, it is obvious that Pax3 and 
Pax7 play a role in myogenesis, neurogenesis and formation of neural crest cell derived 
structures. 
The Pax3 heterozygous mutant mouse Splotch has hypopigmentation defects which 
consist of white spotting of the beIly, feet and tail. This pigmentation disturbance is due to the 
inability of a sufficient number of neural crest cell derived melanocytes to migrate to these 
areas (Auerbach, 1954). Many Splotch alleles exist and are either naturally occurring or 
radiation induced. Characterization of these alleles has shown that they are the result of 
deletions, missense, nonsense or frameshift mutations in Pax3 (Epstein et al., 1991; Epstein et 
al., 1993; Goulding et al., 1993; Vogan et al., 1993). The mutation in the Sp aIle le is complex 
and lies within intron 3 of the Pax3 gene resulting in the production of four distinct, aberrantly 
spliced mRNA transcripts. Three ofthese transcripts result in premature termination with the 
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absence of an intact PD, octapeptide motif, and HO. The fourth lacks exon 4, resulting in the 
loss of the C-terminal part of the PD as weIl as loss of the octapeptide motif (Epstein et al., 
1993). The mutation in the Sp2H mutant aIle le is a 32 basepair deletion in the HO (Epstein et 
al., 1991). 
AlI Sp mutations are lethal in the homozygous state but the longevity of the 
homozygous mutant Pax3 mouse is different between aIleles. Mutant aIle les Sp and Sp2H 
cause embryonic death during mid-gestation due to the absence of a septum in the outflow 
tract of the heart, which is formed only when a sufficient number of cardiac neural crest ceIls 
migrate from the neural tube to the heart. This septum is required to convert the outflow tract 
of the primordial heart into the aorta and pulmonary artery. The absence ofthe septum results 
in constant mixing of oxygenated and non-oxygenated blood and leads to heart failure in mid-
gestation (Conway et al., 1997; Franz, 1989). The Spr (Sp-retarded) aIlele causes pre- . 
implantation death of the embryo in the homozygous mutant. This drastic effect is due to the 
fact that this allele is mutated by a cytogeneticaIly detectable deletion of the Pax3 locus as 
weIl as surrounding loci. In fact, the initiation of a positional cloning effort to define the 
molecular basis of the mouse Splotch phenotype began with an analysis ofSpr mice (Evans et 
al., 1988). The hypomorph Spd (Sp-delayed) allele consists of a missense mutation where 
glycine 9 of the PD (glycine 42 in the Pax3 protein) is changed to an arginine. Sp-delayed 
homozygous mutant embryos survive to term but die soon after birth due to the lack of the 
diaphragm muscle required for breathing (Auerbach, 1954; Beechey and Searle, 1986; Dickie, 
1964). Sp homozygous mutants experience neural tube and neural crest defects as weIl as an 
absence of limb musculature (Auerbach, 1954; Franz, 1990; Franz, 1989; Franz, 1993; Franz 
et al., 1993; Bober et al., 1994; Goulding et al., 1994). The lack of closure in the neural tube 
ofSp mutants results in spina bifida, exencephaly or anencephaly (Auerbach, 1954). Sp 
homozygous mutants display defects in the formation of the peripheral nervous system as 
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weIl. More specificaIly, the absence ofPax3 causes dysgenesis of dorsal root ganglia (Kioussi 
et al., 1995; Serbedzija and McMahon, 1997; Tremblay et al., 1995). Recently, it has been 
found that decreased Pax3 expression induced by maternaI hyperglycemia (diabetic 
pregnancy) leads to an increase in incidence of neural tube defects (Loeken et al., 2006). This 
observation is in line with the beliefthat Pax3 is involved in neural tube formation. 
Homozygous Sp mice also display a disruption in myogenesis. These mice lack 
structural organization of the somites that results in malformations or reduction oftrunk 
musculature. Also, these mice lack any migrating myoblasts that are responsible for 
populating the limb bud and giving ri se to limb muscles, consequently no limb musculature 
results (Bober et al., 1994; Franz et al., 1993; Goulding et al., 1994). 
Humans with only one functional copy ofPAX3 develop Waardenburg syndrome 
(WS). This semi-dominant disorder is characterized by pigmentary disturbances, 
sensorineuronal deafness and craniofacial abnormalities (Waardenburg, 1951). Although there 
are sorne differences in the phenotypes between the Sp mouse and human WS patients, the 
similarities in the structures affected implies that the role ofPax3 is conserved. Although, 
severe Iimb musculature defects are observed in sorne WS homozygotes, none show the 
neural tube defects that are prevalent in Sp mouse homozygous mutants (Ayme and Philip, 
1995; Zlotogora et al., 1995). 
Since no naturally occurring Pax7 mutant allele exists, one was created by 
homologous recombination (Mansouri et al., 1996). Unlike other Pax proteins, no observable 
phenotype exists in the heterozygous mutant. Pax7 homozygous mutants survive to term but 
die soon after birth due to insufficient muscle growth. At birth, Pax7 homozygous mutants are 
grossly normal but upon closer inspection one can observe a decrease in muscle mass and 
fiber caliber. These observations seem to be due to the fact that Pax7-/- mice lack satellite 
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ceUs required for post-natal muscle growth, maintenance and repair (Mansouri et al., 1996; 
Mansouri et al., 1996; Seale et al., 2000). 
A new Pax3 null aUele was made recently by replacing the first exon with a gene 
encoding Cre recombinase (Engleka et al., 2005). This aUele was used with a p-galactosidase 
reporter gene to generate a fate-map ofPax3 derivatives in the developing mouse. As 
expected, neural crest and some somatic derivatives have been identified (Engleka et al., 
2005). However, this study also revealed Pax3-expressing precursors in the colonic 
epithelium of the hindgut and within the urogenital system (Engleka et al., 2005). This Pax3 
expression has not been characterized to date. 
1.2.4 The Pax4IPax6 subfamily 
Members ofthis subfamily conta in both a PD and HD but lack the octapeptide motif 
(Matsushita et al., 1998). Unlike Pax4, Pax6 expression patterns have been thoroughly . 
studied. Like most members of the Pax family, Pax6 is also expressed in the developing 
central nervous system. Pax6 is expressed in the ventral neural tube upon neural tube closure 
and is also expressed in the developing brain, more specificaUy in the forebrain, 
telencephalon, diencephalon and myelecephalon (Puschel et al., 1992; Stoykova and Gruss, 
1994; Walther and Gruss, 1991). Pax6 expression in the eye has been extensively studied and 
early on expression occurs in the optic vesicle and the optic stalk, while later in development 
expression is seen in the retina, cornea and the lens. In accordance with similarities between 
lens and nasal placode formation, Pax6 is also found expressed in olfactory epithelium and the 
olfactory bulbs (Grindley et al., 1995; Puschel et al., 1992; Walther and Gruss, 1991). Pax6 
expression has also been detected in the developing pancreas but only in certain endocrine 
cells (Sander et al., 1997; St-Onge et al., 1997; Turque et al., 1994). Pax4 transcripts have also 
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been detected in endocrine precursor ce Ils of the pancreas (Smith et al., 1999; Sosa-Pineda et 
al., 1997). 
Targeted inactivation ofPax4 led to defects in the pancreas only (Sosa- Pineda et al., 
1997). The adult endocrine function of the pancreas is controlled by four islet cell types 
known as a, p, 0 and pp cell which respectively synthesize glucagons, insulin, somatostatin 
and the pancreatic polypeptide. Development of the se cells occurs from pluripotent 
progenitors that initially commit to the Plo or alPP cell fate and terminally differentiate later 
du ring development (Dohrmann et al., 2000). Pax4-/- mice die soon after birth and exhibit 
growth retardation as weil as dehydration. These mice are unable to form mature p and y cells 
and have an increased number of a cells (Sosa-Pineda et al., 1997). This observation suggests 
that Pax4 plays a role in endocrine cell differentiation during pancreatic development. 
Pax6 mutant alleIes are semi-dominant in both mouse and human. In the heterozygous 
state Pax6 mutations cause the Small eye (Sey) phenotype in mice and aniridia in humans 
(Glaser et al., 1994; Hanson et al., 1993; Hanson et al., 1994; Hill et al., 1991; Hogan et al., 
1988; Hogan et al., 1986; Jordan et al., 1992; Ton et al., 1991). Variations in phenotype exist 
for different Pax6 mutant aIle les in both mice and humans but aIl cause ocular malformations 
in the heterozygous mutants including cataracts and opacification of the cornea, iris 
hypoplasia and absence or reduction in size ofthe lens (Callaerts et al., 1997). Pax6-/- . 
mutants die at birth and exhibit malformations in the central nervous system and lack eyes and 
a no se (agenesis of nasal cavities or olfactory bulbs) (Grindley et al., 1995; Stoykova et al., 
1996). Pax6-/- mice also develop defects in the pancreas. Sorne Pax6 mutant alleIes cause 
agenesis of only glucagon producing a cells while others result in a decrease in number of ail 
4 of the pancreatic endocrine ceIl types (Sander et al., 1997; St-Onge et al., 1997). Therefore, 
a strong correlation exists between the expression patterns ofPax6 and the organs that are 
malformed when Pax6 expression is downregulated. As for many other Pax genes, the semi-
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dominance observed in naturally occurring mutants suggests a dose requirement for Pax6 
during eye development. This is further supported by the observation that transgenic mice that 
overexpress Pax6 also develop ocular defects that are very similar to those that occur when 
Pax6 is underexpressed (Schedl et al., 1996). There is a strong sensitivity of cells involved in 
ocular development to changes in endogenous levels ofPax6 expression. 
The Pax6 homolog in Drosophila, eyeless (ey), results in agenesis of the fly's 
compound eyes when mutated. AIso, when it is ectopically expressed in leg, wing and 
antennal imaginaI discs leads to the formation of ectopie eyes (Hauck et al., 1999; Quiring et 
al., 1994; Xu et al., 1999; Czerny et al., 1999; RaIder et al., 1995). AIso, ectopic lens and 
retinal tissues arise inXenopus when Pax6 is ectopically expressed (Chow et al., 1999). These 
studies suggest that the role ofPax6 in eye development is conserved among species and 
holds a key position in the ocular developmental pathway. 
1.3 The Biochemistry of Pax Proteins 
The conservation of sequence and function of Pax gene homologs among different 
subfamilies as weil as different species suggests that the biochemistry of Pax proteins is 
conserved as weil. There are nevertheless significant differences in primary structure that 
likely have significant functional implications. 
1.3.1 Paired Domain Biochemistry 
1.3.1.l DNA Binding Activity of the Paired domain 
The PD is the structural element that defines the Pax family of proteins and is also the 
element that is the most highly conserved. This is evident by the fact that the PD of the mouse 
and human Pax3 homologs share a 100% sequence identity (Roth et al.,1993; Walther et al., 
1991). AIso, the sequence identity of the PD of Pax proteins within each subfamily is 
typically 90% or more (Walther et al., 1991). At least 55 of the 128 residues that constitute 
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the PD are accepted as invariant among ail PDs across different subfamilies as weil as 
different species (Walther et al., 1991) (Figure 2). 
Figure 2 
Multiple sequence alignment of the PDs ofmouse Pax proteins. Only the entire sequence of 
Pax3 is shown and is aligned with the PD of the rest ofthe eight Pax genes grouped into 
individual subfamilies (Adams et al., 1992; Balling et al., 1988; Dressler et al., 1990; 
Goulding et al., 1991; Jostes et al., 1990; Matsushita et al., 1998; Plachov et al., 1990; Wallin 
et al., 1993; Walther and Gruss, 1991). Invariant residues are shaded in gray while identical 
positions are in dashes. Following the alignment, the number of identical residues among 
subfamily members is shown. With the use ofthe Prd and Pax6 crystal structures, a schematic 
representation of the PD was formulated. This representation shows the secondary structure of 
the PD and is displayed above the sequence alignment (Xu et al., 1999; Xu et al., 1995). (1, p-
tum, p, p-strand). 
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Sequence analysis of the promoter of the Drosophila even-skipped gene (e5) revealed 
the presence of a HD specifie DNA sequence element. Mutations in the Prd protein that 
inactivated HD DNA binding activity did not abrogate Prd affinity for the e5 sequence 
thereby suggesting the presence of another DNA binding element within the Prd protein 
(Treisman et al., 1989). Subsequent deletion studies ofthe Prd protein permitted the discovery 
of the PD as a DNA binding domain and revealed that the e5 sequence held both HD and PD 
specifie DNA binding elements that are adjacent to one another (Treisman et al., 1991). The 
DNA binding capacity of the PD was also supported by studies of the Paxl protein. This 
protein contains only a PD with no HD, and was found to bind weakly to the e5 sequence and 
strongly to e5 sequence derivatives (Chalepakis et al., 1991). Interference studies and analysis 
of DNA sequences with Paxl affinity were used to conclude that the PD recognizes a DNA 
sequence that extends 24 base pairs (Chalepakis et al., 1991). Sequence alignment and 
footprinting studies with the in vivo and in vitro derived DNA binding sequences that have 
affinity to Pax2,5,6 or 8, reveals that the PD binds a relatively degenerate consensus sequence 
(Adams et al., 1992; Barberis et al., 1989; Epstein et al., 1994; Kozmik et al., 1992; Zannini 
et al., 1992). Structure-function studies with the PD ofPax5 resulted in the formation of the 
bipartite structure model of the PD, which suggests that it contains 2 subdomains: the PAl or 
N-terminal and the RED or C-terminal subdomains. According to the model each subdomain 
interacts specifically with different DNA sequences that are relatively degenerate. A truncated 
Pax5 prote in that lacks the last 36 amino acids ofthe PD is only able to recognize DNA via 
the use of the PAl subdomain. The PD DNA sequences recognized only through the use of the 
N-terminal subdomain are termed type II sequences. Binding to Type 1 sequences requires the 
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use of both the PAl and RED subdomains of the PD and this is supported by the observation 
that the truncated Pax5 prote in is unable to bind Type 1 DNA sequences (Czerny et al., 1993). 
Figure 3 
PD recognition sequences. 
A) H2A-2.2 (Czerny et al., 1993), CDI9-2A (Czerny et al., 1993), ND' (Epstein et al., 
1995) and P6CON (Epstein et al., 1994), are sorne type 1 DNA sequences that contain binding 
sites for both the PAl and RED subdomains which are underlined. The DNA sequences e5 
(Treisman et al., 1991), PRS4 (Chalepakis et al., 1991) and H2A2.l (Czerny et al., 1993), are 
sorne type II DNA sequences that hold only N-terminal subdomain specifie binding sites. 
Comparison ofthese sequences permitted the derivation ofa consensus sequence that is 
displayed above the multiple sequence alignment along with a schematic representation of the 
bipartite structure ofthe PD. Bases in type 1 or II sequences that have diverged from the 
consensus sequence are displayed in italics. 
B) The consensus binding sequences of the PD ofPrd (Jun and Desplan, 1996), Pax3 
(Chalepakis and Gruss, 1995; Epstein et al., 1996), Pax6 (Epstein et al., 1994), Pax4 (Fujitani 
et al., 1999), Pax2 (Epstein et al., 1994) and Pax8 (Jun and Desplan, 1996). 
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A) 
Type 1 
Type II 
B) 
Consensus 
H2A-2.2 
CD19·2/A 
Nf3t 
P6CON 
egGT~~GC .. CA.TG .. ~ 
ACAGTCGTCACCCACCGCTGCGTCACAA 
GCGGTGGTCAC GCCTCAGTGC CCCATTC 
GTGTGTGTCACGCTTATTTTCCTGTACT 
GGAATTTTCACGCTTGAGTXCACAGCTC 
eS GATTAGCACCGTTCCGCTCAGGCTGTCCCGT 
PRS4 
H2A-2.1 
Prd 
Pax-3 
Pax-6 
Pax-4 
Pax-2 
Pax-8 
TGGGCTCACCGTTCCGCTCAGGCTGTCCCGT 
TTTCTTGACACGCTGAAGAAATAGTTG 
eCGTCACGgTTgâc 
TCGTCACGETT-A 
A-TTCACGC~@A-T~X-C 
GCT. GGG G--TTGAAGCGTG-TCA-T-
T-GTC~GCàTGA 
~-GTCAC~C-e-~Tî 
In accordance with the model Type II sequences are only halfthe length (10 to 12 base pairs) 
ofthose recognized by both subdomains (24 base pairs) (Figure 3). 
DNA binding studies ofalternatively spliced isoforms ofPax6 (5a isoform), 8 (S 
insertion isoform) and 3 (Q insertion isoform), that create insertions within the PD which alter 
the DNA binding activity of the PAl and RED subdomains, further support the bipartite 
model of the PD (Kozmik et al., 1997; Epstein et al., 1994; Vogan et al., 1996). The Pax6 
isoform contains a 14 amine acid insertion (Pax6-5a) and the Pax8 isoform ho Ids a one amino 
acid insertion (Pax8-S) in the PD (Glaser et al., 1992; Kozmik et al., 1997; Puschel et al., 
1992; Walther et al., 1991). These insertions prevent the PAl subdomain of PAX6 from 
binding DNA and permits the PD ofthese insertion isoforms to bind a new sequence termed 
5aCON exclusively through the use ofthe RED subdomain. This is in contrast to the wildtype 
PD which binds DNA with the use ofthe PAl subdomain al one, or both the PAl and RED 
subdomains, but ne ver with the wildtype RED subdomain alone (Czerny et al., 1993; Epstein 
et al., 1994; Kozmik et al., 1997). These isoforms confirm the DNA binding capacity of the 
RED subdomain and support the bipartite model of the PD. The Pax3 isoform (Pax3/Q+) 
shows a glutamine insertion in the linker between the PAl and RED subdomain (Vogan et al., 
1996). DNA binding studies of sequences that bind the Pax/Q- and Pax3/Q+ isoforms reveal 
that both isoforms bind type II sequences through the PAl subdomain with equal affinity but 
that the Q+ isoform binds type 1 sequences with 2 to 5 fold reduced affinity (Vogan et al., 
1996). Therefore the presence of the extra glutamine residue interferes with DNA binding 
activity of the RED subdomain. Rence the relative contribution of the PAl and RED 
subdomain to DNA binding is modulated by these PD splice variants. 
1.3.1.2 Paired Domain Structure 
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The crystal structures of the DNA bound PD of the Prd and Pax6 proteins confirm the 
bipartite model (Xu et al., 1999; Xu et al., 1995) (Figure 4). 
Figure 4 
DNA bound Structures of the PD ofPrd and Pax6. 
A) The Drosophila Prd DNA bound PD structure determined via X-ray crystallography. 
The DNA sequence used is 15 base pairs long and is a type II sequence (Xu et al., 1995). 
B) The mammalian Pax6 DNA bound PD structure resolved via X-ray crystallography. 
The DNA sequence used is 24 base pairs in length and is a type I sequence (Xu et al., 1999). 
Each subdomain consists ofthree helical folds with the two most C-terminal helices forming a 
helix-tum-helix motif. The six he lices are indicated with numbers 1 through 6. For both the 
Prd and Pax6 PDs the PAl subdomain engages in DNA contacts with the use of the p-hairpin 
motif as weIl as its most C-terminal helix. The linker is not simply a tether between the 
subdomains but adopts an extended conformation on Type I sequences and makes base 
specifie contacts in the minor groove. Unlike the Pax6 PD, the Prd RED subdomain does not 
contact DNA. The RED subdomain ofPax6 binds DNA and makes base specifie contacts in 
the major groove with its most C-terminal helix. 
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The PD consists oftwo globular units, PAl and RED, connected by a short linker 
sequence. The PAl subdomain consists of a three helical fold, very similar to the three helical 
fold ofHDs, with the two most C-terminal helices forming a helix-tum-helix motif. Helices 1 
and 2 pack together in an anti-parallel manner and are perpendicular to helix 3. Helix 2 makes 
non-specific phosphate backbone contacts while helix 3 is involved in making base specific 
contacts with the major groove ofDNA. Preceding the three helical fold lies a p-hairpin and a 
p-tum. The p-hairpin consists oftwo anti-parallel p-strandsjoined by a type 1 p-tum. This 
structure is involved in making non-specifie phosphate-backbone DNA contacts. The p-tum 
that follows the p-hairpin structure is a type II tum and unlike most other DNA binding 
proteins participates in base-specifie contacts in the minor groove ofDNA. The PAl and RED 
subdomains are structurally independent. The type II p-tum and portions of the helix-tum-
helix motif pack against the linker via hydrophobie interactions. The sub-linker amino acid 
sequence is not simply a tether thatjoins the PAl and RED subdomain, but adopts an 
extended conformation on DNA and participates in base specifie contacts via the minor 
groove (Xu et al., 1995; Xu et al., 1999). 
The Pax6 PD is bound to a longer 26 base pair type 1 DNA sequence and has a PAl 
subdomain that is very similar to that of the Prd PAl subdomain. Unlike the Prd RED 
subdomain, the Pax6 RED subdomain contacts DNA with the use of its most C-terminal 
helix, which makes base-specifie contacts in the major groove. The lack ofDNA contact 
formation of the RED subdomain in the Prd crystal structure is in agreement with the 
biochemical data which suggests that Prd binds DNA exclusively through the use of the PAl 
subdomain (Xu et al., 1995). Another difference between the Prd and Pax6 PD structures is 
the specificity observed for the base pair at position 4 ofDNA. The first residue ofhelix 3 of 
the PAl subdomain contacts this base pair. In the Prd prote in, as weIl as most other proteins 
41 
including Pax3, a G/C base pair is preferred at this position, while for the Pax6 prote in an Arr 
base pair lies at this position. This difference in specificity is due to the identity of the first 
residue ofhelix 3. In Prd and other Pax proteins this residue is a histidine, which is able to 
participate in hydrogen bonds with the GC base pair. For Pax6, this residue is instead an 
asparagine that is able to recognize the AT base pair via hydrophobie coupling. The 
methylene group of aspargine undergoes hydrophobie interaction with the methyl group of 
thymine which is reinforced by a water mediated hydrogen bond between the amide in the 
side chain of the asparagine residue and the sugar-phosphate backbone (Xu et al., 1995; Xu et 
al., 1999). 
Despite the resolution of the PD 3D structure, accounting for the degeneration 
observed in the DNA sequences recognized by the PD is not possible. In addition, these X-ray 
crystallography studies did not address the possibility of other proteins binding DNA 
alongside the PD and influencing PD DNA binding specificity. 
1.3.2 Paired-type Homeodomain Biochemistry 
1.3.2.1 DNA Binding Activity of the Homeodomain 
The superfamily ofHOs includes the paired-type HD family which, like most HOs 
consists of60 residues and displays DNA binding activity. Paired-type HDs can be found in 
mammalian Pax3, 7, 4 and 6 proteins as weIl as the Drosophila Prd, Gooseberry and Eyeless 
proteins (Goulding et al., 1991; Jostes et al., 1990; Walther and Gruss, 1991; Walther et al., 
1991). Sorne proteins also contain paired-type HOs without the presence of a PD (e.g. Phox 
protein). Most members of the HD superfamily ofproteins recognize DNA elements that 
contain a T AA T core motif (Gehring et al., 1994). There is sorne specificity for the 2 base 
pairs found immediately 3' to the core motif and the identity ofresidue 50 of the HO is a 
major determinant for this specificity (Treisman et al., 1989). The feature unique to the 
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paired-type family ofHOs is their ability to form cooperative homo and heterodimers on 
palindromic sites of the type 5'-TAAT (Nb3 ATTA-3'. Non-paired-type HOs may dimerize 
on ONA but require domains extrinsic to the HO. Paired-type HOs rely entirely on the 60 
residues within the HO for their dimerization potential. The length half site spacer and the 
extent of cooperation observed during dimerization is determined by the identity of residue 50 
(Wilson et al., 1993). Paired-type HOs which hold a glutamine at position 50 (Q50) 
preferentially dimerize on a palindromic ONA site that contains a 3 base pair spacer (P3 
probes), while HOs with serine at this position (S50) dimerize more efticiently on DNA with 
a 2 base pair spacer (P2 probes). For both S50 and Q50 paired-type HDs, binding ofthe tirst 
HO to ONA increases the affinity of the second HO for the remaining ONA TAA T sequence 
by 50 fold for S50 HOs and over 100 fold for Q50 HOs (Wilson et al., 1993). 
1.3.2.2 Paired-type Homeodomain Structure 
Crystal structures of many HOs have been resolved but the one of particular interest 
for our studies and that serves as a model for cooperative ONA binding of paired-type HDs, is 
the crystal structure of the paired-type HD of the Drosophila Prd prote in bound to the P3 site 
(Wilson et al., 1995) (Figure 5). Of note is that the amino acid identity at position 50 has been 
altered from the native serine to glutamine. This substitution was done in order to optimize 
the cooperativity of the two Prd HOs complex to the P3 ONA sequence (Wilson et al., 1993; 
Wilson et al., 1995). 
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Figure 5 
Schematic representation of the RD dimer bound to DNA. This structure was obtained by X-
ray crystallography of the Drosophila Prd paired-type RD bound to the P3 DNA sequence 
(Wilson et al., 1995). The base specifie contacts made by the RD involve the third helix 
(recognition helix), which binds DNA via the major groove, and the N-terminal arm, which 
contacts the minor groove of DNA. Dimerization on DNA requires the formation of 
reciprocal contacts between the N-terminus ofhelix 2 of one RD with the N-terminal arm of 
the other domain. Dimerization is also supported by water-mediated hydrogen bonds and 
hydrophobie contacts made between N-termini ofthe two recognition helices (Wilson et al., 
1995). 
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When bound to the P3 DNA sequence the Prd paired-type HD adopts a three helical 
fold structure very similar to the structure of the HDs of engrailed and antennapedia (Billeter 
et al., 1993; Kissinger et al., 1990; Qian et al., 1989; Wilson et al., 1995). The two most C-
terminal helices form a helix-turn-helix motifwith helix 2 anchoring the motif over DNA by 
making phosphate backbone contacts and helix3 participating in specifie DNA contacts by 
contacting bases in the major groove ofDNA. The first and second helices are anti-parallei 
and perpendicular to helix3. The third helix is able to make base specifie contacts with the use 
ofthree critical invariant residues: V47, N51 and Q/S50. Residue V47 participates in 
hydrophobie coupling to the methyl group ofa thymine base while N51 makes both direct and 
water mediated hydrogen bonds with both adenine and thymine bases ofDNA. Position 50 is 
involved in water-mediated hydrogen bonds with a thymine base ofDNA as weIl as a base 
immediately 3' to the T AA T core motif (Wilson et al., 1995). Preceding the three helical fold 
lies the N-terminal arm. The N-terminal arm adopts an extended conformation on DNA and is 
able to form specifie contacts with DNA by contacting bases in the minor groove of DNA 
(Wilson et al., 1995). 
The two HDs adopt a head-to-head conformation on DNA. Dimerization on DNA 
requires the formation ofreciprocal contacts between the N-terminus ofhelix 2 of one HD 
with the N-terminal arm of the other domain. Dimerization is also supported by water-
mediated hydrogen bonds and hydrophobie contacts made between N-termini of the two 
recognition helices (Wilson et al., 1995). These reciprocal contacts occur on the interaction 
surfaces between the HDs and are possible only if the DNA helix is distorted from the ideal B 
form by bending approximately 21 degrees (Wilson et al., 1995). The 3D structure of the HD 
on P2 is postulated to be similar to the dimer formed on P3 although slight differences would 
be required in order to accommodate for the missing base pair in the spacer that may bring the 
two HDs closer together (Wilson et al., 1993; Wilson et al., 1995). Even though the Prd HD 
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crystal structure explains the dimerization potential of paired-type RDs, it is not able to 
account for the different half-site preferences of S50 and Q50 RDs. 
1.3.3 Functional Dependence between the Paired and Romeodomains 
Many observations and studies indicate that the paired and RD are structurally and 
functionally inde pendent. For instance, the DNA bound complexes ofboth the PD and paired-
type RD indicate the domains have different DNA binding speciticity. AIso, many naturally 
occurring proteins conta in a PD and no RD (e.g. Paxl) while there are other proteins that 
contain a paired-type RD and no PD (e.g. Phox protein) suggesting that these domains can 
function as autonomous DNA binding domains. Despite this, many studies indicate that when 
present in the same polypeptide chain the paired and paired-type RD can cooperate for DNA 
binding and function interdependently. 
Lack of functional independence between the PD and the RD was tirst observed with 
studies of the Prd prote in and segments of the even-skipped promoter sequence (Treisman et 
al., 1991). The even-skipped promoter sequence contains two elements that can bind the Prd 
protein. The e5 element consists of both a PD and RD recognition sites that overlap and that 
can be bound independently by the PD or the RD. Another element, e4, has paired and RD 
specific DNA sites that lie adjacent to one another. Recognition of e4 by the Prd protein 
requires binding of both domains simultaneously (Treisman et al., 1989). Other studies have 
also indicated that binding of the domains is cooperative. For instance, in vitro selection for 
DNA oligos with high affinity for the Prd protein from a pool ofrandom oligonucleotides has 
led to the discovery of the PRO probe. The PRO probe has a very high aftinity for the Prd 
prote in and contains both a PD and a RD recognition sequence and they are placed in 
juxtaposed fashion and have an inverted relative orientation (Figure 6) (Jun and Desplan, 
1996). 
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Figure 6 
Schematic representation of the Prd protein bound to the PHO and PTE sites that contain 
adjacent PD and HO recognition sites placed in an inverted relative orientation. The PTE site 
(Fujioka et al., 1996) from the even-skipped promoter and the in vitro selected PHO (Jun and 
Oesplan, 1996) sequences are aligned. 
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.. PHO GATCTCTTCAATTAGTCACGCTTGAGTG 
PTE, TTGATGGGCAATTAGCCTCGGTGAGTGG 
\ 
Studies in which the PD and RD are singly mutated or the spacing or orientation of the two 
sites are changed in the PRO sequence have shown that ail these alterations decrease the 
affinity ofthe Prd prote in for the probe by almost a hundred fold. This would indicate that the 
PD and RD cooperate when binding the PRO sequence (Jun and Desplan, 1996). These 
observations are also made when untethered PD and RDs ofPrd were used during the DNA 
binding assays, although tethering was observed to contribute slightly to the cooperativity 
between the PD and RD (Jun and Desplan, 1996). Importantly a PRO-like sequence was 
identified in the promoter region ofthe even-skipped gene, called PTE, that also contains PD 
and HD juxtaposed sites placed in an inverted fashion, which has been shown to regulate 
even-skipped gene expression by Prd (Fujioka et al, 1996). Renee, these studies suggest that 
the PO and HD can bind DNA simultaneously and with cooperativity and that this mode of 
ONA binding has biological relevance. 
Lack of phenotypic rescue by transgenic expression of either the PD or the RD of Prd 
individually in Prd-/- mutants indicates that both domains are required for proper Prd function 
(Bertuccioli et al., 1996; Miskiewicz et al., 1996). AIso, rescue attempts ofthe Prd-/- fly with 
Prd proteins with mutations only in the PD or only in the RD both faHed (Bertuccioli et al., 
1996; Miskiewicz et al., 1996). 
Similar observations have been made with the Pax3 protein; mutations in the PD 
disrupt PD as weil as HO function and mutations in the RD abrogate RD and PD DNA 
binding activity. The Sp-delayed mouse mutant allele contains a G42R mutation that 
abrogates PO DNA binding activity but also decreases the Pax3 HD affinity for the P2 probe 
significantly (Underhill et al., 1995). The DNA binding abilities ofmany PAX3 missense 
mutations that are associated with the human Waadenburg syndrome have also supported the 
functional dependence hypothesis of the PD and HD. Many of the missense mutations map ta 
the PAl (not RED) subdomain and abrogate the PD and affect the HD DNA binding activity 
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as weIl. WS PD mutations studied thus far compromise both PD and HD DNA binding 
activity (Fortin et al., 1997). Also, it was determined that the R53G Waardenburg Syndrome 
mutation in the HD abrogates both the HD as weil as the PD DNA binding activity (Fortin et 
al., 1997). 
Two specifie naturally occurring mutations in the Pax6 PD have been shown to 
severely affect the DNA binding activity of the HD. Interestingly the I87R mutation in the 
RED subdomain abrogates PD and HD DNA binding activity while the R26G PAl 
subdomain mutant has no PD DNA binding activity but has an elevated HD DNA binding and 
transactivation ability in comparison to PAX6 (Singh et al., 2000). This PAX6 study reveals 
that the two subdomains of the PD influence the function of the HO differently. 
In addition to influencing the ability of the HD to bind DNA, the PD has been shown 
to influence HD ONA sequence specificity. Full-iength constructs ofPax3 with a PD and HO 
are able to dimerize only on P2 sequences but when the Pax3 HD is expressed alone, 
dimerization is observed on both P2 as weil as the P3 sequences (Underhill and Gros, 1997). 
Hence, the presence of the PD in Pax3 prevents dimerization ofthe HD on the P3 probe and 
this effect can be transferred onto a heterologous HD. The paired-type HO ofthe Phox protein 
(Q50 HO) is able to dimerize on the P3 probe and monomerize on the P2 probe. Once the 
Phox HO is covalently Iinked to the PD of Pax3 it loses both P2 and P3 binding at both the 
monomer and dimer level (Underhill and Gros, 1997; Fortin et al., 1998). Overall, these 
findings indicate that the paired and HD functionally interact and influence each other's 
recognition of DNA. 
1.3.4 Biochemistry of the Octapeptide 
Ali members of the Pax family except Pax4 and Pax6 (as weIl as the Drosophila Prd) 
contain the octapeptide structural motif that is located in the linker sequence between the PD 
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and the HD. The exact position of the octapeptide within the linker is variable among 
different members ofthe Pax family. As with the PD, the octapeptide sequence identity is 
higher for members within the same subfamilies and the generally accepted consensus 
sequence for the octapeptide is (HIY)S(IN)(N/S)G(IIL)LG (Noll et al., 1993). Little is known 
about the biochemistry of the octapeptide but studies with the Pax2/5/8 subfamily suggest that 
it may have a role in transcription regulation by the Pax protein. More specifically, the 
deletion of the octapeptide in this subfamily resulted in an increase in transcriptional 
activation of Pax target genes by 2 to 3 fold as compared to the unaltered Pax protein 
(Eberhard et al., 2000; Lechner and Dressler, 1996). This possible transcription repressîon 
effect ofthe octapeptide may involve Pax association with co-repressor molecules of the 
Groucho family of proteins (Eberhard et al., 2000, Koop et al., 1996; Stifani et al., 1992). 
Studies with Pax5 and the Groucho family member prote in Grg4 show that the proteins 
interact and that this interaction results in transcription inhibition by the Pax5 C-terrninal 
transactivation domain. This repression requires interaction ofPax5 and Grg4 at two distinct 
locations in Pax5, one ofthem being the octapeptide (Eberhard et al., 2000). Therefore the 
octapeptide may serve a role in protein-protein interaction. Further studies are required to 
elucidate the exact role and mechanism of the octapeptide motif. 
1.3.5 Transcription Regulation by Pax Proteins 
The expression patterns of Pax proteins in the embryo as well as their 
homology to other known regulators of development suggest that Pax genes play a role in 
development (Noll, 1993; Chalepakis et al., 1993). The discovery of nuclear localization 
signais in the protein sequence as weil as the presence ofDNA binding domains supported the 
role of Pax proteins as transcription factors (Bopp et al., 1989; Chalepakis et al., 1991; 
Dressler and Douglas, 1992; Krauss et al., 1992; Walther et al., 1991). Transactivation studies 
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of constructs with Pax binding sites upstream of reporter genes have shown that Pax proteins 
activate transcription (Chalepakis et al., 1991; Chalepakis et al., 1994; Fujitani et al., 1999; 
Glaser et al., 1994; Kozmik et al., 1992; Lechner and Dressler, 1996; Schafer et al., 1994; 
Kozmik et al., 1993; Nomes et al., 1996). Studies done with Pax3, 6 and 9 proteins show a 
dose-dependent bell-shape transactivation response. At low concentrations these transcription 
factors activate transcription but as the concentration increases transcriptional activation does 
not plateau but actually begins to decrease (Chalepakis et al., 1994; Czerny and Busslinger, 
1995; Nomes et al., 1996; Vogan et al., 1996). Also, it has been shown that the transcription 
of certain target genes of Pax2, 4 and 5 is actually repressed fOllowing exposure to the se Pax 
proteins (Fuj itani et al., 1999; Nutt et al., 1998; Schwarcz et al., 2000; Smith et al., 1999). 
These observations suggest that Pax proteins may have both transcription activation as weil as 
repression capabilities. 
1.3.5.1 Repression and Activation Domains of Pax Proteins 
Studies have localized the transactivation domain to the C-termini of Pax proteins 
following both the PD and the IID. The homology of the DNA binding modules among Pax 
proteins is much higher than the homology found for the C-terminal transactivation domain 
(Walther et al., 1991). Despite this, the homology of the C-terminal of Pax proteins is 
sufficiently high to suggest that it holds a conserved function (Adams et al., 1992; Czerny and 
Busslinger, 1995; Dorfler and Busslinger, 1996; Glaser et al., 1992; Kozmik et al., 1993; 
Vorobyov et al., 1997). The C-terminal portion of Pax proteins does not share any homology 
with transactivation domains of other transcription factors but sequence analysis reveal.s that it 
is rich in proline, serine and threonine residues, a characteristic that is typical of 
transactivation domains (Chalepakis et al., 1991; Chalepakis et al., 1993). Deletion studies 
with Pax3IPax7 (Schafer et al., 1994; Chalepakis et al., 1994; Sheng et al., 1997), Pax6IPax4 
53 
(Fujitani et al., 1999; Glaser et al., 1994; Smith et al., 1999), Pax2lPax5lPax8 (Dorfler and 
Busslinger, 1996; Lechner and Dressler, 1996) and Pax9 (Nomes et al., 1996) have shown 
that Pax dependent transactivation requires the C-termini of the proteins, supporting the role 
of the C-terminus as a transcription activation domain. Many ofthese same studies have also 
demonstrated the existence of inhibitory domains in Pax proteins that repress transcription of 
target genes. For instance, Pax2, 4,5, 8 and 9 have C-terminal domains that contain adjacent 
inhibition and activation sequences (Dorfler and Busslinger, 1996; Fujitani et al., 1999; 
Nomes et al., 1996). As mentioned earlier, the octapeptide motifs of Pax2, 5 and 8 possess the 
ability to repress transcription (Eberhard et al., 2000; Lechner and Dressler, 1996), and the 
tirst 90 amino acids ofPax3 conta in transcription inhibitory sequences (Chalepakis et al., 
1994). It was observed that deletion ofthese inhibitory sequences leads to a noticeable rise in 
transactivation of Pax target genes. As was the case with the Pax5/Grg4 study, the inhibitory 
domains of Pax proteins generally do not function independently thereby suggesting that 
repression oftranscription by Pax proteins requires the use ofPax-specitic negative regulators 
(Dorfler and Busslinger, 1996; Eberhard et al., 2000). This discovery implies that the 
transcriptional effect of Pax proteins may be regulated by variations in the combinatorial and 
relative activity oftranscription activating and transcription inhibiting domains. 
1.3.5.2 Regulation of Pax Prote in Transactivation Activity 
The exact molecular mechanism of the regulation of transcription by Pax proteins is 
stilliargely unknown but many factors have been identitied that play a role in modulating the 
ability of Pax proteins to activate transcription. For instance, Pax 3, 5, 6 and 9 transcription 
activation abilities have been shown to be affected by the concentration of the protein 
(Chalepakis et al., 1994; Czerny and Busslinger, 1995; Vogan et al., 1996; Wallin et al., 
1998). As mentioned earlier the transcriptional response of the Pax3, 6 and 9 proteins is dose 
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dependent (Chalepakis et al., 1994; Czerny and Busslinger, 1995; Nomes et al., 1996; Vogan 
et al., 1996). In the case ofPax5, activating and inhibiting DNA sequence elements of certain 
promoters of target genes compete for Pax5 binding and consequently modulate the Pax5 
induced expression of the downstream gene. At 10w concentrations ofPax5 only high affinity 
activating DNA elements are bound by Pax5 and lead to optimal transcription ofthe 
downstream gene. At high Pax5 levels both high affinity activating sequences as weIl as low 
affinity inhibiting sequences are bound by Pax5 leading to less transcription ofthe target gene 
by the Pax5 protein (WaIIin et al., 1998). 
Another factor that influences the transcription activation abilities of Pax proteins is 
alternative splicing. For example, the Q+ and Q- Pax3 isoforms have different DNA binding 
affinity for type 1 sequences and transcription activation of genes downstream of type 1 
sequences differs between the two isoforms (Vogan et al., 1996). Similarly, different Pax6 
isoforms have different DNA binding specificity and transactivation activities (Epstein et al., 
1994). Pax6 isoforms induce the transcription of reporter genes to similar extents when the 
gene is fused upstream to a promoter sequence that contains either RED domain specific 
sequences (5aCON) or PAl and RED specifie Type 1 sequences (P6CON). The Pax(5a) 
isoform has DNA binding affinity for the 5aCON sequence on1y and is actually more efficient 
than Pax6 at inducing transcription from 5aCON DNA sequence containing promoters 
(Epstein et al., 1994). It has been observed that the Pax6(5a) isoform can squelch the 
transactivation ability ofPax6, implying that the relative concentration ofthese isoforms is 
another factor that modulates transcription activation ofPax6 specifie target genes (Czerny 
and Busslinger, 1995; Epstein et al., 1994). This possibility is validated by the fact that 
mutations in Pax6 that change the ratio of these two isoforms result in a unique phenotype 
(Epstein et al., 1994). Unlike Pax3 and 6, isoforms ofPax8 and 9 have been shown to have 
similar DNA binding specificity, but Iike Pax3 and Pax6 isoforms they differ in their ability to 
55 
activate downstream genes (Kozmik et al., 1993; Nomes et al., 1996). This differential 
transactivation ability ofPax8 and 9 isoforms is due to the alternative splicing (shifts in 
reading frame and exon skipping) that results in different C-terminal sequences (Kozmik et 
al., 1993; Nomes et al., 1996). Altogether, these studies suggest that alternative splicing can 
create functional diversity and can also lead to the modulation of target gene transcription. 
1.3.6 Interactions of Pax Proteins with other Transcription Factors 
Many Pax interacting proteins have been identified with the use ofyeast-two-hybrid 
screening and have been characterized as transcriptional co-repressors of Pax target genes 
(Eberhard et al., 2000; Hollenbach et al., 1999; Magnaghi et al., 1998). As was mentioned 
earlier, a known interacting protein ofPax5 that acts as a co-repressor of transcription ~s the 
Groucho Grg4 protein. Other members of the Groucho family can also repress Pax5 mediated 
transactivation (Eberhard et al., 2000). Groucho proteins are known co-repressors of 
transcription that are able to bind to the N-terminal tails of histones and interact with histone 
deacetylases, presumably to activate deacetylation of histones and encourage DNA packing 
and condensation which makes DNA less available for transcription (Chen et al., 1999; Choi 
et al., 1999; Fischer and Caudy, 1998; Parkhurst, 1998). The Pax5/Grg4 complex is a result of 
the interaction of the transactivation domain and octapeptide motif of Pax5 with the glutamine 
rich and serine-proline rich domains of Grg4 (Eberhard et al., 2000). Interaction of Grg4 and 
Groucho with Pax2 and Pax8 also leads to transcription inhibition (Eberhard et al., 2000). 
Pax3 is also known to interact with co-repressors. In vitro studies have shown that 
Pax3 interacts with HIRA, a homolog of the Saccharomyces cerevisiae co-repressor proteins 
Hirlp and Hir2p, that are involved in regulating the cell-cycle dependent transcription of 
histone genes (Magnaghi et al., 1998; Spector et al., 1997). This interaction involves the HD 
ofPax3 and the 2 contiguous domains in the C-terminus ofHIRA (Magnaghi et al., 1998). 
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The suspected role ofHIRA as a co-repressor ofPax3 target genes remains to be shown but 
evidence does exist that the se proteins may interact in vivo. HIRA and Pax3 are both 
expressed in neural crest cell explants and have overlapping expression in the developing 
neuroepithelium and its derived neural crest (Magnaghi et al., 1998). Another protein detected 
via yeast-two-hybrid screening with Pax3 as bait is hDaxx (Hollenbach et al., 1999). The 
interaction requires the proline-serine-threonine rich C-terminal sequence of hDaxx with the 
inter-domain linker (including the octapeptide) and HD ofPax3 (Hollenbach et al., 1999). 
Many reasons suggest that hDaxx may behave as a co-repressor of Pax3 target genes. The 
hDaxx prote in is a nuclear prote in, like Pax3, and has 2 short regions that share homology 
with the co-repressor Sin3 prote in (Hollenbach et al., 1999; Kiriakidou et al., 1997). The 
fusion protein that consists of the hDaxx protein linked to the DNA binding domain ofGAL4, 
represses transcription of a constitutively active gene when the protein is DNA bound. This 
supports a role ofhDaxx as a repressor oftranscription (Hollenbach et al., 1999). Also, 
incubation ofPax3 prote in with increasing amounts ofhDaxx leads to progressive inhibition 
of Pax3 mediated transcriptional activation (Hollenbach et al., 1999). 
Pax proteins may also interact with co-activators to enhance transcription. Pro- . 
glucagon gene expression in pancreatic a cells can be induced by promoter binding ofPax6 or 
cdx2 (a HD protein) individually (Hussain and Habener, 1999). When both Pax6 and cdx2 are 
expressed in this cell type, a heterodimer forms that synergistically activates the pro-glucagon 
gene (Anderson et al., 1999; Hussain and Habener, 1999; Ritz-Laser et al., 1999). This 
synergism is further enhanced when the dimer forms a complex on DNA with the co-activator 
p300 prote in (Hussain and Habener, 1999). Pax6 and cdx2 can interact individually with 
p300, but Pax6/p300 complex formation is enhanced when cdx2 is present (Hus sain and 
Habener, 1999). RecentJy, the PDZ-binding motif containing T AZ protein was identified in a 
yeast two-hybrid screen with Pax3 as bait (Murakami et al., 2006). T AZ and Pax3 expression 
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partially overlap in the embryo and in vitro assays have indicated that T AZ can enhance the 
transcriptional activity ofPax3 on the Mitfpromoter (Murakami et al., 2006). These results 
suggest that TAZ is a bona fide co-activator that promotes expression of Pax3 target genes. 
Interaction of transcription factors with components ofthe basal transcription . 
machinery is yet another mechanism used by transcription factors to modulate transcription 
efficiently. For example, Pax3, 5 and 6 interact with the TBP (TATA-binding prote in) 
component of the basal transcription machinery (Cvekl et al., 1999; Eberhard and Busslinger, 
1999). This interaction has been shown with GST pull-down assays and with co-
immunoprecipitation of endogenous proteins in certain cell-lines and tissues (Cvekl et al., 
1999; Eberhard and Busslinger, 1999). This interaction is mediated by the N-terminal portion 
of the HO suggesting that the partial HO in Pax5 is a protein-protein interaction motif 
(Eberhard and Busslinger, 1999). Other studies have indicated that many other HD containing 
proteins interact with TBP (Zhang et al., 1996; Cvelk et al., 1999; Eberhard and Busslinger, 
1999; Um et al., 1995; Zwilling et al., 1994). The TBP shares sequence homology with the 
prote in-prote in interaction pocket domain of the pRB (retinoblastoma protein), that is required 
for pRB interaction with transcription factors. Consequently TBP and pRB frequently bind to 
the same transcription factors (Hagemeier et al., 1993; Hagemeier et al., 1993; Hateboer et al., 
1993). Pax3 5 and 6 can bind the pocket domain of the activated underphosphorylated form of 
pRB (Cvekl et al., 1999; Eberhard and Busslinger, 1999; Wiggin et al., 1998). Reporter assays 
with Pax3 have shown that this interaction inhibits transcriptional activation (Wiggin et al., 
1998). No c1ear role for these interactions in vivo has been determined as yet, we can only 
speculate that the interaction of Pax proteins with TBP and pRB may modulate the 
transactivation abilities of Pax proteins. Pax3 downregulation is a pre-requisite to terminal 
differentiation of neuronal progenitor cells (Reeves et al., 1998) and pRB is known to also 
promote terminal differentiation by inhibiting progression through the cell cycle (Weinberg, 
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1995). One may speculate that the pRB may promote neuronal differentiation by repressing 
the activity of Pax3, altematively, Pax3 may inhibit pRB to prevent neural differentiation. It is 
interesting to note that the CD 19 promoter contains no TATA box and therefore cannot 
recruit TBP on its own but instead has a Pax5 binding site in the -30 region (Kozmik et al., 
1992). Aiso note that the transcription of the CD19 gene has been shown to have a strict 
requirement for Pax5 (Kozmik et al., 1992). Perhaps the role of the interaction between TBP 
and Pax5 is to recruit TBP to the promoter ofCD19 in order to establish the basal 
transcriptional machinery. 
Pax3 transactivation activity can also be regulated via functional antagonism. Pax3 
and the HD containing Msxl proteins are co-expressed in migrating myoblasts that have 
delaminated from the somite and are headed toward the Iimb bud in order to develop the limb 
musculature (Bendall et al., 1999). Expression ofPax3 in these cells commits them to the 
myogenic lineage and prolonged expression will eventually lead to terminal differentiation 
into myotubes by activating the expression of myogenic regulatory factors such as MyoD 
(Bendall et al., 1999). Msxl expression is necessary for maintaining the committed myoblasts 
in an undifferentiated state during migration in order for the cells to reach and populate the 
limb bud and subsequently give rise to Iimb musculature (Bendall et al., 1999). When Pax3 
binds the PD DNA binding site in the MyoD promoter sequence a mild activation of MyoD 
occurs (Bendall et al., 1999). Msxl expression results in strong repression of MyoD 
expression. In vitro studies have shown that the PD ofPax3 and the N-terminal arm ofthe HD 
ofMsxl interact to form a Pax3:Msxl complex and inhibit Pax3 DNA binding activity on the 
MyoD promoter sequence (Bendall et al., 1999). Therefore the Pax3 and Msxl physical 
interaction mediates the functional antagonism ofthese proteins on MyoD expression and on 
terminal differentiation ofmyoblasts. Also, Pax5 and PU.l can reciprocally inhibit their 
transactivation abilities when they physically interact on enhancer sequences of Pax5 or PU.l 
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target genes such as Igk (Maitra and Atchison, 2000). Altogether, these studies confinn that 
Pax proteins can use functional antagonism as a means to modulate their activity and that this 
antagonism is possible via intennolecular interactions of Pax proteins with other proteins. 
Knockdown experiments in Xenopus have shown that Msx 1 and Pax3 are also both required 
for proper neural crest fonnation (Monsoro-Burq et al., 2005). Perhaps a similar functional 
antagonism mechanism is at play between Msxl and Pax3 during the development of neural 
crest cell derivatives. 
In contrast to functional antagonism there are examples in the literature of the 
formation ofcomplexes between Pax and other proteins that encourages the function of Pax 
as an activator of transcription. For instance, Pax5 is known to cooperate with several 
different members of the Ets family to activate the promoter ofthe mb-l gene (Fitzsimmons 
et al., 1996; Wheat et al., 1999). Examples ofEts proteins that can be recruited by Pax5 to the 
mb-l promoter include the GABPaJ~ heterodimer, Fli-l and c-Ets-l. The mb-l gene is. 
expressed in maturing B cells and encodes the Iga chain which is involved in intracellular 
signaling of the B cell receptor complex (Hagman et al., 2000). The mb-l promoter holds a 
Pax5 recognition site adjacent to a sub-optimal Ets binding site. Pax5 is able to bind the 
promoter on its own but Ets proteins are unable to bind the sub-optimal DNA site unless they 
are recruited by Pax5 to fonn a temary complex. Both the Pax5 and Ets DNA binding sites 
are required for temary complex formation since mutation in either DNA binding site reduces 
mb-l expression (Fitzsimmons et al., 1996). The Ets factors contain a winged helix-tum-helix 
DNA binding domain that consists of four a helices and a ~-sheet fonned by four anti-parallel 
~-strands. The third helix behaves as a recognition helix and makes base specific contacts in 
the major groove of DNA to recognize the core GGAAIT motif (Sharrocks et al., 1997). 
Recruitment by Pax5 requires a critical aspartic acid residue immediately C-tenninal to the 
recognition helix ofEts (Fitzsimmons et al., 1996). Modeling studies and X-ray 
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crystallography studies have confirmed that the Pax5IEts ternary complex on the comp?site 
site of mb-l is mediated by a salt bridge formed between the glutamine residue in the p-
hairpin with the critical aspartic acid of the Ets domain (Wheat et al., 1999; Garvie et al., 
2001). Both the p-hairpin and helix 2 ofthe PD ofPax5 make contacts with Ets when 
recruitment occurs. This suggests a possible role for these structures in Pax proteins as 
protein-protein interaction segments. Thus studies of the Pax3IMsxl and the Pax5IEts 
complexes indicate that physical interactions with other proteins may lead to either functional 
antagonism or functional cooperation. 
1.4 Target Genes of Pax Proteins 
Both biochemical and genetic experiments have revealed that Pax proteins largely 
function as regulators of transcription of downstream targets at various times during 
development. The identification oftarget genes of Pax proteins has proven difficult but 
several have been discovered through phenotypic analysis of Pax mutants. The discovery of 
Pax target genes was facilitated once DNA recognition sequences were defmed for both the 
PD and HO. Proteins with temporal and spatial expression patterns as weil as mutant 
phenotypes similar to those seen with Pax proteins have been identified as possible target 
genes of the Pax family. In sorne cases, a direct regulatory relationship was discovered· 
between Pax and candidate target genes by the identification of Pax responsive elements in 
the promoter or enhancer sequences. Further confirmation of Pax regulation of candidate 
target genes was possible with the observation that the expression of such genes was altered in 
mice deficient in corresponding Pax genes. This approach was used to determine many targets 
of Pax proteins, and includes genes that encode for ceII-adhesion molecules, signal 
transduction molecules, transcription factors and protein products specifie to certain 
terminally differentiated cells. Only an overview ofPax3 target genes will follow. 
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1.4.1 Target Genes and Biological Pathways of Pax3 in Neurogenesis 
Few Pax3 target genes involved in neural tube formation have been discovered to date. 
The genes that are suspected to be transcriptionally regulated by Pax3 in the neural tube are 
not activated but inhibited by Pax3. One possible gene that may be regulated by Pax3 in the 
developing neural tube is Engrailed-l (En-l), a homeobox containing transcription factor that 
shares homology with the Drosophila engrailed protein (Joyner et al., 1985; Davis et al., 
1988). Like members of the Pax2/5/8 subfamily, En-l plays a role in defining the mid-
hindbrain boundary and is expressed in cells bordering this junction (Song et al., 1996). It has 
been observed that in the Pax3IPax7 double knock out, En-l expression is expanded dorsally 
in the neural tube thereby suggesting that Pax3 may inhibit En-l transcription in the dorsal 
neural tube where Pax3 is expressed (Mansouri and Gruss, 1998). One can speculate that the 
mechanism ofthis inhibition may involve the binding ofPax3 to the promoter ofEn-1 which 
may disrupt the assembly and/or function of the transcriptional machinery. This possibility is 
supported by the fact that two putative Pax binding sites have been identified in the enhancer 
sequence of the En-l gene (Song et al., 1996). Pax3 may regulate En-l in order to promote 
proper dorsal-ventral patteming of the neural tube. 
Cross-regulation between Pax3 and Pax7 may be possible in the developing neural 
tube, more specifically Pax7 expression may be negatively regulated by Pax3 (Borycki et al., 
1999). Both Pax3 and Pax7 are expressed in the dorsal neural tube throughout the anterior-
posterior axis but differ slightly in their exact temporal and spatial expression patterns 
(Goulding et al., 1991; Jostes et al., 1990; Stoykova and Gruss, 1994). Pax3 is expressed in 
the dorsal half of the neural tube and expression is initiated prior to closure, white Pax7 
expression occurs in a smaller area of the dorsal neural tube and only following neural tube 
c10sure (Goulding et al., 1991; Jostes et al., 1990; Stoykova and Gruss, 1994). This hypothesis 
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is supported by the observation that in Splotch mice Pax7 expression is up regulated in the 
neural tube and its expression domain is also expanded to include areas in the dorsal tube 
where only Pax3 is normally expressed. AIso, transfection ofPax3 into C2C12 cells decreases 
the levels ofendogenous Pax7 (Borycki et al., 1999). The relevance ofPax7 repression by 
Pax3 during neural tube formation is unknown but may have to do with proper timing of 
neural tube closure. 
1.4.2 Target Genes and Biological Pathways ofPax3 in Myogenesis 
A target gene of Pax3 involved in myogenesis is the Met receptor tyrosine kinase 
signaling protein (Daston et al., 1996; Epstein et al., 1996; Yang et al, 1996). Late in 
development, Met expression occurs in a wide variety of embryonic tissues (Sonnenberg et 
al., 1993) but during early development the prote in is expressed in two distinct populations in 
the developing somite: the ventrolateral and dorsomedially portions ofthe dermo-myotome 
(Bladt et al., 1995; Yang et al., 1996). During early development sorne Met expressing 
myoblasts in the somite delaminate from the ventrolateral portions ofthe somites and migrate 
into the developing limb buds. Upon arrivai to the limb bud, terminal differentiation of the 
myoblasts into myotubes occurs and myogenic differentiation markers are expressed (Epstein 
et al., 1996; Yang et al., 1996). The expression domain of Met overlaps with that of Pax3. 
Pax3 is also expressed in the somite-derived myoblasts prior to and during migration to the 
limb bud to give rise to form limb musculature. Pax3 is actually used as a marker for 
migrating myoblasts (Bober et al., 1994; Williams and Ordahl, 1994; Goulding et al., 1994). 
Also, complete loss-offunction of Met or Pax3 results in very similar mutant phenotypes. 
Both Met-/- and Pax3-/- embryos develop myoblasts with an inability to migrate into the limb 
bud and this leads to the formation of embryos with no limb muscles (Bober et al., 1994; 
Goulding et al., 1994; Bladt et al., 1995). Another observation that indicates that Met is a 
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Pax3 target gene is the observation that Sp/Sp mice have no detectable levels of the Met 
transcript in the ventrolateral somites (Daston et al., 1996; Epstein et al., 1996; Yang et al., 
1996). Promoter studies with Met have led to the identification of a Pax binding site that has 
affinity for Pax3 as shown by electrophoretic mobility assays (Epstein et al., 1996). The 
ability of this site to mediate Pax3 dependent transcription activation is still to be determined 
either in cell culture and/or in the developing embryo. Hence, overlapping expression 
domains, similar loss-of-function phenotypes and the presence of a Pax binding site in the 
promoter sequence of Met indicate that Pax3 regulates expression of Met in migrating limb 
muscle precursor cells. 
Evidence has surfaced which implicates the Dach2, Sixl, Eya2 and Pax3 proteins as 
members of a molecular pathway that is involved in regulation of myogenesis (Heanue et al., 
1999). It has been found that these four proteins have overlapping expression domains in the 
dorsal somite as weIl as in hypaxial myoblast precursors (Heanue et al., 1999). Pax3 and 
Dach2 must positively regulate each other's expression since overexpression of any one of 
these genes leads to the overexpression of the other. Eya2 is able to synergistically activate 
transcription oftarget genes with Sixl or Dach2. Ectopic expression or over expression of 
Eya2 with Dach2, or Sixl in somites leads to a synergistic increase in expression ofPax3 and 
the myogenie specifie genes MyoD, Myogenin and MHC (Myosin heavy chain) (Heanue et 
al., 1999). It remains to be determined whether these myogenic specific genes are direct 
transcriptional targets of the Pax-Eya-Six-Dach pathway, but it has been demonstrated that 
Eya and Six have binding activity at the Myogenin promoter. In addition, it has been shown 
that their binding leads to synergistic activation of Myogenin (Spitz et al., 1998; Ohto et al., 
1999). 
Pax3 is a member of another pathway that is involved in myogenesis and includes the 
basic helix-Ioop-helix myogenic regulatory factors Myf5 and MyoD. Pax3 was implicated in 
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this pathway as a result of misexpression experiments and the analysis of mutant phenotypes 
that result when there is a loss of either of these genes individually or in pairs. Mice with 
either the MyoD or Myf5 genes knocked out show normal development of skeletal muscles 
but the loss ofboth genes results in no myogenesis of skeletal muscles. These observations 
suggest that MyoD and Myf5 either cooperate during muscle formation or have redundant 
functions (Rudnicki et al., 1993). Pax3 Sp/Sp mice lack limb muscles but Pax3/Myf5 double 
knock out mice develop no body muscles and lack MyoD expression, hence the se two genes 
lie genetically upstream from the MyoD gene (Tajbakhsh et al., 1997). The upstream position 
of Pax3 relative to MyoD was also suggested with Pax3 ectopic expression studies. Ectopic 
expression of Pax3 leads to a rise in MyoD expression. Also, Pax3 expression in cell cultures 
induces the expression of reporter genes with MyoD regulatory elements fused upstream. This 
implies that MyoD may be a direct target gene ofPax3 (Bendall et al., 1999; Maroto et al., 
1997). Although the hierarchical relationship between Pax3, Myf5 and MyoD has been 
established, further studies need to be carried to assess the molecular basis of the pathway in 
myogenesis. The different effects ofthe removal of the se three genes on normal development 
of distinct myogenic lineages (head muscles and hypaxial and epaxial muscles) imply that the 
regulatory interactions between these genes are complex and may require the involvement of 
lineage specific proteins. 
1.4.3 Target Genes and Biological Pathways ofPax3 in Melanogenesis 
Pax3, along with Mitf and SoxlO, is implicated in a pathway required for proper 
melanocyte development. AlI three genes have overlapping expression in melanoblasts and 
have similar phenotypes in heterozygote mutants. Human heterozygotes for loss-of-function 
mutations in any ofthese three genes have Waardenburg syndrome, albeit with different 
c1inical subtypes depending on which ofthe genes are mutated (Baldwin et al., 1992; Pingault 
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et al., 1998; Tassabehji et al., 1994). AIl subtypes result in auditory and pigmentary defects. 
Therefore defects in these genes must disturb melanogenesis and therefore pigmentation, but 
the requirement for melanocytes in inner ear development is unknown. What is known is that 
melanocytes contribute to the cochlea and their absence is the cause of sensorineural deafness 
in Waardenburg syndrome (Auerbach, 1954; Hodgkinson et al., 1993; Southard-Smith et al., 
1998; Steingrimsson et al., 1994). Mitfhomozygote mutants are viable albinos that suffer 
from microphtalmia (small eye phenotype) (Baldwin et al., 1992; Pingault et al., 1998; 
Tassabehji et al., 1994). Mitf, a basic helix-Ioop-helix zipper transcription factor, regulates the 
expression of dopachrome tautomerase, tyrosinase and tyrosinase-related protein-l (Trp-l), 
which encode proteins essential for the synthesis of melanin from tryptophan and tyrosine 
amino acids. This observation provides a molecular basis for the pigmentation defects 
observed in Mitfheterozygote mutants (Bertolotto et al., 1998; Yasumoto et al., 1997). AIso, 
ectopie Mitf expression in fibroblasts changes these cells into melanocytes and therefore Mitf 
seems to be critical for the initiation of melanogenesis pro gram during development 
(Tachibana et al., 1996). Pax3 involvement in melanogenesis is also supported by the 
discovery that Pax3 can transactivate both the Mitf and Trp-l genes (Galibert et al., 1999; 
Watanabe et al., 1998). AIso, Dopachrome tautomerase, an enzyme involved in melanin 
synthesis, is regulated directly or synergistically by Pax3 and Mitf (Jiao et al., 2006). The Mitf 
promoter can be bound and regulated by the SoxlO prote in, but when Pax3 and SoxlO bind 
Mitf gene regulatory elements synergistic activation results (Bondurand et al., 2000; Potterf et 
al., 2000; Verastegui et al., 2000; Watanbe et al., 1998). A recent study in transgenic mice 
showed that during melanogenesis, Pax3 is essential for the proliferation of committed 
melanoblasts whereas Mitf ensures melanoblast cell survival within and immediately 
following emigration from the dorsal neural tube (Homyak et al, 2001). Pax3 simultaneously 
functions to initiate a melanogenic cascade in specific neural crest cells while acting 
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downstream to prevent terminal differentiation by competing with Mitf and Sox 10 for 
occupancy of an enhancer required for expression ofthe mature melanocyte specific 
dopachrome tautomerase (Dct), an enzyme required in melanin synthesis (Lang et al, 2005). 
Pax3 mediated repression ofDct and competition with Mitffor binding to the Dct proIl).oter is 
carried out with Grg4, a prote in known to bind Pax proteins and to function as a co-repressor 
(Lang et al., 2005). This is presumably to permit the increase melanoblast cell number prior to 
differentiation into melanocytes. These studies suggest that there is a hierarchy among the 
Pax3, Mitf and Sox 10 transcription factors during melanogenesis and this accounts for the 
pigmentary disturbances associated with the Waardenburg syndrome. It is interesting to note 
that Pax3 regulation elements can be found in the Mitf promoter and contain PD and HD 
binding DNA sequences (Corry et al., 2005). The Trp-l promoter contains only a PD binding 
site (Corry et al., 2005). This suggests that Pax3 can regulate target genes through altemate 
modes ofDNA recognition. The role ofPax3 in melanogenesis is also supported by the 
observation that PAX3 re-expression is consistently observed in cutaneous malignant 
melanoma (CMM) and appears linked to progression ofCMM (Blake et al., 2005). 
Hair graying is an evident indication of aging, but not much is known about its causes. 
Recent papers have revealed evidence that hair graying is a result of incomplete melanocyte 
stem cell maintenance and inducate that Pax3 and Mitf are key molecules that help regulate 
the balance between melanocyte stem cell maintenance and differentiation and play a role in 
hair graying (Steingrimsson et al., 2005). 
Interestingly, Pax3 also commits somitic cells to the myogenic lineage, but unlike in 
melanogenesis, Pax3 is also able to initiate myogenic differentiation by inducing the 
expression of myogenic regulatory factors such as MyoD (Bendall et al., 1999). As mentioned 
earlier Pax3-controlled myoblast differentiation is actually inhibited by Msxl in migrating 
limb muscle precursors in order to sustain the proliferative and migratory capacity of the 
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migrating myoblasts until they reach and populate the limb bud (Bendall et al., 1999). In other 
words, Pax3 commits sorne neural crest cells to the melanogenesis pathway and 
simultaneously inhibits their differentiation to maintain their proliferative state, while Pax3 
expression in myoblasts commits cells to the myogenic lineage and induces differentiation as 
weil. These findings confirm the role of Pax3 in cell commitment and cell differentiation, 
although, for differentiation it may serve to activate or inhibit it. 
1.4.4 Target Genes and Biological Pathways ofPax3 in Heart Formation 
The role of Pax3 in heart formation was first identified when it was determined that 
Sp/Sp mice die in mid-gestation due to heart failure (Conway et al., 1997; Franz, 1989). Upon 
cIoser inspection it was found that septation of the outflow tract of the developing heart did 
not occur in these mice. This condition is known as persistent truncus arteriosus and is 
characterized by the lack of septation between the pulmonary artery and the aorta. In wildtype 
mice Pax3 is expressed in a subset of neural crest cells known as cardiac neural crest cells that 
migrate to the developing heart. Upon arrivaI to the heart these cells populate within the 
outflow tract and lead to the formation of the pulmonary artery/aorta septum. It was found 
that in Sp/Sp mice there is an elevated level of expression of the Msx2 gene in cardiac neural 
crest cells (Kwang et al., 2002). When Msx2 was knocked out in Sp/Sp mice cardiac neural 
crest cells were able to septate the outflow tract. AIso, a 560 base pair element was identified 
upstream of the Msx2 gene that had affinity for Pax3 in vitro (Kwang et al., 2002). These 
observations indicate that perhaps Pax3 binds to an Msx2 regulatory sequence and represses 
Msx2 expression which, for still unknown reasons, is required for proper function of cardiac 
neural crest cells and septation of the outflow tract. 
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1.5 Pax3 and Tumorigenesis 
Typical characteristics of tumor or cancerous cells are uncontrolled proliferation, 
resistance to terminal differentiation and cell immortality; in contrast, normal cells proliferate 
in a pre-programmed controlled manner. In order to support the quick processes of 
organogenesis and growth, many developmental genes, inc1uding the Pax genes, serve to 
maintain the proliferative, undifferentiated and anti-apoptotic potential of embryonic ceUs. 
Henee, the de-regulation of developmental control genes is frequently associated with 
tumorigenesis. 
The ehromosomal translocation between human chromosome 13 (FKHD gene 
containing locus, 13qI4) and chromosome 2 (PAX3 gene containing locus 2q35) results in a 
pediatrie tumor known as alveolar rhabdomyosarcoma (ARMS) (Barr et al., 1999). This 
translocation fuses the N-terminus of the PAX3 gene with the C-terminus of the Forkhead 
related (FKHR) gene (Barr et al., 1993; Davis et al., 1994). The resulting fusion prote in 
eonsists of the PD and HD ofPax3 fused to the transctivation domain ofFKHR (Davis et al., 
1994; Galili et al., 1993; Shapiro et al., 1993). The structural nature of the fusion protein 
suggests that the molecular basis for ARMS is misexpression of PAX3 target genes. The 
transaetivation ability of the PAX3-FKHR fusion protein is greater than that ofPAX3 despite 
the fact that the chimeric protein binds P AX3 specific DNA sequences with lower affinity 
(Bennicelli et al., 1995; Fredericks et al., 1995; Sublett et al., 1995). The gain in 
transactivation ability ofthe fusion prote in is due to a weakened susceptibility to the N-
terminal repression domain ofPAX3. The PAX3 and FKHR proteins have transactivation 
domains of similar potency but the P AX3 and P AX3-FKHR proteins do not. This implies that 
the transactivation domains are modulated differently and it may be possible that they are 
differentially regulated by the N-terminal repression domain of Pax3 (Bennicelli et al., 1996). 
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Deletion of the PAX3 repression domain in PAX3 and PAX3-FKHR proteins results in the 
relief of transcriptional repression in both proteins, but the fusion protein only experiences ten 
to one hundred folds less relief from repression (Bennicelli et al., 1996). This suggests that the 
repression domain is able to inhibit transcriptional activity ofPAX3 more efficiently than that 
of the fusion protein, thereby possibly accounting for the more potent transcriptional activity 
observed for the fusion protein. Microarray studies have recently shown that PAX3-FKHR 
expression in ARMS tumors display an expression profile that is different from PAX3 
expressing cells (Davicioni et al., 2006). The Met receptor, a transcriptional target of Pax3, 
has a role in PAX3-FKHR-mediated transformation (Taulli et al., 2006). AIso, PAX3-FKHR 
induced expression in C2C12 cells promotes proliferation whilst blocking myogenesis (Wang 
et al., 2005). This is in line with the beliefthat PAX3-FKHR retains cells in a proliferative 
state by inhibiting terminal differentiation. Terminal differentiation in these cells has been 
shown to be a result ofrepression of MyoD and myogenin expression (Wang et al., 2005). 
The chimeric protein has many oncogenic effects including a potent transformation 
activity. This activity requires the HD ofPAX3 and the transactivation domain ofFKHR 
(Lam et al., 1999; Scheidler et al., 1996; Xia et al., 2004). PAX3-FKHR prote in is also a more 
potent inhibitor ofmyogenic differentiation than PAX3, as shown in C2C12 myoblasts 
(Epstein et al., 1995). Like PAX3, the fusion protein is able to induce the expression ofmany 
muscle related genes, in agreement with the muscle characteristics of ARMS (Khan et al., 
1999). Sorne studies have also shown that, like PAX3, the fusion protein has anti-apoptotic 
activity which is presumably the cause oftumor cell survival. ARMS cells express high levels 
of PAX3 protein as weIl as the fusion protein (Bernasconi et al., 1996; Schafer et al., 1994). 
RNAi mediated depletion of P AX3 expression in ARMS tumor cells results in reduced cell 
viability and ectopic expression of PAX3 can prevent apoptosis. This implies that an elevated 
level ofPAX3 expression is required for the survival oftumor cells (Bemasconi et al., 1996; 
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Margue et al., 2000). Supporting this hypothesis is the finding that both PAX3 and the fusion 
protein can bind the promoter and activate the expression of the anti-apoptotic BCL-XL gene 
(Margue et al., 2000). Perhaps the anti-apoptotic activity ofPAX3 and PAX3-FKHR is 
mediated via the activation of this gene. RNAi studies, in which the expression of wildtype 
PAX3 in the somites of a normal embryo is repressed, have shown that these cells experience 
an increased frequency of apoptosis, which implies that the cell-survival, anti-apoptotic 
function ofPax3 is not specific to tumor cells (Borycki et al., 1999). 
Tumors have evolved numerous mechanisms for evading the immune system; this is 
also the case with the PAX3-FKHR oncoprotein. PAX3-FKHR alters expression ofgenes that 
are normally regulated by the Janus kinase/signal transducer and activator of transcription 
(ST AT) signaling pathways (Nabarro et al., 2005). This occurs as a result of a specific 
interaction between PAX3-FKHR and the ST AT3 transcription factor, which results in a 
dramatic reduction in tumor MHC expression and an alteration in cytokine concentrations to 
inhibit surrounding inflammatory cells and immune detection (Nabarro et al., 2005). . 
71 
Chapter 2 
Site-Specifie Modification of Single Cysteine Pax 3 Mutants Reveals Reciprocal Regulation 
ofDNA Binding Activity of the Paired and Homeodomain 
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Abstract 
The mechanism by which the paired domain (PD) and the homeodomain (HD) act together in 
the intact Pax3 protein to recognize DNA is unclear and was studied in a Pax3 mutant (Pax3-
CL) devoid of cysteines. Pax3-CL binds to PD (P6CON-P30PT sites) and RD (P2, P1I2 sites) 
ONA site sequences with near wild-type aetivity but, contrary to Pax3, in an N-ethyl 
maleimide (NEM) insensitive fashion. The Pax3-CL baekbone was used for cysteine seanning 
mutagenesis and for site-specific NEM modification. Five single cysteine replacements were 
independently introdueed in the PO, while eight were inserted in the HO. NEM sensitivity of 
PD and HO ONA binding was investigated in ONA-binding competent mutants. In the PO 
mutant C82, NEM abrogated ONA binding by the PD but also abolished ONA binding by the 
Cys-Iess HO. Likewise, in the HO mutant V263C, NEM modification abrogated DNA 
binding not only by the HO, but also by the Cys-less PO. The transfer ofNEM sensitivity to 
the PD seen in V263C was specifie and not due to simple loss of HO ONA binding since 
alkylation of adjacent V265C and S268C, although impairing RD ONA binding did not affect 
PD ONA binding. Thus, the PO and HO do not function as independent DNA binding 
modules in Pax3 but seem funetionally interdependent. 
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Introduction 
Pax-3 is a member of the mammalian Pax family (Stuart et al., 1994), a group o.fnine 
DNA-binding transcription factors structurally defined by a highly conserved DNA binding 
domain known as the PD, which was initially identified in the paired segmentation gene of 
Drosophila (Bopp et al., 1986). Pax proteins play a key role in directing tissue patterning and 
development of different organs during embryogenesis (Dahl et al., 1997), and mutations in 
Pax genes impair normal development of the skeleton (Paxl), kidney (Pax2), eye (Pax6), 
pancreas (Pax4), and thyroid (Pax8) (Balling et al., 1988; Sanyanusin et al., 1995; Torres et 
al., 1995; Jordan et al., 1992; Glaser et al., 1992; Hill et al., 1991; Sosa-Pineda et al., 1997; 
Mansouri et al., 1998; Macchia et al., 1998). Pax3 is expressed in the developing neural tube, 
in neural crest cell derivatives, and in migrating limb muscle precursor cells (Bober et al., 
1994; Goulding et al., 1991), and a naturally occurring mutation in mouse Pax3 (splotch) 
causes profound defects in neurogenesis (spina bifida and exencephaly) and myogenesis (no 
limb musculature) (Bober et al., 1994; Beechey et al., 1986; Auerbach et al., 1954; Franz et 
al., 1990; Franz et al., 1989; Goulding et al., 1994). Likewise, mutations in human P AX3 
cause Waardenburg syndrome, a pathology associated with pigmentary disturbances, cranio-
facial abnormalities, and sensorineuronal deafness (Baldwin et al., 1992; Baldwin et al., 
1995). It has been proposed that Pax3 plays a dual role in neurogenesis and myogenesis via 
transcriptional regulation of specific targets genes and by maintaining replicative potential of 
specifie, Pax3 positive, epithelial, and migratory cell populations (Dahl et al., 1997). 
Pax proteins show a modular structure. In addition to the PD, certain Pax proteins 
possess a second DNA binding domain, the paired-type HD (Stuart et al., 1994; Noll et al., 
1993). A highly conserved octapeptide motif is also found in certain Pax proteins in the linker 
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separating the PD from the HD. Finally, the C-terminal half of Pax proteins shows a P/srr 
domain resembling transactivating domains of other transcription factors. A high-resolution 
three-dimensional structure has been obtained for the PD-DNA complex ofPrd and Pax6 and 
shows this domain to be bipartite (Xu et al., 1995; Xu et al., 1999) with N-terminal (PAl) and 
C-terminal subdomains (RED) each folding into three ~helices, with the last two forming a 
helix-turn-helix (HTH) DNA binding motif. In the PAl subdomain, a unique ~-hairpin 
structure, consisting of 2 antiparallel ~-strands joined by a type 1 ~-turn, contacts the sugar-
phosphate backbone to help anchor the subdomain to DNA. PAl ho Ids a type II ~-turn lying 
immediately C-terminal to the hairpin and makes base specifie contacts with the minor 
groove. Helix 3 of PAl fits directly into the major groove and participates in base specifie 
contacts with DNA (Xu et al., 1995; Xu et al., 1999). Both N- and C-terminal subdomains 
contribute to DNA binding to certain type of sequences (CDI9/2, P6CON) (Czerny et al., 
1993; Epstein et al., 1994). Other Pax proteins bind DNA mostly through the PAl domain, 
while certain isoforms ofPax6 and Pax8 bind DNA exclusively through the RED domain 
(Kozmik et al., 1997; Epstein et al., 1994). Finally, the linker segmentjoining the PAl and 
RED domains also make base-specifie contacts in the minor groove (Xu et al., 1999), and 
alternative splicing ofa single glutamine residue in this segment ofPax3 generates proteins 
with distinct DNA binding properties (Vogan et al., 1996; Vogan et al., 1997). 
Paired-type HDs found in Pax proteins define a specific highly conserved subgroup 
(Kappen et al., 1993). The crystal structure ofthe DNA bound form of the paired-type HD has 
been determined and shows three a helical segments with helices 2 and 3 forming a HTH 
motif (Wilson et al., 1995). Although helix 1 does not make DNA contacts, residues N-
terminal to it contact the minor groove. Helix 3 makes extensive DNA contacts in the major 
groove and is important for sequence specificity (Wilson et al., 1993; Treisman et al., 1989). 
A unique characteristic of paired-type HDs is their ability to cooperatively dimerize on 
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palindromic sequences of the type TAAT-(N2-3)-ATIA. Position 50 (helix 3) of the HD plays 
a key role in binding specificity and dimerization potential ofHDs; while the HD ofPhox 
(Gln50) can only dimerize on T AA T -(N3)-A TI A sequences showing a three-nucleotide 
spacer, the HD of Pax3 (Ser50) can only dimerize (in the context of a PD) on sequence.s 
harboring a two-nucleotide spacer (Wilson et al., 1993; Schafer et al., 1994). 
Although both the PD and HD of Prd and Pax3 can bind DNA on their own (Underhill 
et al., 1995), a large body of data suggests that they do not function independently in intact 
Pax3, perhaps conferring additional sequence binding specificity to the protein. Indeed, both 
PD and HO are required for function in Pax3 and Pax6 and mutations in either domain show 
similar loss-of-function phenotypes in vivo (Glaser et al., 1992; Baldwin et al., 1995; Lalwani 
et al., 1995). Interestingly, a mutation (G42R) in the PD ofPax3 found in the splotch-delayed 
mouse mutant (Spd) not only shows reduced DNA binding to PD oligos, but also causes 
reduced ONA binding to HO-specifie oligos (Underhill et al., 1995). Conversely, a WS 
mutation in the HO (R53G) also modulates binding ofPax3 to PD-type sequences (Fortin et 
al., 1997). Additional studies in Pax3-Phox chimeras have shown that the Pax3 PD can 
modulate the DNA binding specificities and dimerization potential of a heterologous HD 
(Fortin et al., 1998). Oeletion ofhelix 2 of the PD in the context of the Spd mutation restores 
ONA binding by the HO, identifying this helix as a key structural element in this regulation 
(Forti et al., 1998). These results have suggested that the PD and HD are functionally 
interdependent and interact for final target site selection. However, the mechanistic basis and 
the prote in segments involved in this functional interaction remain poorly understood so far. 
Site-specifie modification of cysteines with thiol-specific reagents is a versatile tool 
for structure: function studies (Frilligos et al., 1998; Loo et al., 2000). This is best 
accomplished in the Cys-Iess molecular backbone in which single cysteines are inserted by 
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mutagenesis in predetermined strategie locations (Frilligos et al., 1998). For example, 
important information on the chemical environment of a specifie residue or protein segment 
(e.g., transmembrane domains vs. solvent-exposed loops) can be obtained by reacting the 
modified protein with thiol reagents of different chemical and physical properties, such as 
varying size and degree ofhydrophobicity. Residues in substrate-binding pockets can be 
identified by Cys-scanning mutagenesis as positions that confer NEM sensitivity to substrate 
binding and, conversely, at which prior reaction with substrate protects against NEM 
alkylation. Dynamic changes in structure following substrate binding or catalytic activity can 
be further studied in quenching experiments, using purified prote in modified by fluorescent 
sulfhydryl reagents (Frillingos et al., 1998). Finally proximity relationships can be studied in 
mutants containing Cys pairs, by a variety ofmethods inc1uding cross-linking with 
bifunctional reagents (Frillingos et al., 1998; Loo et al., 2000), FRET (Qu et al., 2001), 
excimer fluorescence (Wang et al., 1992; Jung et al., 1993; Sen et al., 1990), and several 
others. In the present study, we have created and functionally characterized a Pax3 mutant in 
which ail Cys residues have been replaced by Ser or Gly. We have used this mutant backbone 
to reintroduce Cys residues at strategically located positions of the PD and HD in individual 
mutants. The effect of site-specifie modification of the se single Cys mutants by sulfhydryl 
reagents on the DNA binding properties of the PD and RD was characterized. 
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Materials and Methods 
Mutagenesis. The construction of the pMU expression plasmid encoding a portion of 
wildtype (wt) Pax3 cDNA (positions 297-1801) has been previously described (Underhill et 
al., 1995). This pMT2Pax3 construct encodes the full-Iength 479 amino acid murine Q+ 
isoform ofPax3. A 1.3 kb Pstlintemai Pax3 fragment from upstream the initiator AUG to 
nucleotide position 1581 (residues 1-429) that encodes the PD and the RD was inserted into 
the corresponding site ofplasmid vector pAlter-I™ (ProMega) to create pAlterPax3. The 
fragment was also inserted into the Pst 1 site of a eukaryotic expression plasmid pMT2 (Fortin 
et al., 1997) to generate pMT2Pax3(B). The pAIterPax3 plasmid encodes the first 429 
residues ofPax3 and consequently encodes for six of the seven endogenous cysteines ofPax3. 
Altered Sites II in vitro mutagenesis systems (Promega) was used with the pAlterPax3 
plasmid to mutate ail but the most C-terminal cysteine ofPax3, creating pAlterPax3CL/C429. 
pAlterPax3CL/C429 was used for mutagenesis in the construction of the single cysteine 
mutants. The mutagenic oligonucleotides used to generate the Cys-Iess (CL), and the single 
cysteine mutants are listed in Table 1. The five most N-terminal endogenous cysteines of 
Pax3 (Cys70, 82, 88, 143,355) were substituted to serine or glycine. The single Cys mutants 
CL/C82 andCL/C88 were obtained at intermediate steps of this process. 
The pMT2Pax3(B) plasmid was further modified by PCR-mediated mutagenesis in 
order to insert in-frame at the C-terminus of the protein, both a polyhistidine tail (His6) and an 
antigenic hemagglutinin A epitope followed by a new termination codon. This was carried out 
using sequence-specifie oligonucleotide primers (5')-CAGGTGACAACG-
CCTGACGTGGAG-(3') and (5')-CCTITGGAA TTCCT-
GCAGTCAATGATGATGATGATGATGTCGC-
GAAGCGTAGTCTGGCACATCGTATGGGTATACG-
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Table 1.Oligonucleotides used for Pax3 mutagenesis 
Substitution 
C70S 
C82S 
C88S 
C143S 
C355S 
S152C 
S153C 
S155C 
R221C 
S222C 
V263C 
V265C 
S268C 
R270C 
A272C 
W274C 
Mutagenic primer (5'-3') 
CATTCGGCCGAGCGTCATTTC 
GTCCCATGGATCCGTCTCTAAG 
CTAAGATCCTAGGCAGGTAC 
GGACGCTGTCAGCGATCGGAACACTGTG 
CAGCTCTGCCTACAGTCTICCCAGCACCAG 
GTGCCCTCAGTGTGTTCTATCTCGCGAATCCTGAGGAG 
CACTGTGCCCTCAGTCAGCTGTATCAGCCGCATCCTG 
CAGTGAGTTCTATCTGCCGCATICTGAGGAGTAAATTTG 
GAGGAAGCAGCGCTGTAGCAGAACCACC 
GCAGCGCAGGTGC~GIACGACCTTCACGGC 
GCTTACCGAGGCGCGCTGTCAGGTCTGGTTTAG 
CGAGTGCAGTGTTGGTTTAGCAACCGCCGTGCACGATGGAG 
GCAGGTCTGGTTTTGCAACCGGCGCGCCAGATGGAGGAAAC 
GGTTTAGCAAITGCCGTGCAAG 
GCAGGTCTGGTTTTCGAACCGCCGTTGCAGATGGAGGAAAC 
CGTGCAAGATGTAGGAAACAAGCCGGCGCCAATCAACTG 
Nucleotide substitutions leading tQ amino acid changes are indicated 
in bold and those tllat ÎntrQduce silent resmctÎ()n sites are underlined. 
TACCTCGAGCTGGCTGACACCGTGGTC-(3 '). The mutagenic oligonucleotide also 
replaces Cys429 by a serine. The resulting 1049 bp PCR product was digested with restriction 
enzymes Apa land Eco RI (sites embedded in the oligo) and ligated into the corresponding 
sites ofpMTIPax3(B) to produce pMT2Pax3C429SIHA. The 12 single Cys mutants 
generated in pAlterPax3CLlC429 plasmid (mutant oligonucleotides listed in Table 1) were 
reconstructed in pMT2C429SIHA using endogeneous Pax3 restriction sites Sma l (Pax3; pst 
342-672) or Kpn l (Pax3; pst 563-1500). This permitted the production of the following 
expression plasmids: pMTIPax3CL, pMTIPax3CLlC82, pMT2Pax3CLlC88, 
pMTIPax3CLlS 152C, pMT2Pax3CLlS 153C, pMT2Pax3CLlS 155C, pMT2Pax3CLIR221 C, 
pMT2Pax3CLlS222C, pMTIPax3CLN263C, pMT2Pax3CLN265C, pMT2Pax3CLlS268C, 
pMT2Pax3CLlR270C, pMTIPax3CLlA272C, and pMT2Pax3CL/W274C. Each mutation 
was verified by nucleotide sequencing, and the accessibility of restriction sites used for 
cloning was verified by endonuclease fragmentation. 
Expression and Detection of Pax3 Mutants. The pMTIPax3 expression plasmids were 
introduced into COS7 cells via transient transfection. One million cells were plated in 
Dulbecco's modified Eagle medium (DMEM) containing 10% fetal bovine serum and were 
transfected by the calcium phosphate coprecipitation method using 15 ug of plasmid DNA 
doubly purified by ultracentrifugation on cesium chloride density gradients. Ce Ils were 
exposed to calcium-DNA precipitates for 5 h and then treated with HBS (0.14 M NaCI, 5 mM 
KCI, 0.75 mM Na2HP04, 6 mM dextrose, 25 mM HEPES, pH 7.05) containing 15% glycerol 
for 1 min. Following this treatment the ce Ils were washed once and placed in complete 
DMEM. Whole cell extracts were prepared 24 h following HBSI15% glycerol treatmeIit by 
sonication in a buffer containing 20 mM HEPES (pH 7.6), 0.15 M NaCI, 0.5 mM tris(2-
carboxyethyI)phosphine (TCEP), 0.2 mM EDTA, 0.2 mM EGTA, and a cocktail ofprotease 
inhibitors: aprotinin, pepstatin, and leupeptin at 1 Jlg/mL and phenylmethysulfonyl fluoride at 
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1 mM. These extracts were stored frozen at -70 1) C until use. To assess Pax3 mutant protein 
expression and stability, aliquots ofwhole cell extracts were analyzed by electrophoresis on 
acrylamide-containing SDS gels (SDS-PAGE), followed by electrotransfer onto nitrocellulose 
membranes and immunoblotting. Immunodetection was performed with mouse monoclonal 
anti-HA antibody (BabCO, Berkeley, CA) at a dilution of 1: 1 000 and visualized by enhanced 
chemiluminescence using a sheep antimouse horseradish peroxidase conjugated secondary 
antibody (Amersham). 
Electrophoretic Mobility Shift Assays. Electrophoretic mobility shift assays were 
performed as previously described (Underhill et al., 1995). Each protein:DNA binding 
reaction was carried out using approximately 8 Jlg oftotal cell extracts from transiently 
transfected COS-7 monkey cells and 10fmol (0.06 JlCi) ofradioactively labeled double 
stranded oligonucleotides containing either PD or HD recognition sites. The final 
concentration oflabeled oligonucleotide in the binding reaction is 0.0005 I~M. Whole cell 
extracts were incubated with 32P-Iabeled PD specific probes in a volume of20 I~L containing 
10 mM Tris-HCl (pH 7.5),50 mM KCI, 1 mM DIT, 2 mM spermidine, 2 mg/ml BSA, and 
10% glycerol. To reduce nonspecific binding, 1 Jlg ofpoly(dI-dC)poly(dI-dC) was included in 
binding studies with PD-specific probes, while 2 Jlg ofheat-inactivated salmon sperm DNA 
was added to binding reactions involving HD specific probes. Following a 30 min incubation 
at room temperature, samples were electrophoresed at 12V/cm in 6% acrylamide:bis-
acrylamide (29:1) gels containing 0.25 or 0.5X TBE (lX TBE is 0.18 M Tris-HCl, 0.18 M 
boric acid, 4 mM EDTA, pH 8.3). Gels were dried under vacuum and exposed to Kodak BMS 
film with an intensifying screen. Sorne films were used to perform densitometry studies to 
quantitate the amount of radiolabeled probe that was protein-bound using a Fuji LAS-l 000. 
PD-specific sequences P6CON (5')-
TGGAA ITCAGGAAAAA TTTTCACGCTTGAGTTCACAGCTCGAGTA-(3') (Epstein et 
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al., 1994) and P30PT (5')-TGGTGGTCACGCCTCATIGAATATIA-(3') (Chalepakis et al., 
1995; Epstein et al., 1995) and HO-specifie sequences P2 (5')-
'GATCCTGAGTCTAATIGATIACTGTACAGG-(3') (Wilson et al., 1993) and P1I2 (5')-
GATCCTGAGTCTAATIGAGCGTCTGTAC-(3') (Wilson et al., 1993) were synthesized as 
complementary oligonucleotide pairs and were designed in order to have recessed 3' ends for 
end labeling with [a}2p] dATP (3000 Ci/mmol; NEN) using the Klenow fragment ofQNA 
polymerase. 
Thiol-specific reagents N-ethylmaleimide (Pierce) and dibromobimane (Molecular 
Probes) were prepared as 10 mM stocks in water and 100% dimethyl sulfoxide, respectively, 
and were stored frozen until use. They were added as a 0.5 )lL aliquot to a 4 )lL volume of 
whole cell extract, followed by a 30 min incubation at room temperature prior to the addition 
of the e2P]-labeled probe and EMSA. 
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Results 
Construction and Characterization of a Pax3 Mutant Devoid ofCysteines. The analysis of 
structure:function relationships by site-specifie modification with sulfhydryl reagents is most 
conveniently carried out in a protein backbone lacking cysteine residues (Cys-Iess), where 
single Cys can be introduced at strategie sites by site-directed mutagenesis. Pax3 has 7 Cys 
residues at positions 70,82,88, and 143 in the PD and at positions 355, 429, and 449 
downstream ofthe HD. A Cys-less Pax3 mutant was created in a Pax3 cDNA fragment 
(residues 1-429), which lacks the last 50 residues (including Cys449 but which retains wi1d-
type DNA binding activity by the PD and by the HO (Underhill et al., 1995). An alignment of 
human and mouse Pax protein sequences (Table 2) was used to guide the choiee of amino 
acid to be substituted for each Cys residue. Cys70, Cys82, and Cys 143 in the PD are invariant 
among Pax family members and were replaced by Ser. Serine and Cysteine have a very 
similar structures, differing only by the size ofthe Oxygen vs Sulfur atom in the side chain, 
and therefore these substitution are expected to have a minimal structural consequence. 
Indeed, a C70S mutation in Pax8 has been previously shown to be without consequence on 
DNA binding (Tell et al., 1998). Five Pax proteins harbor a Gly at position 88 (Table 2); thus, 
the Cys88 ofPax3 was mutated to Gly. Finally, Cys355 and Cys429 in the P/Srr-rich trans-
activation domain are not conserved in other Pax proteins (Table 2) and were substituted to 
Ser. Ail mutations were introduced sequentially by site-directed mutagenesis, and the integrity 
of the final cDNA was verified by nucleotide sequencing. 
The Cys-less (CL) Pax3 construct was further modified by the addition ofa 
hemagglutinin (HA) epitope tag at its C-terminus to facilitate protein detection and was 
introduced in the pMT2 expression vector followed by transient transfection into COS-7 
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Table 2. Conservation of cysteine residues in IDOltSe and human Pax proteins 
Endogenotls Cysteines of Pax3 
Cys70 Cys82 Cys88 Cysl43 Cys355 Cys429 
Pax 
Proteins 
Pax3fPAX3 Cys Cys Cys Cys Cys Cys 
Pax4IPAX4 Cys Cys Gly Cys Cys Pro 
Pax6IPAX6 Cys Cys Gly Cys Met Ser 
Pax7fPAX7 Cys Cys Cys Cys Ser Cys 
PaxlfPAXI Cys Cys Ala Cys Cys Leu 
Pax9/PAX9 Cys Cys Ala Cys SeT Leu 
Pax2IPAX2 Cys Cys Gly Cys Thr SeT 
PaxSfPAXS Cys Cys GIy Cys Pro Ser 
Pax8/PAX8 Cys Cys Gly Cys GIy Tyr 
Substitution Ser Ser Gly Ser Ser Ser 
Made 
Monkey cells. Immunoblotting ofwhole cell extracts with an anti-HA monoclonal antibody 
indicates similar stability and levels of expression ofboth the wild type (wt) and Cys-less 
(CL) Pax3 proteins in COS7 cells (Figure lA). The effect of Cys replacement on DNA 
binding properties of the PD and HD ofPax3 was examined by electrophoretic mobility shift 
assays (EMSA). DNA binding by the PD was examined using oligonucleotide probes P30PT 
(Epstein et al., 1994) and P6CON (Chalepakis et al., 1995; Epstein et al., 1995), previously 
shown to reveal binding determinants present in both the amino (PAl) and carboxy (RED) 
subdomains of the PD. Results in Figure lB indicate that the wt and CL Pax3 can both bind 
these probes, and semiquantitative analysis in the form of dilution series suggests similar 
affinities of both proteins for P30PT (Figure 1 C) and P6CON (data not shown). The effects 
of Cys replacement on DNA binding properties of the HD were evaluated using a target 
sequence (P2) containing the sequence T AA T(N)2 T AA T previously shown to support 
cooperative dimerization of Pax3 (Wilson et al., 1993). In addition, an oligonucleotide 
eontaining half of this sequence (half site, P1I2) and revealing monomeric Pax3 binding by 
the HO was used. Results in Figure lB,C indicate that CL Pax3 can bind to P1I2 (monomer, 
empty arrowhead) and can dimerize on P2 (shaded arrowhead), albeit with somewhat reduced 
proficiency. Similar levels ofwt and CL Pax3 proteins were present in aIl experiments, as 
revealed by immunoblotting. Taken together, these experiments indieate that removal of aIl 
Cys residues from Pax3 does not have a major effect on DNA binding by either the PD or the 
HO. 
Effects ofThiol-Specific Reagents on DNA Binding by WT and Cys-Less Pax3. 
Sulhydryl or thiol-reactive compounds such as N-ethyl maleimide (NEM) or dibromobimane 
(OBB) can form covalent adducts with Cys residues and can be used efficiently for site-
specifie modification in structure:function studies. The effect ofNEM and DBB on DNA 
binding by the PD and HO of WT and CL-Pax3 proteins was tested in EMSA. In these 
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Figure 1 
PD and HD DNA binding properties ofwild-type and ofCys-less Pax3. (A) Immunodetection 
ofwild-type (wt) and Cys-less Pax3 (CL) proteins in whole cell extracts from COS7 monkey 
cells transfected with corresponding Pax3 cDNAs modified by the in-frame addition of a 
Haemophilus influenza hemagglutinin A (HA) epitope tag at the C-terminus of each protein. 
Proteins were resolved by SDS-PAGE (10% acrylamide) and transferred to a nitrocellulose 
membrane. Detection was by enhanced chemiluminescence using a mouse anti-HA 
monoclonal antibody and a HRP-conjugated secondary antibody. The "mock" labeled lane 
refers to who le cell extracts from untransfected COS7 cells. (B) Electrophoretic mobility shift 
assays were used to measure the DNA binding properties of either Pax3 (wt) or CL Pax3 
against PD (P30PT, P6CON) and HO specifie binding sites (P2, P1I2). Protein-DNA 
complexes were formed using total COS7 cell extracts and were resolved on 6% acrylamide 
nondenaturing gels, as described in Materials and Methods. Open arrowheads identify 
monomeric Pax3IDNA complexes, while c10sed arrowheads identify Pax3 dimers bound to 
the P2 probe. Free oligonucleotide probe is identified by an asterisk. (C) Dilution series of 
Pax3 (wt) and CL Pax3 proteins to compare relative affinities for P30PT (PD) and for P1I2 
(HO) probes. For each panel, lanes 2,3 and 4 correspond to 1.5-,2-, and 4-fold dilutions of 
total cell extract in lane 1. 
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experiments, extracts from COS cells expressing each protein were incubated with various 
amounts ofNEM prior to EMSA with PD specific (P30PT, P6CON) and HO specific (P2, 
P1I2) oligonucleotides (Figure 2). In WT Pax3, PD-specific DNA binding to P30PT was 
completely abrogated by 1 mM NEM. Studies with a narrower NEM concentration range 
showed that 0.3 mM reduced DNA binding by 50%, white no binding was detectable at 0.5 
mM (Figure 2, lower panel, Figure 6B). Identical results were obtained wh en P6CON was 
used as the PD target sequence; in sorne experiments, a Pax3-independent, NEM-sensitive 
P6CON complex of slower electrophoretic mobility was detected in aIl samples including the 
negative control (Figure 2; asterisk). NEM sensitivity ofDNA binding by the PD was also 
seen when other PD probes (ND', CDI9-2A) were used in these experiments (data not 
shown). A similar analysis of the HO revealed that dimerization of the WT Pax3 on P2 
sequences is also NEM-sensitive and is abrogated by NEM concentration of -0.5 mM 
(Figures 2 and 6B). Likewise, monomeric binding ofWT Pax3 to a P1I2 probe is also largely 
abrogated by NEM concentrations in the range of 0.1-1 mM; however, we note that a sm aIl 
proportion ofmonomeric binding to PI/2 is NEM-insensitive, and quantitation of the signal 
indicates that up to 20% ofWT Pax3 binding to P1I2 is NEM-insensitive (Figure 2, lower 
panel and Figure 6B). In contrast, DNA binding by the PD and the HO in the CL Pax3 mutant 
was completely NEM insensitive in the same assay for ail concentrations tested up to 3.6 mM 
(Figures 2 and 6B). FinaIly, identical results were obtained when dibromobimane was used in 
place ofNEM in these experiments (data not shown). 
Together, results in Figures 1 and 2 indicate that a Pax3 mutant devoid of Cys residues 
can still bind DNA through its PD and HO. Thus, inactivation ofPax3 DNA binding by NEM 
(Figure 2) is probably due to introduction of one or more bulky groups into the molecule 
rather than the removal of a critical sulfydryl group. Importantly, these results show that the 
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Figure 2 
Effects of N-ethyl maleimide treatment on the PD and HD DNA binding properties of WT 
and CL Pax3. Total cell extracts from COS7 monkey cells (mock) or from cells expressing 
either wild-type Pax3 (WT) or the Cys-Iess Pax3 mutant (CL) were incubated in increasing 
concentrations of N-ethyl male imide (NEM) prior to electrophoretic mobility shift assay. The 
ONA binding properties of the PO were evaluated with target sites P30PT and P6CON, while 
the HO was tested using the P2 and P1I2 sites. Two series ofNEM concentrations (in mM) 
were tested for WT and are indicated on top of each panel. Monomeric Pax3/DNA complexes 
are indicated by an open arrowhead, while dimers formed on P2 are identified by a shaded 
arrowhead. The presence of a Pax3-independent band detected in sorne of the EMSA with 
P30PT and P6CON is identified by an asterisk. AlI gels were exposed for similar time. 
periods. 
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CL Pax3 mutant can be used as molecular backbone for site-specific modification in Pax3 
mutants containing single cysteines inserted by site-directed mutagenesis. 
Construction and Characterization of Single Cysteine Pax3 Mutants. Site-specific 
modification in single cysteine mutants has been used to study, in a dynamic fashion, 
structural changes in proteins associated with ligand binding or catalysis (Frillingos et al., 
1998). Our goal was to use such mutants to study possible interactions between the PD and 
HO ofPax3, including reciprocal regulation ofDNA binding properties. Hence, we aimed to 
study the effect of site-specific modification of single Cys residues in one domain on DNA 
binding properties of the other domain. Ideal substitutions for this type of analysis would be 
Cys insertions in one domain that do not affect DNA binding by this domain but that are 
strategically positioned close to the DNA molecule so that formation of a bulky adduct at that 
position upon sulfhydryl modification would hinder DNA binding by this domain. In addition, 
these insertions should be accessible to NEM, a parameter that must be determined 
experimentally. The high-resolution crystal structures of the PD ofPax6 (Xu et al., 1999) and 
of the HO of Prd (Wilson et al., 1995) proteins bound to DNA were used to guide the choice 
of residues to be mutated to Cys (Figure 3). Five mutations were independently created in the 
C-terminal helices of each HTH motif ofthe PD (he lices a3 and a6). These two helices make 
key contacts in the major groove and are essential for DNA binding (Xu et al., 1999). C82 and 
C88 (a3 helix) are endogenous cysteines highly conserved in Pax proteins; these were re-
created as single cys mutants. Likewise serines 152, 153, and 155 in a6 are weIl conserved in 
Pax proteins, contact ONA (Figure 3A), and were individually mutated to S152C, S153C, and 
S155C. In the HD, the N-terminal arm (pst 219-227) is important for regulation ofDNA 
binding (Wilson et al., 1995), through DNA contact with the minor groove (Figure 3B); R221 
and S222 in this segment were mutated to Cys. Residues ofhelix 3 ofthe HTH motif, 
including four highly conserved arginines, make extensive base-specific and phosphate 
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Figure 3 
Figure 3 Site-directed mutagenesis ofthe PD and HD ofPax3. (A) Schematic representation 
of the N-terminal and C-terminal subdomains of the PD, together with structural features 
based on the three-dimensional structure of the PD of the Drosophila Prd prote in (p,p-strand; 
1", p-tum; a, a-helix) (Xu et al., 1995; Xu et al., 1999). The amino acid sequence for positions 
34-162 of Pax-3 is shown, and invariant residues among ail known PDs are identified below. 
The type of predicted DNA contacts made by these residues (p, phosphate; m, minor groove; 
M, major groove) is shown. The position and nature of the mutations introduced in Pax-3 to 
create the Cys-Iess (CL) mutant, as weil as the positions of single cysteine mutants 
corresponding either to endogenous Cys positions (CL/C82; CL/C88) or novel insertions, are 
shown below. (B) Schematic representation of the Pax3 HD, including the presence and 
position of predicted structural features, invariant amino acid residues, number and types of 
DNA contacts, and positions of single cysteine insertions (as for panel A). 
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contacts in the major groove; thus, R221C, S222C, V263C, V265C, S268C, R270C, A272C, 
and W274C were created in this segment. AlI mutants were created by site-directed 
mutagenesis, and the corresponding HA-tagged proteins were expressed by transient 
transfection in COS-7 cells. 
Immunoblotting experiments show that aIl mutant variants could be expressed to 
similar levels in COS-7 cells (Figure 4A), indicating that none ofthe mutations affect protein 
expression or stability. The effect of single Cys mutations on DNA binding by the PD and HD 
was analyzed by EMSA, using P6CON-P30PT and P2-Pl/2, respectively (Figure 4B). AIl the 
PD SC Ms, except C82, have PD and HD DNA binding activities similar to CL Pax3. C82 is 
the only PD SCM that behaves similarly to WT with respect to DNA binding properties and 
NEM sensitivity (Figure 4B). Therefore, none of the single Cys mutants inserted in the PD 
abolished the DNA binding properties of either domain. Most HD SCMs showed near-wild-
type activity for PD sequences (P6CON, P30PT). HD SCMs R221C, R270C, and A272C 
show a reduction in PD DNA binding activity, though this reduction is small. However, HD 
mutations had a marked effect on DNA binding by the HD. Although several mutants tetained 
sorne DNA binding for Pl/2, mutants at highly conserved positions R221, R270, and A272 
showed severely reduced binding activities. In addition, none except S222C was capable of 
cooperative dimerization on P2 (Figure 4B). These results confirm the key role of a3 helix in 
DNA binding by the HD. Reduced Pl/2 binding by the mutants is concomitant to an inability 
to dimerize on P2, showing that integrity of a3 is also essential for cooperative 
homodimerization of the HD. Of the HD SCMs with binding activity for Pl/2, aIl but S222C 
have activities less than that of CL Pax3. Due to their severe reduction ofHD DNA binding 
activity, mutants R221C, R270C, and A272C could not be studied further. Nevertheles~, 
several single Cys mutants in the PD and HO did retain robust DNA binding by both domains 
and were thus suitable for site-specific modification studies. 
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Figure 4 
PD and HD DNA binding properties of Pax3 mutants bearing single cysteine replacements. 
(A) Pax3 mutants bearing single cysteine (single Cys) insertions onto the backbone of a Cys-
less (CL) Pax3 mutant were created by site-directed mutagenesis, cloned into pMT2 
expression plasmid, and total cell extracts from transiently transfected COS7 Monkey cells 
were separated by SDS-PAGE and analyzed by immunoblotting with a mouse anti-HA 
monoclonal antibody, as described in the legend to Figure 1. (B) EMSA analysis of the DNA 
binding properties of either Pax3 (wt), CL Pax3 (CL), or single Cys mutants against PD 
(P30PT, P6CON) and HD specifie binding sites (P2, Pl/2) was as described in Figure 1. 
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Effect of Thiol Specifie Reagents on DNA Binding by Single Cysteine Pax3 Mutants. 
Initially, whole cell extracts from COS-7 cells expressing individual mutants were incubated 
with 1 mM N-ethyl maleimide (NEM), and the ability of each mutant to bind to P30PT and 
Pl/2 was monitored by EMSA. Results were quantitated by densitometry and are expressed as 
a fraction of prote in bound to DNA, expressed as a percentage (Figure 5). For the PD single 
Cys mutants, only the C82 mutant demonstrated NEM sensitivity to PD binding sites 
(P30PT). For the HD, mutants V263C, V265C, and S268C showed NEM sensitivity for 
binding to the Pl/2 site, while mutants S222C and W274C were NEM insensitive. 
Importantly, NEM treatment of PD mutant C82 not only abrogated DNA binding to PD sites 
P30PT, but also impaired binding ofthis mutant to the HD sequence Pl/2. Conversely, NEM 
treatment of the HD mutant V263C not only impaired DNA binding to HD site Pl/2, but also 
strongly reduced binding ofthis mutant to a PD site (P30PT) (Figure 5). The NEM sensitivity 
of PD and HD binding seen in V263C was specific and distinct from that of adjacent mutants 
V265C and S268C, which displayed NEM sensitive binding to HD site but NEM-inserisitive 
binding to PD site. Finally, although the severe reduction ofPl/2 binding displayed by 
mutants R221C, R270C, and A272C (Figure 4B; see above) precluded the testing ofNEM 
sensitivity toward this sequence (data not shown), NEM treatment did not affect DNA binding 
ofthese mutants to the PD site P30PT. For aIl mutants studied, identical results were obtained 
when another sulfhydryl reagent, dibromobimane, was used (data not shown). 
Additional dose response studies with NEM concentrations ranging from 0 to 3.6 mM 
were conducted on single Cys mutants showing NEM sensitivity for DNA binding to PD and 
HO target sites. Primary EMSA results are shown in Figure 6A and are plotted in Figure 6B 
after quantitation of the radioactivity in the gel retarded complex. In these studies, the effect 
ofNEM on possible dimerization ofC82 on a P2 site was also investigated. For the C82 
mutant, NEM concentrations >0.1 mM were sufficient to impair binding to P30PT and 
97 
Figure 5 
Figure 5 Effects of N-ethyl maleimide treatment on the PD and RD DNA binding properties 
of Pax3 mutants bearing single cysteine replacements. The effect ofNEM treatment ofwhole 
cell extracts from COS7 transfected cells on the DNA binding properties of individual 
mutants was tested for the PD sequence P30PT and for the RD sequence Pl/2, as described in 
the legend to Figure 2. The signaIs were quantitated by densitometry from a minimum of 
three independent experiments, and results are expressed as a ratio (% activity) of the amount 
of radioactivity present in the DNAIprotein complex for each mutant in the absence and 
presence of prior incubation of the extract with 1 mM NEM. 
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P6CON sequences (lCso - 0.35 mM; Figure 6B), but also to P1I2 (lCso - 0.4 mM; Figure 6B), 
with a residual amount ofNEM insensitive binding seen for that site (Figure 6A). As 
expected, NEM also impaired homodimerization of C82 on a P2 HD site (Figure 6A). For the 
V263C mutant, half-maximal inhibition for binding to PD sites (P30PT, P6CON) and the HD 
site (P1I2) were obtained and in both cases were -0.4 mM NEM (Figure 6A,B). Finally, in 
both the HD mutants V265C and S268C, although NEM concentrations >0.1 mM were 
sufficient to abrogate binding to Pl/2, binding to PD sites in the se mutants was insensitive to 
[NEM] ofup to 3.6 mM (Figure 6A), confirming uniqueness and specificity ofNEM 
sensitivity seen in V263C and C82. 
Together, these results demonstrate a reciprocal effect of site-specifie modifications of 
single Cys mutants in the PD and HD of Pax3 on DNA binding by the modified and 
unmodified site. They support a model in which the PD and HD do not function 
independently in the mature prote in, but rather functionally interact to regulate DNA binding. 
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Figure 6 
Figure 6 Dose-dependent effect of N-ethyl maleimide on DNA binding properties of certain 
single Cys mutants. (A) The NEM-sensitive DNA-binding properties of single Cys mutants in 
the PD (C82) and in the HO (V263C, V265C, S268C) were investigated in dose-response 
experiments as described in the legend to Figure 2 and for NEM concentrations ranging 
between 0.001 and 3.6 mM. NEM effects on ONA binding by the PD were tested using 
P30PT and P6CON, while HO ONA binding was measured with P2 (for WT, CL, and C82) 
and with P1I2 (for aIl mutants). Gels were exposed for similar periods oftime for mutants and 
WT prote in extracts. (B) The signaIs were quantitated, and results are expressed as a ratio (% 
activity) of the amount of radioactivity present in the ONA/protein complex for each mutant 
in the absence and presence ofprior incubation of the extract with the indicated concentration 
ofNEM. 
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Discussion 
We have created and functionally characterized a Pax3 mutant devoid of cysteine 
residues. One ofthe challenges ofusing a Cys-less mutant is that ideally, removal of the Cys 
residues should not affect function, so that reinsertion of single cysteines can be done in the 
context of an active protein. At the time of initiating these studies, little information was 
available on the role of cysteines in Pax proteins. In a study of the isolated PD from Pax5 and 
Pax8, it was observed that the 3 Cys of the PD (also conserved in Pax3) must be reduced for 
PD binding to DNA (Tell et al., 1998). Trypsin digestion and mass spectroscopy analysis 
were used to demonstrate that in the oxidized state a reversible disulfide bridge is formed 
between Cys37 and Cys49 (Cys70, Cys82 in this study) which inhibits DNA binding by the 
PD (Tell et al., 1998). In normal nuc1ear extracts, it was shown that the PD ofPax5 and Pax8 
are kept in a DNA-binding competent state by the reducing activity ofthe Ref-l protein (Tell 
et al., 1998). These results established that at the very least, eliminating intramolecular 
disulfide bonds formation in Pax3 should not be detrimental to DNA binding. The CL-Pax3 
mutant created herein could bind to PD and HD target site sequences with characteristics 
similar to that ofwild type Pax3, and this binding was resistant to NEM concentrations ofup 
to 3.6 mM. In the wild type Pax3, NEM blocks DNA binding by the PD and HD at 
concentrations >0.3 mM. These results show that none of the Cys residues in Pax3 are 
essential for DNA binding and that it is the introduction of a bulky maleimide group as. 
opposed to removal of a functional thiol moiety that accounts for NEM inhibition ofwild type 
Pax3 activity. The differential effect ofNEM on WT and CL-Pax3 indicates that over the 
concentration range tested, NEM appears to specifically modify cysteines and does not seem 
to alter other residues important for DNA binding. Second, the observation that in wild-type 
Pax3, HO DNA binding is NEM-sensitive despite the absence of Cys residues in this domain 
suggests a possible role of the Cys-containing PD on HO activity. Finally, the observations 
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that NEM inhibition of Pax3 DNA binding occurs both over a narrow range and at the same 
concentration for PD and HD targets suggest that alkylation of one or few critical Cys may be 
responsible for the effect. In purified PD from Pax5/Pax8, Cys82 appears to be most sensitive 
to reduction (Tell et al., 1998) and is a good candidate for the NEM effect seen in WT Pax3. 
The unique sensitivity to NEM of the single cysteine mutant C82 also agrees with results of 
this study. 
Functional studies ofPax3 proteins carrying PD mutations found in certain naturally 
occurring mutant alleles of the Splotch mouse (Spd) (Underhill et al., 1995) or in certain 
Waardenburg Syndrome patients (Fortin et al., 1997) initially suggested possible regulation of 
HD DNA binding by the PD. Here we used the CL-Pax3 mutant to further investigate 
possible functional interdependence of the 2 DNA-binding domains ofPax3. In particular, we 
wished to determine whether NEM sensitivity of one of the two domains caused by alkylation 
of a single Cys inserted in this domain wou Id also result in NEM sensitivity in the other, Cys-
free domain, and vice-versa. In these studies, we wanted to avoid introducing mutations that 
would grossly affect the integrity of the DNA binding domains, but rather, we wanted to 
insert single Cys at neutral positions in close proximity to the DNA molecule in the DNA-
bound complex. Alkylation at such positions could impair DNA binding, thus providing a 
convenient method of ascertaining accessibility of the inserted Cys to thiol reagents. We 
focused our Cys insertion sites on the a3 helix of each of the HTH motifs of the PD and HD, a 
helix known to play a key role in DNA binding. In the PD, independent reinsertion of Cys 82 
and 88 of PAl was as expected without consequence on PD and HD activity. Likewise, three 
independent insertions in the RED domain had no effect on DNA binding. In the HD, two 
insertions were in the N-terminal arm and six were in the a3 helix. Interestingly, 3/8 
mutations impaired partly or completely monomeric binding to the P 1/2 half site, whilè 7/8 
mutations aboli shed cooperative dimerization on P2, but none had an effect on PD binding 
104 
properties. Thus, dimerization on P2 seemed more mutation sensitive than monomeric binding 
to Pl/2 for the mutant set, possibly reflecting either a threshold effect for dimerization, 
reduced affinity for P2 compared to Pl/2 or both. Therefore, subsequent studies were limited 
to the five mutants having retained significant monomeric binding to Pl/2. 
The effect of alkylation on the DNA binding properties of each mutant was tested in 
dose response experiments for both NEM and dibromobimane with identical results. In the 
experimental scheme used, we did not ascertain the NEM accessibility of each single Cys 
insertion. NEM accessibility can be inferred only for insertions that imparted NEM sensitivity 
to DNA binding by the targeted domain, and we willlimit our discussion to these positions. 
NEM-insensitive insertions could reflect lack of effect of alkylation on DNA binding, or 
inaccessibility ofthe residue to NEM and will not be discussed further. As described ab ove, 
WT Pax3 binding by the PD (P30PT, P6CON) and by the HD (P2) was NEM sensitive. Of 
note was a small amount ofNEM-insensitive binding to Pl/2 (10-20%), detected even at the 
highest NEM concentration tested. Interestingly, this residual binding was not seen in single 
Cys HD mutants V263C, V265C, or S268C modified by alkylation. This suggests a small 
amount ofNEM-independent monomeric binding to Pl/2 by the HD ofPax3 (as expected 
from its lack of cysteine), which can be abrogated by sulfhydryl modification of a single Cys 
insertion in helix 3 ofthis domain. 
In the PD, NEM alkylation ofCys82 impaired DNA binding by the PD. As shown in 
Figure 7, examination ofCys82 in the published structures ofDNA-bound Pax6 and inPrd 
indicates that this residue makes phosphate and base specific contacts in the major groove. 
Thus, it is not surprising that modification by a bulky maleimide group would affect DNA 
binding. Surprisingly, the NEM sensitivity of PD DNA binding imparted by Cys82 also 
caused NEM sensitivity for DNA binding by the otherwise unmodified HD. Thus, a small 
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structural change in the PD abrogates the ability ofthe HD to bind DNA, again suggesting 
functional interdependence in the form of regulatory interactions between the two domains in 
the wild type protein, and possibly interrupted by NEM modification of Cys82. Interestingly, 
WSI mutations have been identified at the flanking Gly81 (081A) and Ser84 (S84F) (Baldwin 
et al., 1995) positions. These mutations do not affect DNA binding by either the PD or the HD 
(Fortin et al., 1997), suggesting that another molecular aspect ofPax3 function may be 
impaired in these mutants. 
In the HD, alkylation ofV263C had similar effects to those seen for Cys82 in the PD, 
in that it not only impaired DNA binding by the HD but also abrogated DNA-binding by the 
Cys-less PD present in this mutant. Although Val263 does not make DNA contacts per se, it 
is tucked between R262 and V265 residues in a3 helix that make phosphate contacts and 
base-specific contact in the major groove, respectively. Thereby, sulfhydryl modification at 
V263C may adversely affect important DNA contacts made by neighboring residues, possibly 
uncoupling DNA binding by the HD. Surprisingly, NEM modification ofV263C also 
impaired DNA binding by the PD, therefore mirroring in a reciprocal fashion the effect seen 
for Cys82 in the PD. The transfer ofNEM sensitivity in DNA binding by the PD seen for 
V263C is specific for this residue and cannot be explained by either (a) a nonspecific . 
disruption of the HD or (b) a general effect ofloss ofHD DNA binding on PD binding. 
Indeed, alkylation of downstream positions in a3 in mutants V265C and S268C although 
impairing DNA binding by the HD was without consequences on PD DNA binding, 
demonstrating that it is possible to impair DNA binding by the HD without affecting PD 
activity in the same molecule. Interestingly, the loss of HD DNA binding while retaining PD 
binding seen after NEM modification of V265C is identical to the phenotype of a WS 1 
mutation (V265F) previously reported at that position (Fortin et al., 1997). Close examination 
of the structures of the HD bound to DNA suggests a possible mechanistic basis for the 
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Figure 7 
Figure 7 DNA-bound structure of the N-terrninal subdomain of the PD and of the HO. 
The N-terrninal subdomain of the PD (A) and the RD (B) are shown as green ribbons drawn 
through the :x.carbon backbone. The DNA strands are shown as gray ribbons through the sugar 
phosphate backbone, and bases are shown as protrusions from the ribbons. The position of the 
endogenous PD cysteine C82 is indicated (A) and faces the major groove. (B) The RD is 
shown bound to DNA as a monomer. The positions ofV263, V265, and S268 residues ofthe 
HO indicate that V265 and S268 face DNA while V263 is on the opposite face of the helix. 
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distinct effect of alkylation of V265C/S268C and V263C on DNA binding by the PD and HO 
(Figure 7). V265 and S268 make key base-specifie contacts in the major groove separated by 
approximately one tum of the a3 helix (Wilson et al., 1995). On the other hand, V263 is 
solvent-exposed and on the other side of the helix in close proximity (tightly packed) to 
helices al and a2 (Figure 7). Therefore, it is tempting to speculate that introduction of a large 
maleimide group at V263C may not only affect the binding of a3 to DNA but may also alter 
the packing of the two other helices (al, a2) of the HD; this latter disruption may have an 
allosteric effect on the PD activity, an effect not seen after modification of either V265C or 
S268C. Studies of the Phox-l protein have previously shown that its HD is responsible for the 
recruitment and physical interaction with the nuclear factor SRF (Grueneberg et al., 1992). 
This property is specific to HDs of the paired class (Pax), is independent ofthe DNA binding 
specificity of the HD, and is mediated by pairs ofcharged residues on the solvent exposed 
face ofhelices 1 and 2 of the HD (Grueneberg et al., 1995). Such residues are conserved in 
Pax3 PD, and they may participate in interactions between the HD and PD which may be 
disturbed by alkylation ofV263C. Additional Cys-scanning mutagenesis in helices of the 
HTH motif will be required to further characterize this possible allosteric effect. 
Together, results of site-specific modification experiments agree with the proposition 
that the PD and HD do not function as independent DNA binding modules in the fulliength 
Pax3 protein. Rather, it appears that both domains may functionally interact, such that one 
domain can modulate the DNA binding properties of the other domain. These interactions 
may be critical for target site selection by the Pax3 protein. 
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The study discussed in Chapter 2 is a successful "re-enactment" of observations made 
with naturally occurring Pax3 proteins that abrogate DNA binding activities of the paired and 
HO. Alkylation ofCys82 with NEM was meant to abrogate PD DNA binding activity in order 
to determine the effect of an impaired PD on RD DNA binding activity. Like the naturally 
occurring Splotch-delayed G42R PD mutation, NEM alkylated Cys82 abrogates Pax3 PD and 
HO ONA binding activities (Underhill et al., 1995). This observation confirms what has been 
suggested by the characterizations of several naturally occurring PD mutations; that is, the 
HO DNA binding activity is influenced by the PD. Likewise, alkylation ofV263C with NEM 
was meant to abrogate HO DNA binding activity in order to assess the effect of abrogated HO 
activity on PD DNA binding activity. Like the Waardenburg syndrome RD mutant R53G, 
NEM alkylated V263C does not retain HO nor PD DNA binding activities (Fortin et al., 
1997). This discovery confirms what has been suggested by the characterizations of other 
naturally occurring HO mutations: the PD DNA binding activity is influenced by the HO. 
To account for the observations made with the alkylated single cysteine mutants we 
postulate that DNA binding of one domain is sensed by or communicated to the other domain. 
For example, PD DNA binding may induce a conformational change in the PD as weIl.as the 
HO and both these conformational changes might be required for proper Pax3 DNA binding 
by the PD. We propose a similar situation exists for the HO as weIl. 
To study possible conformational changes ofboth domains when Pax3 is DNA bound 
by either domain a protease sensitivity approach was implemented. This study required the 
use of Pax3 mutants with engineered Factor Xa protease cleavage sites and is presented in 
chapter 3. 
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Chapter3 
Cross-talk between the Paired Domain and the Homeodomain ofPax3: DNA Binding by each 
Domain causes a Structural Change in the other Domain, Supporting Interdependence for 
DNA Binding 
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Abstract 
The Pax3 protein has two DNA binding do main s, a paired domain (PD) and a paired-type 
homeodomain (HD). Although the PD and HD can bind to cognate DNA sequences when 
expressed individually, genetic and biochemical data indicate that the two domains are 
functionally interdependent in intact Pax3. The mechanistic basis ofthis functional 
interdependence is unknown and was studied by protease sensitivity. Pax3 was modified by 
the creation of Factor Xa cleavage sites at discrete locations in the PD, the HD, and in the 
linker segmentjoining the PD and the HD(Xal72, Xa189, and Xa216) in individual Pax3 
mutants. The effect of Factor Xa insertions on protein stability and on DNA binding by the PD 
and the HD was measured using specifie target site sequences. Independent insertions at 
position 100 in the linkerseparating the first from the second helix-tum-helix motifofthe PD 
and at position 216 immediately upstream of the HD were found to be readily accessible to 
Factor Xa cleavage. The effect of DNA binding by the PD or the HD on accessibility of Factor 
Xa sites inserted in the same or in the other domain was monitored and quantitated for 
multiple mutants bearing different numbers of Xa sites at each position. In general, DNA 
binding reduced accessibility of ail sites, suggesting a more compact and less solvent-exposed 
structure of DNA-bound versus DNA-free Pax3. Results of dose response and time course 
experiments were consistent and showed that DNA binding by the PD not only caused a local 
structural change in the PD but also caused a conformational change in the HD (P30PT 
binding to Xa216 mutants); similarly, DNA binding by the HD also caused a conformational 
change in the PD (P2 binding to Xa 100 mutants). These results provide a structural basis for 
the functional interdependence of the two DNA binding domains of Pax3. 
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Introduction 
Pax3 is a member of a family of 9 transcription factors (Stuart et al., 1994), defined by 
a DNA binding module, the PD, that was tirst identitied in the Drosophila protein Paired 
(Prd) (Bopp et al., 1986). Pax proteins play critical roles during normal embryonic 
development, and inactivating mutations cause major defects in development of skeleton, 
muscles, nervous system, eyes, kidneys, and the immune system (Dahl et al., 1997; Balling et 
al., 1988; Sanyanusin et al., 1995; Torres et al., 1995; Jordan et al., 1992; Glaser et al., 1992; 
Hill et al., 1991; Sosa-Pineda et al., 1997; Mansouri et al., 1998; Macchia et al., 1998). Pax3 
is expressed in developing somites and in neural tube and neural crest cell derivatives and 
plays a role in the proliferation, migration, and differentiation of cells involved in 
neurogenesis and myogenesis (Goulding et al., 1991; Bober et al., 1994). ThePax3 mouse 
mutant (splotch, Sp) displays spina bitida and exencephalyand lacks limb muscles; likewise, 
mutations in human PAX3 cause Waardenburg syndrome (WS), a condition characterized by 
pigmentary disturbances, craniofacial abnormalities and sensorineuronal deafness (Bober et 
al., 1994; Beechey et al., 1986; Auerbach et al., 1954; Franz et al., 1989; Franz et al., 1990; 
Goulding et al., 1994; Baldwin et al., 1992; Baldwin et al., 1995). P AX3 also plays a role in 
cell transformation as shown by the translocation t(2; 13) (q35;q 14) involving PAX3 (Barr et 
al., 1993) and forkhead-related transcription factor (Galili et al., 1993) associated with the 
solid tumor alveolar rhabdomyosarcoma. The translocation leads to the expression of a fusion 
prote in containing the N-terminal DNA binding domain ofPAX3 and the C-terminal 
activation domain of forkhead-related transcription factor (Galili et al., 1993). 
Several members of the Pax family, including Pax3, encode a second DNA binding 
domain, the paired-type HO (Stuart et al., 1994; Noll et al., 1993). Aiso conserved in the Pax 
family is the presence of an octapeptide (OP) motif in the segment linking the PD and the HO, 
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as weIl as a proline-serine-threonine (PST)-rich C-terminal domain. Both the OP and PST 
domain are involved in protein-protein interactions to recruit additional transcription factors 
required for transcription oftarget genes. The three-dimensional structures of the DNA-bound 
PD of Prd (Xu et al., 1995) and Pax6 (Xu et al., 1999) reveal that it is bipartite consisting of 
an N-terminal (PAl) and a C-terminal (RED) subdomains, each formed by a three-helical fold 
with the two most C-terminal helices forming a helix-turn-helix (HTH) motifthat makes 
DNA-specific contacts in the major groove ofDNA. The sublinker, connecting the two 
subdomains of the PD, adopts an extended conformation on DNA and makes base contacts in 
the minor groove. Unique to the PAl subdomain is the ~-turn and ~-hairpin, which precede the 
three-helical fold and participate in DNA binding (XU et al., 1995; Xu et al., 1999). The DNA 
sequences recognized by the PD are oftwo classes: binding to Class 1 sequences requires both 
the PAl and RED subdomains, whereas binding to class II sequences only requires the PAl 
subdomain (Epstein et al., 1994; Czerny et al., 1993). Sorne isoforms ofPax6 and Pax8 
produce, by alternate splicing, isoforms that bind PD targets exclusively through the RED 
subdomain (Epstein et al., 1994; Kozmik et al., 1997). 
The crystal structure of the DNA-bound form of the paired-type HD (pt-HD) consists 
of a three-helical fold containing a HTH motif; helix3 makes specifie contacts in the major 
groove ofDNA and confers DNA binding specificity of the HD (Kappen et al., 1993; Wilson 
et al., 1993; Wilson et al., 1995; Treisman et al., 1989). Like other HDs, the extended N-
terminal arm motif, preceding thethree-helical fold, is also used to make specifie DNA 
contacts but in the minor groove ofDNA (Wilson et al., 1993; Wilson et al., 1995; Treisman 
et al., 1989). The pt-HD class ofHDscan bind the TAAT motif but can also uniquely 
dimerize on palindromic sequences of the type T AA T(N2-3)A TT A (Wilson et al., 1993; 
Schafer et al., 1994). The identity of residue 50 in helix3 determines both DNA specificity and 
dimerization potential in this class ofHDs (Wilson et al., 1993; Schafer et al., 1994). When 
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covalently linked to a PD the pt-HD of Pax proteins (Ser-50) only permits the dimerization of 
the HD on palindromic sequences with a twonucleotide spacer (Wilson et al., 1993; Schafer 
et al., 1994; Underhill and Gros, 1997). 
Although the PD and HO can bind to cognate DNA sequences when expressed 
individually, genetic and biochemical data indicate that the two domains are functionally 
interdependent in the intact Pax3 protein. The Splotch-delayed (Spd) mouse mutant bears a 
single G42R mutation in the PD, which abrogates DNA binding by the PD but also impairs 
DNA binding by the HD. Deletion ofhelix 2 of the PAl subdomain in the context of the Spd 
mutation has been shown to restore HD DNA binding (Underhill et al., 1995; Fortin et al., 
1998). Studies in chimeric PAX3 proteins have shown that the PD can modulate DNA binding 
specificity and dimerization potential ofheterologous HOs (Fortin et al., 1997; Underhill and 
Gros, 1997). On the other hand, a mutant P AX3 variant from a WS patient bearing a mutation 
at position 53 of the HD (R53G) shows not only loss ofDNA binding by the HD but also by 
the PD (Fortin et al., 1997). More recent biochemical studies by cysteine scanning 
mutagenesis and site-specific modification of single cysteine mutants with sulfhydryl reagents 
have shown that modification of a single cysteine in the PD (Cys-82) disables DNA binding 
by the PD but also by the HO (Apuzzo et al., 2002). Conversely, modification of a single 
cysteine at position 263 of the HO (V263C) of the HO abrogates DNA binding by both 
domains (Apuzzo et al., 2002). 
The mechanistic basis ofthis functional interdependence, includingthe prote in 
subdomains involved, remains poorly understood but is likely to be relevant for target site 
selection by Pax3 in vivo. One plausible mechanism is that DNA binding by one orboth of the 
DNA binding sites of Pax3 causes conformational changes at or near the other binding site to 
alter its properties. Thus, we wanted to get insight into the conformations adopted by the Pax3 
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protein when DNA-free and when bound to PD or HDtargets. A number ofphysicochemical 
approaches have been used to monitor the effect of substrate binding on protein conformation, 
including differential immunoreactivity with specifie antibodies (Mechetner et al., 1997), 
tryptophan fluorescence (Weber et al., 1993; Weber et al., 1997; Zhou et al., 1997; Walmsley 
et al., 1999; Menezes et al., 1990), and site-specifie modification of cysteine residues (Liu et 
al., 1997; Liu et al., 1996). Protease sensitivity has also been used extensively to monitor 
conformational changes in proteins (Gomes et al., 1996; Stout et al., 1998; Rothman et al., 
1997; Morsomme et al., 1998; Zhang et al., 1998). Although partial proteolytic digestion with 
enzymes such as trypsin, chymotrypsin, and papain has been used in such studies, delineating 
the cleavage sites is complicated by the necessity to identify proteolytic fragments by epitope 
mapping with specifie antibodies and/or peptide sequencing (Julien et al., 2000). Another 
implementation ofthis method involves creating recombinantproteins bearing single 
heterologous protease cleavage sites (such as Factor Xa) inserted at pre-determined po~itions 
in individual mutants. Proteolytic products can be identified using antibodies against antigenic 
epitope also engineered at convenient positions. In this approach, conformational changes can 
be studied in a set of recombinant proteins for which structural and functional integrity has 
been ascertained. 
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Materials and Methods 
Mutagenesis-The construction of the pMU expression plasmidcontaining the entire 
protein-encoding region ofwild type Pax3 cDNA has been previously described (Underhill et 
al., 1995; Apuzzo et al., 2002). This pMT2/Pax3 construct encodes for aIl 479 amino acids of 
the murine Q+ isoform ofPax3 (Vogan et al., 1996). This cDNA was modified by the in-
frame addition of antigenic epitope derived from the human c-Myc prote in (c-Myc epitope, 
EQKLISEEDL) at the N terminus as weil as a polyhistidinetail (His6) and an HA 
hemagglutinin epitope (YPYDVPDY AS) and a termination codon at the C terminus of the 
protein. This was accompli shed by PCR-mediated mutagenesis with mutagenic primers: P3-
Myc (5'-
CTCGAATTCATGGAGCAGAAGTTAATCAGCGAAGAGGATCTCACCACGCTGGCC 
GGCGCTGTGCCCAGGATG-3') and P3-HA (5'-
TTTAGCGGATCCGAATTCTTAGTGATGGTGGTGATGGTGTCCCGCGGCGTAATCT 
GGAACGTCATATGGATATCCGAACGTCCAAGGCTT ACTfTG-3'). Both primers were 
engineered with EcoRI restriction sites at their ends. The resulting 1.5-kb PCR product was 
digested with EcoRI and ligated into the corresponding site of mammalian expression vector 
pMT2, and the resulting construct was designated pMT2/Myc-Pax3-HA. 
Factor Xa cleavage sites (IEIDGR, Table 1) were introduced at different positions in 
Pax3 by two procedures. The wild type sequence was mutated (without addition of extra 
amino acid residues) to convert near matches to IEIDGR via PCR-mediated mutagenesis. 
Individual mutants were created in two independent reactions using complementary 
oligonucleotide pairs defining each mutation (listed in Table II) as weIl as P3-Myc and P3-
HA; mutated DNA fragments were annealed and repaired, and the full-iength cDNAs were 
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synthesized. Mutants Pax3Xa55, Pax3Xa71, Pax3Xa114, Pax3Xa131,Pax3Xa252, and 
Pax3Xa259 were created in this fashion and were introduced in pMT2. Mutants Pax3Xa66, 
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Table 1: Factor Xa cleavage sites introduced in individual Pax3 mutantsa 
XaMutant Wild type sequence Xa Mutant Sequence 
Xa55b IRHK IEGR 
Xa71 VISR IEGR 
Xa114 VEKK IEGR 
Xa131 WEIR IEGR 
Xa252 LAQR IDGR 
Xa259 TEAR IEGR 
Xa66(1)c,d ~ HGIR HGSIEGROIR 
Xa66(2) HGIR HGSIEGRASIIEGRGIR 
... 
Xa 1 00(2) PGAI PGAGIEGRGAGIEGRGAI 
Xa 1 00(4) PGAI PGAGIEGRGAGIEGRGAGIEGRGAGIEGRGAI 
... 
ADLDIEGRLE Xal72(l) ADLE 
Xal72(3) ADLE ADLDIEGRLDIEGRLDIEGRLE 
... 
Xa189(1) IDOI IDIEGRIDGI 
Xa189(2) IDOI IDIEGRIDGRIDOI 
... 
Xa216(1) LKRK LKIDGRSIKRK 
Xa216(2) LKRK LKIDGRIDGRSIRK 
aIntroduced amino acids are underlined and engineered Xa protease sites are indicated in boldo 
bMutants are designated according to the Pax3 amino acid position at which individual Factor Xa cleavage 
sites were introduced by site-specifie modification of wildtype sequence. 
CThese mutants were created by insertion mutagenesis at the position indicated by an arrow. 
~e number of Factor Xa sites introduced at that position is indicated in parenthesis. 
Table 2 : 
Xa55 
Xa71 
Xa114 
Xa131 
Xa252 
Xa259 
Oligonucleotides used for Site-directed5 and Insertion Mutagenesis 
F 
R 
F 
R 
F 
R 
F 
R 
F 
R 
F 
R 
GGAGTATTTATCAACGGCQGGCCgCTGCCCAACCATATCGAAGGCAGAATAGTGGAGATGGCCCAC 
GTGGGCCATCTCCACTATTCTGCCTTCGATATGGTTGGGCAGQGGCCgGCCGTTGATAAATACTCC 
GGCATTCGGCCTTGCATTGAAGgTCGACAGCTTCGCGTGTCC 
GGACACGCGAAGCTGTCGA~CTTCAATGCAAGGCCGAATGCC 
AAACCCAAGCAGGTGACAACTccgGACATCGAGGGACGTATTGAGGAATACAAAAG 
CTTTTGTATTCCTCAATACGTCCCTCGATGTC~GGAGTTGTCACCTGCTTGGGTTT 
AACCCGGGCATGTTTTCAATTGAAGGCAGAGACAAATTGCTCAAGGAC 
GTCCTTGAGCAATTTGTCTCTGCCTTCAATTGAAAACATGCCCGGGTT 
ATTTACACCAGGGAGGAGATCGACGGCCGGGCGAAGCTTACCGAGGCC 
GGCCTCGGTAAGCTTCGCCCGGCCGTCGATCTCCTCCCTGGTGTAAAT 
GCCCAGAGGGCGAAGCTTATCGAGGGCCGIGTACAGGTCTGGTTTAGCAAC 
GTTGCTAAACCAGACCTGIACACGGCCCTCGATAAGCTTCGCCCTCTGGGC 
KasI(lOO)b F 
R 
GGCTCCATCCGACCTGGQGCCATCGGCGGCAGC 
GCTGCCGCCGATGGQGCCAGGTCGGATGGAGCC 
AflII(216)C F 
R 
TCTGAACCTGATTTACCGCTIAAGAGGAAGCAGCGCAGG 
CCTGCGCTGCTTCCTCTTAAGCGGTAAATCAGGTTCAGA 
Xa66(1)d ATCCATAGAAGGTAGAGG 
Xa66(2) ATCCATAGAAGGTAGAGGATCCATAGAAGGTAGAGG 
XalOO(2) GCGCCGGCATAGAAGGTAGAGGCGCCGGCATAGAAGGTAGAG 
XalOO(4) GCGCCGGCATAGAAGGTAGAGGCGCCGGCATAGAAGGTAGAGGCGCCGGCATAGAAGGTAGAGGCGCCGGCATAGAAGGTAGAG 
Xal72 (1) CTAGATATCGAAGGTCGT 
Xa172(3) CTAGATATCGAAGGTCGTCTAGATATCGAAGGTCGTCTAGATATCGAAGGTCGT 
Xa189(1) CGATATCGAAGGTAGAAT 
Xa189(2) CGATATCGAAGGTAGAATAGACGGCCGAAT 
Xa216(1) TTAAGATCGACGGTAGATCTA 
Xa216(2) TTAAGATCGACGGTAGAATAGACGGCCGATCTA 
5Nucleotide substitutions leading to ami no acid changes are indicated in bold, and those that 
introduce silent restriction sites are underlined. 
bThese oligos were used to introduce a unique KasI restriction site at position 595 of the 
wildtype pax3 cONA sequence. 
CThese oligos were used to introduce a silent and uniqe AflII restriction site at position 940 of 
the wildtype Pax3 cDNA sequence. 
dOligonucleotide sequences used (double stranded) for insertion mutagenesis in the creation of 
the corresponding Xa mutants as listed in Table 2. 
Pax3Xal72, and Pax3Xa189were created by insertion mutagenesis. For this, pMTI/Myc-
Pax3-HA plasmid was digested with Bsml, Xbal, or CIal, and single or multiple Xa cleavage 
sites were introduced using double-stranded oligonucleotides with cohesive ends (Tables 1 and 
II). These oligonucleotides have a sequence just long enough to encode for one or a few Xa 
protease sites when placed in-frame with the rest of the Pax3 encoding region. For mutants 
Pax3Xa 1 00 and Pax3Xa216, the Pax3 cDNA was modified to introduce unique Kasl and Atm 
sites at nucleotide positions 595 and 940, respectively, using mutagenic primers listed in 
Table II. These modified Pax3 cDNAs were subcloned into the EcoRI site of pBluescript 
(lacks Kasl and AtlII sites), and one or several Factor Xa sites were independently introduced 
at the KasI or Atm sites by insertionmutagenesis to create mutants XalOO (2), XalOO (4), 
Xa216 (1), and Xa216 (2) (Tables 1 and II). In aIl cases, the presence of the Factor Xa 
mutations and the integrity of the rest ofthe Pax3 sequences were verified by nucleotide 
sequencing. The accessibility of restriction sites used for cloning was verified by restriction 
enzyme fragmentation. 
Expression and Detection of Pax3 Mutants-The expression plasmids were used to 
transiently transfect COS-7 Monkey cells. One million cells were plated in Dulbecco's 
modified Eagle medium containing 10% fetal bovine serum and were transfected by the 
calcium phosphate co-precipitation method using 15 J.lg of plasmid DNA doubly purified by 
ultracentrifugation on cesium chloride density gradients. Calcium-DNA precipitates were 
placed onto the cells for 5 h and then treated with HBS (0.14 M NaCI, 5 mM KCI, 0.75 mM 
Na2HP04, 6 mM dextrose, 25 mM HEPES, pH 7.05) containing 15% glycerol for 1 min. The 
cells were then washed and placed in complete Dulbecco's modified Eagle medium. Whole 
cell extracts were prepared 24 h following glycerol shock by sonication in a buffer containing 
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20 mM HEPES (pH 7.6),0.15 M NaCI, 0.5 mM OIT, 0.2 mM EOTA, 0.2 mM EGTA, and a 
mixture of protease inhibitors: aprotinin, pepstatin, and leupeptin used at 1 mg/ml and 
phenylmethysulfonyl fluoride used at 1 mM. These extracts were stored frozen at -70 oC until 
use. Toassess Pax3 mutant protein expression and stability, aliquotsofwhole cell extracts 
were analyzed by electrophoresis on acrylamide-containing SOS gels (SOS-PAGE), followed 
by electrotransfer onto nitrocellulose membranes and immunoblotting. Immunodetection was 
performed with mouse monoclonal anti-HA antibody (BabCO, Berkeley, CA) at a dilution of 
1: 1 000 and visualized by enhanced chemiluminescence using a sheep anti-mouse horseradish 
peroxidase conjugated secondary antibody (Amersham Biosciences). Following anti-HA 
probing the membranes were submerged in stripping buffer (100 mM 2-mercaptoethanool, 2% 
SOS, 62.5 mM Tris-HCl, pH 6.7) and incubated at 50 oC for 30 min. The membranes were 
then washed with TBST buffer (10 mM Tris-HCl, pH 8, 150 mM NaCI, 0.1 % Tween 20) at 
room temperature. Following blocking, the membranes were probed with mouse monoclonal 
anti-Myc antibody (BabCO) at a dilution of 1:1000 and visualized by enhanced 
ehemilumineseence using a sheep anti-mouse horseradish peroxidase conjugated secondary 
antibody (Amersham Biosciences). 
Electrophoretic Mobility Shift Assay-Electrophoretic mobility shift assays were 
performed as previously described (Apuzzo et al., 2002). Each protein:DNA binding reaction 
was earried out using ~ 10 flg of total cell extracts from transiently transfected COS-7 monkey 
cells and 10 fmol (0.06 flCi) of radioactively labeled double-stranded oligonucleotides 
eontaining either PO or HO recognition sites. The final concentration of labeled 
oligonucleotide in the binding reaction was 0.5 nM. Whole cell extracts were incubated with 
32P-Iabeled PD-specifie probes in a volume of20 fll containing 10 mM Tris-HCI (pH 7.5), 50 
mM KCI, 1 mM OIT, 2 mM spermidine, 2 mg/ml bovine serum album in, and 10% glycerol. 
Whole cell extracts were also incubated with 32P-Iabeled HO-specifie probes in a volume of 
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20 ~l containing 10mM Tris-HCl (pH 7.5),50 mM NaCl, 1 mM DTT, 2 mM MgCh, 1 mM 
EDTA, and 5% glycerol. To reduce non-specifie binding, 1 ~gofpoly(dI-dC)poly(dI-dC) was 
included in binding studies withPD-specific probes, whereas 2 ~g ofheat-inactivated salmon 
sperm DNA was added to binding reactions involving HO-specifie probes. Following a 30-
min incubation at room temperature, samples were electrophoresed at 12 V/cm in 6% 
acrylamide:bis-acrylamide (29:1) gels containing 0.25 or 0.5x TBE (lx TBE is 0.18 M Tris-
HCI, 0.18 M borie acid, 4 mM EDTA, pH 8.3). Gels were dried under vacuum and exposed to 
Kodak BMS film with an intensifying screen. PD-specifie sequences P6CON (5'-
TGGAA TTCAGGAAAAA TTTTCACGCTTGAGTTCACAGCTCGAGTA-3') (Xu et al., 
1995) and P30PT (5'-TGGTGGTCACGCCTCATTGAATATTA-3') (Julien et al., 2000; 
Vogan et al., 1996; Epstein et al., 1996), and HO-specifie sequences P2 (5'-
GATCCTGAGTCTAATTGATTACTGTACAGG-3') (Wilson et al., 1993; Kozmik et al., 
1997) and P1I2 (5'-GATCCTGAGTCTAATTGAGCGTCTGTAC-3') (Wilson etaI., 1993; 
Kozmik et al., 1997) were synthesized as complementary oligonucleotide pairs and were 
designed to have recessed 3' ends for end labeling with [a)2P]dATP (3000 Ci/mmol; 
PerkinE1mer Life Sciences) using the Klenow fragmentofDNA polymerase. 
Factor Xa Treatment ofXa Mutants-For time course studies, 10 ~g oftotal cell extracts from 
transiently transfected COS-7 monkey cells was incubated with or without double-stranded 
oligonucleotides (final concentration of2 ~M) correspondingto PD and HO binding sites, in a 
final volume of 1 0 ~l. The whole cell extract was incubated with DNA for 30 min at 20 oC 
followed by addition of 0.2 ~l of 1 ~g/~l (0.2 ~g) of Factor Xa protease (New England 
Biolabs). The proteolysis reaction was carried out for pre-determined periods of time (2-180 
min) at 20 oC and was stopped bythe addition of5 ~l ofLaemmli sample buffer (2% (w/v) 
SDS, 10% (v/v) glycerol, 62.5 mM Tris-HCl, pH 6.8, 100 mM DTT, 0.05% bromophenol 
blue). For the dose-response assays, 10 ~goftotal cell extracts from transiently transfected 
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COS-7 monkey cells was incubated for 30 min at 20 oC with oligonucleotides (final 
concentration of 2 ~M) corresponding to PD and HD binding sites or nonspecific 
oligonucleotides, in a final volume of20 ~l. Binding reactions done with PD probes (and with 
a nonspecific oligonucleotide) contained 10 mM Tris-HCl (pH 7.5),50 mM KCI, 1 mM DTT, 
2 mM spermidine, 2 mg/ml bovine serum album in, 10% glycerol, and 1 ~g ofpoly(dI-
dC)poly(dI-dC). Binding reactions done with HD probes (and with a nonspecific 
oligonucleotide) contained 10 mM Tris-HCl (pH 7.5),50 mM NaCI, 1 mM DIT, 2 mM 
MgCb, 1 mM EDTA, 5% glycerol, and 2 ~gofheat-inactivated salmon sperm DNA. Various 
concentrations of Factor Xa protease, ranging from 0 to 200 ng ofXa protease/microgram of 
whole cell extract, were then added to the reaction mixture, and proteolytic cleavage was 
allowed to take place for 15 min at 20 oC. The reaction was stopped by addition of 1 0 ~I of 
Laemmli sample buffer. For both assays the proteolytic degradation products were separated 
by SOS-PAGE on 12% polyacrylamide gels, followed by transfer onto nitrocellulose 
membranes. Immunodetection ofPax3 products was carried out using anti-HA antibody 
followed by anti-Myc antibody as described above. Films were used to perform densitometry 
studies to quantify the amount of chemiluminescence using a Fuji LAS-l 000. 
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Results 
Construction of Pax3 Mutants Bearing Factor Xa Protease Cleavage Sites-A large 
body of biochemical and genetic data indicate that the PD and the HD of Pax3 are functionally 
interdependent with strong cooperativity between the two sites. The structural basis for this 
interdependence remains unclear and was investigated. A major objective ofthis study was to 
determine whether or not ONA binding at eitherthe PD or HD ofPax3 causes a 
conformational change at the other site, thereby providing a possible structural basis for their 
reported functional interdependence. Possible conformational changes were assessed by 
protease sensitivity by monitoring accessibility of c1eavage sites strategically inserted in the 
PD and HO of Pax3. A Pax3 cDNA was modified by the in-frame addition ofhemagglutinin 
(HA) and c-Myc epitope tags at the C and N termini of the prote in, respectively (Fig. 1), to 
facilitate detection of specifie proteolytic fragments by immunoblotting. This cDNA was used 
to insert Factor Xa cleavage sites (IEGR, IDGR; cleavage immediately C-terminal ofR) by 
site-directed mutagenesis. Using the known three-dimensional structures ofPax6 and Paired 
as molecular templates, Factor Xa sites were introduced either in the PD, in the HO, in the 
flexible linker separating the PD and the HO, as well as in solvent-exposed segments near the 
end ofindividual helices in the HTH motifs of the PD and the HD (see Figs. 1 and 3). Two 
strategies were used for mutagenesis. First, near-matches in the wild type Pax3 sequence 
mapping to the highly conserved HTH modules of the PD and HD were independently 
converted to I(EID)GR (Table 1) to minimize adverse structural changes possibly impairing 
ONA binding. Targeted in this group of six mutants were helices 1 (al, Xa55), 2 (a2, Xa71), 4 
(a4, Xal14), and 5 (a5, Xa131) ofthe PD as weIl as the C terminus ofhelix 2 (Xa252) and the 
N terminus ofhelix 3 (Xa259) of the HO (Table 1 and Fig. 1). Second, and to maximize 
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accessibility to proteolytic cleavage, several solvent-exposed, and less conserved linker 
segments were also targeted for insertion of one or several 
Figure 1 
Insertion of Factor Xa protease sites in the PO and in the HO ofPax3. Schematic 
representation of the PO and HO, including position of a-he lices and ~-strands (arrows) 
deduced from the known structures of the Drosophila Prd, and mammalian Pax6 protetns 
(BalIing et al., 1988; Xu et al., 1995; Xu et al., 1999). The amino acid sequence ofPax3 
(positions 34-278) is shown, with invariant residues in members of the Pax family identified 
below. The type of ONA contacts made by these residues (p, phosphate; m, minor groove; M, 
major groove) is indicated. Pax3 sequences targeted for modification to create Factor Xa 
cleavage sites are boxed. The position of the c-Myc and hemagglutinin (HA) epitope tags 
inserted in-frame at the amino and carboxyl termini ofPax3, respectively, is shown. 
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PD 
34 43 53 63 73 83 93 103 113 123 133 143 153 
1 1 ~~~ ._ •• l.~ ~ 1 1 ~ 1 ~ 1 ~ 1 1 pax3 wtGQGRVNQLGGVFINGRPLP~~Iv~P~LRVSHGCVSKILCRYQETGSI~GGSKPKQVTTP~IEEYKRENPGMF~DKLLKDAVCDRNTVPSVSSISRILRSKF 
Invariant -----NQLGG-F-NGRPLP---R--IV--A--G-RpC-IsR-L-VS-GCVsKIL-R---TG---P--IGGSK------P-----I----------F-WEI---L-----------PS-S-I-R--R---
DNA Contact -------------mm------------------------------MMMM-MM---------------mmmm--m--------------------------------------------M---M--M---
-----pp----p-ppppp----p-----------ppp---p---pp--p-pp---p--------ppss-ss-pppp-------------------ppp------------------p--p-pp--p---
HD 
-----------------------f"-"(IXtll-'r--..1 IX2 IX3 ~f-[-HA 
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GKGEEE~KEAEESEKKAKH~IDGI~SERASAPQSDEGSDIDSEPDL~RRSRTTFTÀEQLEELERAFERTHYPDIYTRE~K~QVWFSNRRARWRKQÀ 
--R-RT-F---Q---LE--F-RT-YPD---RE-LA----L-EAR-QVWFSNRRA--R---
--m-m-----------------------------------------M--MM---------
-----p------------------p-----p------------p----p---p-p-p---
Xa sites (Table 1 and Fig. 1). Targeted in this group of 10 mutants were the linker separating 
helix 1 and 2 of the PD (Xa66, 1 and 2 sites), the segment linking the first and second HTH 
motifs of the PD (XalOO, 2 and 4 sites), and the fragment separatingthe PD and the HD 
(Xal72, 1 and 3 sites; Xa189, 1 and 2 sites; Xa216, 1 and 2 sites). Multiple Xa sites were 
inserted at individuallocations not only to maximize accessibility to protease fragmentation 
but also to provide validation of observed effects. 
DNA Binding Properties of Pax3Xa Mutants-Wild type Pax3 along with the various 
Pax3Xa mutants were introduced in the pMTI expression plasmid, followed by transient 
transfection into COS-7 Monkey cells. Immunoblotting of who le cell extracts with either anti-
HA or anti-c-Myc monoclonal antibodies indicate similar stability and comparable levels of 
expression of ail mutants in COS-7 cells, with the notable exception of mutants Xa252 and 
Xa259 (Fig. 2). Reduced levels of expression for Xa252 and Xa259 were noted in multiple 
transfections and for independent DNA preparations suggesting that mutations at these two 
positions in the HD may alter protein folding, or processing possibly reducing half-life. The 
effect ofintroducing Factor Xa sites on DNA binding properties of the PD and HD ofPax3 in 
the various mutants was examined by electrophoretic mobility shift assays (EMSAs). DNA 
binding by the PD was examined using oligonucleotide probes P30PT (Epstein et al., 1996; 
Chalepakis et al., 1995) and P6CON (Epstein et al., 1994), previously shown to reveal binding 
determinants present in both the amino (PAl) and carboxyl (RED) subdomains ofthe PD (Fig. 
2). Mutants at position 55 (Xa55), 66 (Xa66(1); (Xa66(2», and 71 (Xa71) were found to be 
severely impaired for DNA binding to P30PT and P6CON highlightingthe critical role of the 
N-terminal HTH domain (PAl) for DNA binding by the PD. HD Xa mutants Xa252 and 
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Xa259 also appeared compromised for DNA binding by the PD; however, interpretation of 
DNA binding results for these mutants was complicated by their low level of 
Figure 2 
PD and HD DNA binding properties ofwild type Pax3 and Pax3 mutants modified by 
insertion of Factor Xa protease sites. Wild type (wt) and mutant Pax3 cDNAs bearing single 
or multiple Factor Xa protease sites inserted at the position indicated at the top, were cloned 
into pMTI expression plasmid, and total cell extracts from transiently transfected COS-7 
Monkey cells were separated by SDS-PAGE (12% acrylamide) and transferred to 
nitrocellulose membranes. Immunodetection ofPax3 (top Iwo panels) was with mouse anti-c-
Myc (Mye) and anti-HA (HA) monoclonal antibodies and a horseradish peroxidase-
conjugated secondary antibody. Extracts from control non-transfected cells (mock) and from 
cells expressing individual Pax3 mutants were used in electrophoretic mobility shift assays to 
evaluate the DNA binding properties ofPax3 Xa mutants against PD (P6CON and P30P1) 
and HD-specific binding sites (P2 and P 1/2). Protein-DNA complexes were formed using 
total COS-7 cell extracts and were resolved on 6% acrylamide non-denaturing gels, as 
described under "Materials and Methods." 
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expression in COS-7 cells. The effect ofinserting Factor Xa sites on DNA binding properties 
of the HDwas evaluated using a target sequence (P2) containing the sequence 
T AA T(N)2 T AA T previously shown to support cooperative dimerization of Pax3 (Wilson et 
al., 1993). In addition, an oligonucleotide containing halfofthis sequence (half site, P1I2) and 
revealing monomeric Pax3 binding by the HD was used (Wilson et al., 1993). Results shown 
in Fig. 2 indicatethat DNA binding by the HD was also impaired in the Xa66 mutant, whereas 
mutants Xa55 and Xa71 show impaired monomeric bindingto P1I2 but retain sorne 
dimerization potential on P2. Importantly, aIl other mutants (positions 100, 114, 131, 172, 
189, and 216) retained WT binding activity toward the 4 oligonucleotides tested (summarized 
in Fig. 3), indicating that Factor Xa insertions in the RED subdomain of the PD are not 
detrimental to function by contrast to mutations at the homologous positions of the other, PAl 
subdomain. Finally, aIl insertions in linker segments did not affect DNA binding. 
Accessibility of Inserled Xa Sites 10 Proleolylic Cleavage-The accessibility of the 
inserted Factor Xa sites to proteolytic cleavage was investigated in mutants showing wild type 
ONA bindingactivity. Briefly, whole cell extracts from COS-7 cells expressingeither WT or 
individual Pax3-Xa mutants were incubated withFactor Xa protease (0.2 /lg), and at 
predetermined time points (2-180 min) digestion was stopped and samples were analyzed by 
SOS-PAGE and immunoblotting with anti-HA (Fig. 4) or anti-c-Myc (Fig. 5) antibodies. The 
size of the predicted cleavage products immunoreactive with each antibody are shown in 
Table III. Under these conditions, wild type Pax3 (WT) was almost completely resistant to 
Factor Xa cleavage, with the full-iength 55-kDa immunoreactive species being the prominent 
band at aIl time points (empty arrowhead; Figs. 4 and 5). Additional minor bands were 
detected either prior to addition of the protease (35 kDa, 0 min) or at very late time points (30 
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and 15 kDa, 90-180 min). Although these immunoreactive fragments are derived from the 
full-Iength protein, their appearance is Iikely caused by nonspecific c1eavage by Factor Xa at 
Figure 3 
Summary of DNA binding properties and accessibility of protease Xa sites of individual Pax3 
mutants. Shown is a schematic representation ofthe PD and RD ofPax3 according to 
structural features described in Fig. 1. The sites of modifications to create Factor Xa sites are 
indicated by arrowheads, together with the name of the mutant. The DNA binding properties 
of each mutant toward PD (P6CON and P30P1) and RD targets (P 1/2 and P2) is summarized 
below the schematic diagram (-, absent; +++, wild type). Gray arrowheads identify mutants 
that show important or complete loss ofDNA binding; Filled (black) and empty arrowheads 
identify mutants that retain wild type DNA binding for ail sequence targets, and in which the 
created Factor Xa protease sites are either accessible (jilled arrowheads) or inaccessible 
(empty arrowheads), under experimental conditions described in Fig. 4. 
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Figure 4 
Accessibility to protease cleavage of Factor Xa sites inserted in selected Pax3 mutants: effect 
of DNA binding. A, ten micrograms ofwhole cell extracts from COS-7 Monkey cells 
transfected with either wild type Pax3 (W1) or with Pax3 mutants XalOO (2), XalOO (4), 
Xa216 (1), and Xa216 (2) were incubated with Factor Xa protease (0.2 Ilg), either in the 
absence (no DNA) or after a 30-min incubation with PD (P30PT) and HD target sites (P 1/2 
and P2) under DNA binding conditions. At pre-determined time points (0-180 min, indicated 
at the top) aliquots were removed and analyzed by SDS-PAGE on 12% acrylamide gels and 
by immunoblotting with anti-HA antibody. Shown immediately to the left of each Pax3 series 
are empty arrowheads that indicate the position ofthe full-Iength intact Pax3 products, and 
filled (black) arrowheads that show the position ofmajor predicted, HA epitope-bearing 
Factor Xa cleavage products (see Table III). The position and size, in kilodaltons of the 
molecular mass markers are displayed as dashes on the left and numbers on the right, . 
respectively. Ali immunoblots probed with anti-HA antibody, including those of Fig. SI, were 
scanned by densitometry (B). The intensity of the immunoreactive intact full-Iength WT 
prote in and of individual Pax3 mutants was determined at both the 0 time point and at the 20-
min time points. The amount of intact protein remaining at 20 min (compared with 0 min) was 
determined for ail mutants and for ail DNA binding conditions and is expressed as the fraction 
of intact protein (expressed as a percentage). Several mutants showing inaccessible Factor Xa 
cleavage sites (XaI14, Xa131, Xal72/3, and Xa18912) were also included in the analysis as 
negative controls. 
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Figure 5 
Accessibility to protease cleavage of Factor Xa sites inserted in selected Pax3 mutants: effect 
ofDNA binding. A, wild type Pax3 and the different Pax3 mutants were incubated with 
Factor Xa under different conditions, and digestion products were analyzed by 
immunoblotting as described in the legend to Fig. 4, except that blots were probed with an 
anti-c-Myc antibody directed against the N-terminal c-Myc epitope present in ail mutants. B, 
ail immunoblots probed with anti-Myc antibody, including those of Fig. S2 were scanned by 
densitometry (Fig. 4B). The intensity of the immunoreactive intact full-length WT prote in and 
of individual Pax3 mutants was determined at both the 0 time point and at the 20-min time 
points. The amount of intact prote in remaining at 20 min (compared with 0 min) was 
determined for ail mutants and for ail DNA binding conditions and is expressed as the fraction 
of intact protein (expressed as a percentage). Several mutants showing inaccessible Factor Xa 
cleavage sites (Xa 114, Xa 131, Xa 172/3, and Xa 189/2) were also included in the analysis as 
negative controls. 
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Table 3: Expected size of Factor Xa proteolytic 
fragments in individual pax3 mutants 
pax3 Mutants 
Xa55 
Xa71 
Xa114 
Xa131 
Xa252 
Xa259 
Xa66(1) 
Xa66(2) 
Xa100(2) 
Xa100(4) 
Xa172(1) 
Xa172(3) 
Xa189(1) 
Xa189(2) 
Xa216(1) 
Xa216(2) 
aAmino 
Terminal 
Fragment(1) 
6.7 
8.6 
13.8 
15.9 
30.5 
31.4 
8 
8 
12.6 
12.6 
20.8 
20.8 
22.7 
22.7 
25.5 
25.5 
b Carboxy 
Terminal 
Fragment(2) 
49.5 
47.6 
42.4 
40.2 
25.7 
24.8 
48.9 
49.6 
44.3 
44.3 
36.1 
36.1 
34.3 
34.7 
31.6 
31.6 
aExpected specifie amine terminal proteolytic 
fragment (kD) detectable using anti-cMyc antibody. 
bExpected specifie carboxy terminal proteolytic 
fragment (kD) detectable using anti-HA antibody. 
suboptimal sites, or cleavage at specific sites by additional proteases contaminating either the 
cell extract or the commercial Factor Xa preparations. For reasons discussed below (see 
"Discussion"), these fragments were not considered in our analysis. Stripping the blot and 
reprobing with anti-c-Myc antibody (Fig. 5) confirmed the resistance ofWT Pax3 to digestion 
by Factor Xa under the conditions tested. Analysis of mutants Xal14, Xa131, Xal72(1/3), and 
Xa 189( 1 12) showed results similar to WT Pax3, and indicated almost complete resistance of 
these proteins to digestion by Factor Xa (supplementary data, Fig. SI), with little if any 
predicted proteolytic fragments immunoreactive with the HA antibody detected even after 180 
min of incubation. Similar results were obtained using the anti-c-Myc antibody to analyze 
digestion products (supplementary data, Fig. S2). These results indicate that the C-terminal 
RED subdomain and the linker domain immediately downstream of the PD are probablynot 
solvent-exposed and assume a compact conformation underthe conditions tested (Fig. 3). In 
contrast, mutant Xa 1 00 (2) yielded the expected 44-kDa C-terminal HA-immunoreactive 
cleavage product upon incubation with Factor Xa (jilled arrowhead, Fig. 4). The 44-kDa HA 
fragment was abundant at the earliest time point tested (2 min), and digestion was largely 
completed by 10 min. Similar rapid cleavage ofXalOO (2), as demonstrated by disappearance 
of the full-length 55-kDa protein, was verified by immunoblotting with the anti-c-Myc 
antibody (Fig. 5), although the N-terminal 12-kDa c-Myc-reactive digestion product was not 
retained on the gel. Increasing the number ofXa sites from two to four in mutant XalOO (4) 
produced similar outcome with even more rapid and more complete cleavage at the targeted 
site. Thus, cleavage at position 100 is specific in these mutants and strongly suggests that the 
linker separating the PAl and RED subdomains of the PD is solvent-exposed and prote;tse-
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accessible. Analysis of mutants Xa216 (1) and Xa216 (2) showed similar results. Both of the 
specific C-terminal HA-reactive 32-kDa and N-terminal c-Myc-reactive 26-kDa digestion 
products appeared at 2 min, and digestion of the full-Iength prote in was almost complete by 
20-45 min (Figs. 4 and 5). These results indicate that the protein segment immediately 
upstream of the HD is solvent-exposed and accessible to protease cleavage (Fig. 3). 
Effect of DNA Binding on Protease Sensitivity of Pax3 Mutants Xal 00 and Xa216-
The effect ofPax3 binding to PD (P30PT) and HD (Pl/2, P2) target sequences on the 
conformation of each domain was analyzed by monitoring the effect of DNA binding on 
accessibility ofXa cleavage sites present in mutants XalOO (PD) and Xa216 (HD). Aiso 
included in the se experiments were WT Pax3 as weIl as Pax3-Xa mutants previously observed 
to be resistant to Factor Xa cleavage in time course studies (see supplementary data). Briefly, 
cell extracts expressing Pax3 proteins were incubated with or without target DNA, followed 
by addition of Factor Xa and detection of HA (Fig. 4) and c-Myc (Fig. 5) immunoreactive 
cleavage products appearing over time. The extent of protection from proteolytic 
fragmentation was further quantitated after densitometry ofthe immunoblots and is expressed 
as the fraction of intact full-Iength Pax3 remaining following 20 min of incubation with Factor 
Xa (Figs. 4B and 5B). For the WT Pax3, binding to PD or HD target sequences had no effect 
on digestion profiles, as expected, with full-Iength Pax3 remaining the predominant species 
throughout the incubation period. Likewise, DNA binding by the PD or the HD of mutants 
Xal14, Xa131, Xal72, and Xa189 did not affect their previously noted resistance to Factor 
Xa cleavage (Figs. 4B and 5B and Figs. SI and S2 in supplementary data). This suggests that 
DNA binding by either domain in these mutants does not cause a conformational change that 
increases soivent exposure of the respective Xa bearing segments. By contrast, incubation of 
mutant Xal 00 (2) with P30PT increased resistance to proteolysis (persistence of 55-kDa 
prote in), suggesting that DNA binding to the PD causes a conformational change reducing 
140 
solvent accessibility of the PD. In addition, monomeric binding to P1I2 and in particular 
dimerization on P2 both also caused a dramatic increased resistance to proteolytic cleavage of 
Xal00 (2) (from 10% to 40% intact prote in), suggesting that ONA binding by the HD in this 
mutant also causes a conformational change in the PD. Identical results were obtained with 
Xal00 (4), although the increased susceptibilityto cleavage caused by the four consecutive 
Xa sites at position 100 was maintained in this mutant for ail ONA binding conditions tested. 
ln the case of mutants Xa216 (1) and Xa216 (2), mutantsthat bear Xa sites immediately 
upstream of the HO, ONA binding by the HO, in particular dimerization on P2, caused a 
strong increased resistance to proteolysis (from 25% to 85% intact protein) suggestive of a 
conformational change at that site. In addition, binding ofboth mutants to the PD target 
sequence (P30PT) also increased resistance to proteolysis, suggestingthat ONA binding by 
the PD also causes a conformational change in the HO. In ail cases, results of immunoblotting 
with anti-HA (Fig. 4) and anti-c-Myc antibodies (Fig. 5) were in complete agreement (Figs. 
4B and 5B). Together, results from XalOO and Xa216 are remarkably similar and suggest that 
DNA binding at either the PD or HO causes a conformational change at both sites. This 
change appears to reduce the amount of solvent-exposed area in the prote in, suggesting a 
more compact conformation of the ONA-bound prote in. 
Specificity ofthe protective effect of PD and HD target sequences on accessibility of 
the Xa sites in Xa 100 and Xa216 mutants was investigated in dose-response studies. In the se 
experiments, the Pax3 mutants were incubated with PD or HO oligonucleotide probes and 
DNA-Pax3 complexes were allowed to form; followingthis, increasing amounts of Factor Xa 
protease was added to the reaction mixture, which was further incubated for 15 min, and the 
appearance of specifie proteolytic cleavage products was monitored by SOS-PAGE and 
immunoblotting with the anti-HA antibody (Fig. 6A). In these studies, two additional control 
probes were tested to further validate the specificity oftheONA effect observed in time 
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course studies: a second, independently derived PD oligonucleotide P6CON, and a PD and 
HD nonspecific oligonucleotide, which was used as a negative control. Typical immunoblots 
are shown in Fig. 6A, and quantitation of the protective effects of the DNA probes by 
Figure 6 
Effect ofDNA binding on accessibility of Factor Xa sites in Pax3 mutants XalOO and Xa216: 
dose-response experiments. A, who le cell extracts (10 Jlg) from COS-7 Monkey cells 
transfected with Pax3 mutants Xal00 (2), or Xa216 (2) were incubated 30 min with either 
PD-specifie (P30PT and P6CON) or HO-specifie (Pl /2 and P2) oligonucleotides or with a 
nonspecific (NS) oligonucleotide. The buffer conditions for PD versus HO DNA binding were 
different (see "Materials and Methods"), and the negative control was included in each case. 
Increasing amounts of Factor Xa protease (from 0 to 200 ng/Jlg ofwhole ceIl extract) were 
added followed by a 15-min digestion period. Proteolytic fragments were separated by SDS-
PAGE and detected by immunoblotting using the anti-HA antibody, as described in the 
legend to Fig. 4. The positions of the full-Iength intact XalOO (2) and Xa216 (2) proteins 
(emptyarrowheads), and of the major predicted, HA-immunoreactive product (filled 
arrowhead, see Table III) are shown. B, for quantifying the effect ofDNA binding on 
accessibility of Factor Xa cleavage sites in dose-response studies, the immunoblots in A were 
scanned by densitometry. The intensity ofthe immunoreactive intact Xal00 (2) and Xa216 
(2) full-Iength proteins was determined in the absence of Factor Xa and after digestion with a 
Factor Xa amount indicated by the arrow at the top of each immunoblot series. The amount of 
intact prote in remaining after Factor Xa digestion was determined for Xal 00 (2) (black) and 
Xa216 (2) (gray) and for aIl DNA binding conditions and is expressed as the fraction of intact 
protein (expressed as a percentage). 
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densitometry is shown in Fig. 6B (percentage of uncleaved Pax3 at concentration indicated by 
the arrow in Fig. 6A). These experiments showed that incubation of mutants Xa 1 00 (2) and 
Xa216 (2) with PD oligonucleotides P6CON and P30PT reduced sensitivity ofboth proteins 
to increasing doses of Factor Xa. Likewise, incubation ofboth proteins with RD probes P1I2 
and P2 similarly increased resistance to FactorXa fragmentation. The effect of the two PD 
probes and two HO probes on protease sensitivity was specifie and not seen in control ONA-
free conditions (data not shown) and upon incubation with a nonspecific target sequence (Fig. 
6, A and B). Therefore, resuIts of dose response experiments are consistent with those obtained 
in time course experiments and show that DNA bindingto the PD and to the HO ofPax3 
cause a conformational change both locally as weIl as in the other DNA binding site. 
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Discussion 
The effect of inserting Factor Xa sites in different domains of Pax3 provides 
information on the importance of the targeted subdomains in DNA binding by the protein. In 
the PD, insertion of Factor Xa sites at the three locations tested in the N-terminalPAI 
subdomain caused loss of PD DNA binding. Because helix 3 makes critical base and 
phosphate contact in the major groove of DNA and is mutation-sensitive, it was not targeted 
for insertions. Nevertheless, we observed that mutations in helix 1 (Xa55), in the linker 
separating he lices 1 and 2 (Xa66), and in helix2 (Xa71) aIl impaired binding to PD 
oligonucleotides. Insertion ofXa sites may either disrupt important phosphate contacts made 
between the se helices and DNA (Fig. 1) and/or may destabilize the who le PAl domain. By 
contrast, two insertions created in helices 1 (Xa 114) and 2 (Xa 131) of the C-terminal RED 
domain had no major effect on DNA binding to PD sequences. Tbese results highlight the 
critical role of the PAl domain in DNA binding by the PD and are in agreement with (a) the 
high degree of primary amino acid sequence conservation of this domain (compared with the 
RED subdomain) in the PaxIPrd gene family (Xu et al., 1995; Epstein et al., 1994; Czerny et 
al., 1993; Epstein et al., 1994), (b) the cIustering of inactivating WSl mutations to the PAl 
subdomain ofPAX3 (Fortin et al., 1997), and (c) the fact that Pax proteins can bind DNA 
exc1usively through their PAl subdomain (Czerny et al., 1993). We note that mutationsXa55 
and Xa71 in the PAl domain impaired DNA binding to PD oligonucleotidesonly, whereas the 
Xa66 mutant showed impaired DNA binding to both PD and RD sequences. This behavior is 
similar to WS 1 mutants G48R1S and P50L (upstream helix 1 of PAl), respectively, and has 
been suggested to reflect functional interdependence ofthe PD and RD in DNA binding 
(Fortin et al., 1997). Interestingly, insertionoftwo or even four Xa sites in the linker joining 
the PAl to the RED (Xa 1 00) had no effect on DNA binding; this linker is weIl conserved 
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among Pax proteins, and sequences immediately downstream the insertion site make extensive 
phosphate and base-specific contacts in the minor groove of DNA (Fig. 1). As expected, the 
three insertions (Xal72, Xa189, and Xa216) in the poorly conserved linker joining the PD and 
the HD, including one within the octapeptide motif (XaI89) conserved in other Pax proteins 
(HSIDGILG) (Burri et al., 1989), had no major impact on DNA binding ofthe corresponding 
mutants to PD and HD sites. With respect to the HD, two mutations inserted either 
downstream helix 2 (Xa252) or upstream ofthe major DNA binding helix 3 (Xa259) appeared 
to either strongly diminish or abrogate monomeric or dimeric DNA binding to HO target 
sequences (Fig. 2). Although this conclusion is supported by both the high degree of 
conservation of the targeted sequences in thepaired-type HDs of the Pax family (Fig. 1-), and 
the fact thatmany WSI mutations map to the HD ofPax3 (Fortin et al., 1997), our inabilityto 
express high levels of the se mutants precluded a more detailedanalysis. 
Evaluating the accessibility of inserted Xa sites to protease cleavage can readily 
provide insight into the solvent exposure of the corresponding Pax3 subdomains. Results of 
time course studies were very clear and showed that ofthe seven sites in which insertions 
preserved DNA binding only two, Xa 1 00 and Xa216, were readily accessible to proteolytic 
c1eavage at the earliesttime points ofanalysis (Fig. 4). In agreement with the proposed 
structural model of the PD (Fig. 7A), the se results showed thatthe PAl to RED subdoniain 
linker (Xa 1 00 mutant) is clearly exposed to solvent. Although this domain is not believed to 
play a critical role in DNA binding, current structural models suggest that it is in close 
proximity to DNA (Xu et al., 1995). In addition, alternative splicing of a glutamine residue at 
position 108 of Pax3IPax7 is known to alter DNA binding specificity of the PD (Vogan et al., 
1996; Vogan et al., 1997). Therefore, mutants XalOO should be ideally suited to monitor 
structural changes associated with DNA binding by the PD. By contrast, downstream 
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insertions into helices 1 (XaI14) and 2 (Xa131) of the RED domain were completely resistant 
to protease cleavage, possibly suggesting that the HTH motif is either compact or buried in the 
Figure 7 
Structures of the PD and HD bound to DNA. The structure of the DNA-bound PD (A) is 
adapted from that published for Pax6 (Balling et al., 1988; Xu et al., 1999). The structures of 
the HD bound to DNA either as a monomer (B) or as a dimer (C) are taken from that 
published for the HD of the Drosophila Prd protein (Wilson et al., 1995). The DNA strands 
are shown as gray ribbons through the sugar phosphate backbone, and bases are shown as 
protrusions from the ribbons. The Pax3 segments are in green, with the positions of discrete 
sites targeted for modification to Factor Xa sites identified as causing 10ss-ofDNA binding 
(red), as having no effect on DNA binding and being either accessible (purple) or not (blue) 
to Factor Xa protease fragmentation. 
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-v 
core of the prote in or both (Fig. 7A). PD-HD linker insertions mapping far upstream of the HD 
(Xa 172 and Xa 189) were resistant to protease cleavage. Considering the observed 
accessibility of neighboring position 216, this is somewhat surprising; however, it is important 
to note that Xa sites at positions 172 and 189 were engineered immediately upstream of a 
hydrophobie residue (Leu and Ile, respectively), a situation known to reduce the efficacy of 
cJeavage by the Factor Xa protease (He et al., 1993). 
The effect of binding to PD and HD oligonucleotides on accessibility of all inserted Xa 
sites was investigated in time course studies (Figs. 4, 5, SI, and S2). In all cases, DNA 
binding did not increase accessibility ofXa sites, suggesting that DNA binding as a whole 
does not dramatically increase solvent exposure in the protein. However, this conclusion only 
applies to the subdomains analyzed and is limited by the fact that the primary amino acid 
sequence context of individual sites is not identical, possibly influencing protease cleavage 
irrespective of the three-dimensional structure (DNA-free or DNA-bound) ofthis subdomain. 
On the other hand, DNA binding by the PD reduced accessibility of the Xa 1 00 site, reflecting 
a conformational change to a more compact and less solvent-accessible position of the PAl to 
RED linker. The effect was specific, was seen in independent mutants bearing different 
number ofXa sites inserted, was noted upon bindingto independent PD site, and was not seen 
upon binding to an unrelated target site sequence. These results are in accordance with circular 
dichroism spectroscopy studies with Pax5 and Pax8 PDs that reveal increased helical content 
in the DNA-bound form of the PD (Tell et al., 1998). Likewise, DNA binding by the HD also 
resulted in decreased accessibility of the HD N -terminal linker (Xa216), reflecting a more 
compact structure of the DNA-bound state ofthis domain. These results are in agreement with 
x -ray crystallography and NMR studies of HD proteins that reveal an increased order of the 
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HTH motif, including the N-terminal arm and the recognition helix, ofthe DNA-bound form 
ofPbx (Sprules et al., 2003; Sprules et al., 2000; labet et al., 1999; Piper et al., 1999), 
Antennapedia (Qian et al., 1994), engrailed (Clarke et al., 1994), and Oct-l (Cox et al., 1995) 
proteins. Increased resistance to protease cleavage of the Xa216 site was more pronounced 
upon incubation with P2 than with the half site P1I2. This could reflect different stability and 
steady-state level of conformationally similar HDs in the DNA-bound state (supported by the 
EMSA data; Fig. 2) or could be indicative oftwo distinct conformations ofDNA-bound HDs 
in Pax3 monomers and dimers complexed to P1I2 and P2, respectively. 
lmportantly, DNA binding by the PD also caused a conformational change in the HD 
(P30PT binding to Xa216 mutants); likewise, DNA binding by the HD also caused a 
conformational change in the PD (P2 binding to Xa 100 mutants). These results provide for the 
first time a structural basis for the functional interdependence of the two DNA binding 
domains previously noted in the studyof(a) PD and HD DNA binding properties ofPAX3 
mutants from WSl patients (Fortin et al., 1997), and (h) the effect of PD and HD DNA 
binding on site-specific modifications of Pax3 mutants bearing single cysteine residues in each 
domain (Apuzzo et al., 2002). These results furthersuggest that the PD and HD ofPax3 can 
functionally interact for the final selection oftarget site sequences in vivo. Finally, results in 
Fig. 5 indieate that dimerization of Pax3 on P2 results in a conformation that appears distinct 
from that created in the same mutant upon binding to the PD oligonucleotide. Indeed, 
comparison of the digestion profile ofP2-bound versus P30PT-bound Xa216 mutants 
identifies a novet nonspecific but c-Mye-immunoreaetivecleavage product (shaded arrow, 
Fig. 5), whieh is present in the former but absent in the latter set of digest. This non specifie 
cleavage product is detected only upon binding of Xa216 mutants to P2 and not to P 112, 
strongly suggesting that it is caused by dimerization of Pax3 on P2, as opposed to monomerie 
binding to the half site. 
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The results of protease sensitivity studies presented here are in agreement with ~he 
structural model for combined PD and RD binding to chimeric target sequences proposed for 
the Drosophila Prd protein by Jun and Desplan (Xu et al., 1995). This model, based in part on 
the sequence arrangement ofbinding sites selected in vitro by sequential amplification from 
random DNA oligomers (Systematic Evolution of Ligands by EXponential (SELEX) 
enrichment procedure), suggests that the N terminus of the PAl domain is closely apposed to 
the N terminus ofthe RD when bound to the combined PRO site (Jun et al., 1996). Their 
model predicts that RD and PD bind to opposite sides of the DNA helix, with helix 2 of the 
PAl domain in very close proximity of the N-terminal extension of the RD, which was 
targeted for Xa site insertion in the present study. This model may be used to explain the 
interaction of the PD ofPax3 with the N-terminal arm of the RD of Msxl (Bendall et al., 
1999). Therefore, the critical position of the N-terminal extension of the RD identified in 
these studies agrees with our observation that DNA binding by either the PD or RD causes a 
structural change at that site. Finally, the importance of the N-terminal extension of the RD 
and ofhelix2 of the PAl domain in Pax3 function is highlighted by previous studies from our 
group showing that (a) alteration of the N-terminal RD extension abrogates the ability of the 
PD to modulate DNA binding specificity of the RD (Fortin et al., 1998), and (h) that deletion 
ofhelix 2 of the PAl domain restores DNA binding by the RD in the context of an otherwise 
inactivating mutation (Spd) in the PD (Fortin et al., 1998). 
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Supplementary Figure SI 
Accessibility to Protease Cleavage of Factor Xa sites inserted in Additional Pax3 Mutants: 
Effect ofDNA Binding. Results are shown as described in legend to Figure 4 (anti-HA 
probed). 
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Supplementary Figure S2 
Accessibility to Protease Cleavage of Factor Xa sites inserted in Additional Pax3 Mutants: 
Effect of DNA Binding. Results are shown as described in legend to Figure 5 (anti-Myc 
probed). 
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Protease sensitivity studies with Pax3 mutants with engineered Xa cleavage sites have 
shown that DNA binding of one domain induces a conformational change in the other DNA 
binding domain. As chapter 3 has indicated, this conformational change was monitored by 
differential protease sensitivity, more specifically; a reduction ofprotease sensitivity was 
observed when Pax3 is DNA bound. We postulate that the se conformational changes might be 
induced by intramolecular physical interactions between the PD and the HD. 
The objective ofthe following study was to identifY residues or segments in the PD 
that may be involved in HO physical interaction in order to shed more light on the functional 
interdependence of the two domains. The approach used was the same for the study described 
in chapter 1: cysteine scanning mutagenesis. As mentioned in the literature review, the Pax3 
Sp-delayed mutant holds a G42R mutation in the ~-hairpin of the PAl subdomain that 
abrogates paired and HD DNA binding activity (Underhill et al., 1995). Deletion ofhelix 2 
and flanking regions, in the PAl subdomain restores HD DNA binding activity in this mutant 
protein (Fortin et al., 1998). Based on these observations we postulate that helix 2 and 
flanking sequences, may form a site where HO physical interaction with the PD occurs. 
Consequently, this region of the PAl subdomain was targeted for study using cysteine 
scanning mutagenesis since we believe it holds a HD interaction site. 
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Chapter4 
The Paired Domain of Pax3 Contains a Putative Homeodomain Interaction Pocket Defined by 
Cysteine Scanning Mutagenesis 
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Abstract 
Pax3 is a transcription factor that plays an important regulatory role during neurogenesfs, 
myogenesis, and formation of neural crest cell derived structures. Pax3 has two DNA binding 
domains, a paired domain (PD) and paired-type homeodomain (HO) that show complete 
interdependence for DNA binding, with mutations in one domain impairing DNA binding by 
the other domain. Cooperative interactions between the PD and HO ofPax3 suggest that the 
two domains may physically interact for DNA binding. Site-specifie modification with thiol 
reagents in single cysteine Pax3 mutants was used to determine which segment of the PD may 
interaet with the HO. Twenty-four single cysteine mutants were independently introduced in 
the second a-helix (a2, positions 59-80) and in the ~-hairpin structure (positions 40-41) at the 
amino terminal portion of the PD. These mutants were tested for their ability to bind to PD 
(P6CON, P30PT) and HO-specifie DNA targets (P2), and the effect oftreatment with N-
ethylmaleimide on the se binding properties was established. In the PD, single cysteine 
mutants CLlQ40C, CLlI59C, CLN60C, CL/P69C, CLlS70C, CLII72C, CLlS73C, CLIL76C, 
CLN78C, and CLlS79C displayed NEM sensitive DNA binding toward both PD and HO 
targets. Three PD mutants (CLIL41C, CLlA63C, and CL1H64C) showed unusual behavior, 
with DNA binding to PD targets being NEM insensitive while DNA binding by the HO was 
abrogated by NEM treatment. Three-dimensional modeling of the NEM sensitive PD cysteine 
mutants reveal that they are not randomly distributed, but rather that they cluster in a 
hydrophobie pocket. We propose that this hydrophobie poeket may serve as a doeking site for 
the HO during ONA binding by the intact protein. 
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Introduction 
Pax3 is a member of the Pax family ofnine transcription factors that play critical roles 
in different aspects of mammalian development (Stuart et al., 1994). Pax3 expression occurs 
in the developing somites, neural tube, and neural crest cell derived structures. Heterozygosity 
for a loss-of-function mutation at Pax3 in splotch (Sp) mice causes pigmentary defects (white 
belly spot) while homozygotes show defects in neurogenesis (spina bifida), myogenesis 
(absence of limb muscle), and formation of neural crest cell derivatives including melanocytes 
(Bober et al., 1994; Beechey et al., 1986; Auerbach et al., 1954; Franz et al., 1990; Franz et 
al., 1989; Goulding et al., 1994). In humans, mutations in P AX-3 cause Waardenburg 
syndrome, a pathology characterized by pigmentary disturbances, craniofacial abnormalities, 
and sensory deafness (Baldwin et al., 1992; Baldwin et al., 1995). 
Pax proteins are defined by a unique DNA binding domain, the PD first identified in 
the Drosophila paired (Prd) protein (Bopp et al., 1986). Several Pax proteins, including Pax3, 
contain a second DNA binding domain known as the paired-type HD. Pax3 also shows a 
conserved octapeptide and a proline-serine-threonine rich C-terminal trans-activation domain, 
both of which are involved in prote in-prote in interactions (Stuart et al., 1994; Mansouri et al., 
1998). The crystal structure of DNA-bound Pax6 has been solved and reveals that the PD is a 
bipartite structure, with each domain consisting ofthree a-helices with the last two forming a 
typical helix-turn-helix (HTH) motif (PAl and RED) (Xu et al., 1995; Xu et al., 1999); the C-
terminal helix of each HTH makes cri tic al contacts in the major groove ofDNA (XU et al., 
1995; Xu et al., 1999). Located upstream of the N-terminal subdomain (PAl), a p-turn motif 
makes contacts in the minor groove ofDNA (Xu et al., 1995; Xu et al., 1999). The crystal 
structure of the DNA-bound paired-type HD of the Prd prote in (Wilson et al., 1995) reveals a 
conserved three helical foid with the two most C-terminai helices forming a HTH motifwith 
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a3 making DNA specifie major groove contacts (Wilson et al., 1995; Wilson et al., 1993; 
Treisman et al., 1989). The HD of Pax proteins has the unique ability to homodimerize on 
palindromic sequences of the type TAAT(N2/3)ATIA (Wilson et al., 1993; Schafer et al., 
1994). The identity of the amino acid residue at position 50 in a3 ofHD determines both 
DNA binding specificity and dimerization potential (Wilson et al., 1993; Schafer et al., 1994). 
Although the PD and HO can bind to cognate DNA sequences when expressed 
individually, genetic and biochemical data indicate that the two domains are functionally 
interdependent in intact Pax3 (Baldwin et al., 1995; Glaser et al., 1993; Lalwani et al., 1995; 
Underhill et al., 1995). For instance, the Splotch-delayed (Spd) aIlele ofPax3 bears a mutation 
(G42R) in the p-hairpin of the PD that not only abrogates DNA binding by the PD but also 
impairs DNA binding by the HD (Underhill et al., 1995). Conversely, studies of the HD 
mutation R53G found in a Waardenburg patient show that R53G not only impairs DNA 
binding by the HD but also uncouples DNA binding by the PD (Fortin et al., 1997). 
Additional studies in chimeric PAX3 proteins have shown that the PD can modulate both 
DNA binding specificity and dimerization potential ofheterologous HDs (Fortin et al., 1998). 
Previously, we have created a Pax3 mutant (Cys-Iess; CL-Pax3) in which aIl 
endogenous cysteine residues had been removed. CL-Pax3 retains both PD and HD DNA 
binding activity, and we have used this mutant backbone for the reintroduction of single 
cysteine residues at strategic locations ofthe PD and HD (Apuzzo et al., 2002). We have 
monitored the effect of site-specific modification of such single cysteine mutants by N~ethyl 
maleimide on the DNA binding properties of either domain (Apuzzo et al., 2002). 
Introduction ofa cysteine at position 82 (a3 helix of PAl domain; C82) did not affect DNA 
binding by Pax3, but site-specific modification of C82 impaired DNA binding by both PD 
and HD (Apuzzo et al., 2002). Conversely, NEM modification ofthe single cysteine HD 
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mutant V263C abrogated both the HO and PD DNA binding activity, while modification of 
independent mutations at nearby positions (V265C and S268C) had no effect on PD activity 
(Apuzzo et al., 2002). These studies further demonstrated the reciprocal regulation of the PD 
and RD in intact Pax3. 
Recently, we modified the Pax3 protein by insertion of single or multiple Factor Xa 
protease cleavage sites at strategie positions in or near the PD and HO. Protease sensitivity 
studies in Pax3 mutants modified at position 100 in the PD linker separating the PAl and RED 
motif, as weil as at position 216 immediately upstream of the HD, revealed that DNA binding 
by Pax3 resulted in a more compact and less solvent exposed protein (Apuzzo et al., 2004). In 
addition, it was observed that DNA binding by the PD not only caused a structural change in 
the PD but also caused a conformational change in the HO; similarly, DNA binding by the 
HO also caused a conformational change in the PD, providing a structural basis for the 
functional interdependence of the two DNA binding domains ofPax3 (Apuzzo et al., 2004). 
The major objective ofthis study was to try to identify individual residues in the Pax3 
PD that may come in close proximity to the RD during DNA binding by the intact protein. 
We reasoned that such residues may play a key role in the regulation ofDNA binding that the 
PD ofPax3 exerts on its own HD or on heterologous HD fused to it (Fortin et al., 1998). We 
focused our search on two regions of the amino terminal portion of the PD. We have 
previously shown that the G42R mutation in the PD of the Spd allele ofPax3 impairs both PD 
and HD DNA binding but that removal ofhelix 2 of the PD (PAl) restores DNA binding by 
the HD (Underhill et al., 1995; Fortin et al., 1998). In addition, DNA binding studies with the 
Prd Drosophila protein using hybrid DNA targets optimized for both PD and HD (PHO probe) 
show that the PD and HO bind their respective sites only when they are everted and 
juxtaposed in the same molecule (e.g. PHO probe) (Jun et al., 1996). Modeling studies using 
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the available structures from the PD ofPAX6 and the HD ofPrd suggests that when Pax 
proteins, with a PD and a HD, are bound to the PHO DNA sequence, the protein segment N-
terminal to the HD cornes in close proximity to helix 2 of the PAl subdomain ofthe PD (lun 
et al., 1996). Together, these studies suggest that helix 2 may be a candidate for interaction 
with the HD. Finally, structural studies of the temary complex formed between the PD of 
Pax5 and the Ets domains ofEts-l (Garvie et al., 2001) reveal that the p-tum within the p-
hairpin structure at the amino terminus of the PD is involved in protein:protein interactions. 
More specifically, residues in helix 2 of the PAl subdomain as weil as residues equivalent to 
Pax3 Q40 and L41 in the p-hairpin make contact with the Ets domain (Garvie et al., 2001). 
Therefore, we hypothesized that residues in the p-hairpin structure and in helix 2 of the PD 
may play a role in intramoleeular interactions between the PD and the HD ofPax3. 
We have used site-specifie modification of single cysteine mutants to identify the 
residues in the amino terminal portion of the PD that may be involved in functional or 
physical interaction with the HD. Clustering ofNEM sensitive single cysteine mutants 
impairing DNA binding by the HD on the three-dimensional structure of the PD identifies a 
hydrophobie pocket whieh may serve as a doeking site for the HD during DNA binding by the 
intact prote in. 
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Materials and Methods 
Mutagenesis. The construction of the pMT2 expression plasmid containing the entire 
protein-encoding region ofwild-type Pax3 cDNA has been previously described (Underhill et 
al., 1995). This pMT2/Pax3 construct encodes for a1l479 amino acids ofthe murine Q+ 
isoform ofPax3 (Underhill et al., 1995). This cDNA was modified by the in-frame addition of 
antigenic epitope derived from the human c-Myc protein (c-Myc epitope, EQKLISEEDL) at 
the N-terminus as well as a poly-histidine tail (His6), an HA hemagglutinin epitope 
(YPYDVPDYAS), and a termination codon at the C terminus of the protein. This was 
accomplished by PCR-mediated mutagenesis with mutagenic primers: P3-Myc (5'-
CTCGAATTCATGGAG-CAGAAGTTAATCAGCGAAGAGGATCTCACCA-
CGCTGGCCGGCGCTGTGCCCAGGATG-3') and P3-HA (5'-
TTTAGCGGATCCGAATTCTTAGTGATGGTGGT-
GATGGTGTCCCGCGGCGTAATCTGGAACGTCA-
TATGGATATCCGAACGTCCAAGGCTTACTTTG-3'). Both primers were engineered with 
Eco RI restriction sites at their ends. The resulting 1.5-kb PCR product was digested with 
EcoRI and Iigated into the corresponding site ofmammalian expression vector pMT2, and the 
resulting construct was designated pMT2/Myc-Pax3-HA WT (wild type). The seven 
endogenous cysteines of Pax3 were sequentially mutated to either serine or glycine in order to 
generate the cysteine-Iess construct, pMT2/Myc-Pax3-HA CL, as previously described 
(Apuzzo et al., 2002). The CL construct was then digested at the unique CIal site at position 
189 of the Pax3 coding region, and two protease Xa cleavage sites were introduced in-frame 
with the rest of the Pax3 encoding region using double-stranded oligonucleotides with CIal 
compatible cohesive ends, as described (Apuzzo et al., 2004). The oligonucleotide used to 
introduce 2 protease Xa sites, (5')-CGATATCGAAGGTAGAATAGACGGCCGAA T -(3'), 
permitted the generation ofthe pMT2/Myc-Pax3-HA 2Xa CL plasmid. 
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Twenty-four single cysteine mutants were created in the PD, at amino acid positions 
40 and 41 in the ~-hairpin structure, and at positions 59-80, which includes the entire length 
of the a2 helix of the PAl subdomain and flanking regions. AlI mutants were created by PCR-
mediated mutagenesis using the mutagenic oIigonucIeotides listed in Table 1 along with 
pMT2/Myc-Pax3-HA 2Xa CL plasmid as a template. The generation of aIl single cysteine 
mutants also required the use of the flanking primers: (5')-ATGACCA-
CGCTGGCCGGCGCTGTG-(3') and (5')-AGTGAGAGGGGAGAGAGCATAGTC-(3'). In 
ail cases, a PCR product of 1247bp was produced and digested with SmaI. The 330bp SmaI 
fragment was swapped into the endogenous Pax3 SmaI sites (pst 342-672) of the pMT2/Myc-
Pax3-HA 2Xa CL plasmid. Each mutation was verified by nucleotide sequencing, and the 
accessibility of restriction sites used for cloning was verified by endonuclease fragmentation. 
Expression and Detection of Pax3 Mutants. The expression plasmids were used to 
transiently transfect COS-7 monkey ceIls. One million ceIls were plated in Dulbecco's 
modified Eagle medium containing 10% fetal bovine serum and were transfected by the 
calcium phosphate coprecipitation method using 15 ~g of plasmid DNA doubly purifie.d by 
ultracentrifugation on cesium chloride density gradients. Calcium-DNA precipitates were 
placed onto the cells for 5 h and then treated with HBS (0.14 M NaCI, 5 mM KCI, 0.75 mM 
Na2HP04, 6 mM dextrose, 25 mM HEPES, pH 7.05) containing 15% glycerol for 1 min. The 
cells were then washed and placed in complete Dulbecco's modified Eagle medium. Whole 
cell extracts were prepared 24 h following glycerol shock by sonication in a buffer containing 
20 mM HEPES (pH 7.6), 0.15 M NaCI, 0.5 mM DIT, 0.2 mM EDTA, 0.2 mM EGTA, and a 
mixture of protease inhibitors: aprotinin, pepstatin, and leupeptin used at 1 mg/mL and 
phenylmethylsulfonyl fluoride used at 1 mM. These extracts were stored frozen at -70 0 C 
until use. To assess Pax3 mutant prote in expression and stability, aliquots ofwhole cell 
extracts were analyzed by electrophoresis on acrylamide-containing SDS gels (SDS-PAGE), 
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Table 1.0ligonucIeotides used for Pax3 mutagenesis 
Substitution 
PDSCM 
Q40C 
L4lC 
I59C 
V60C 
E61C 
M62C 
A63C 
H64C 
H65C 
G66C 
I67C 
R68C 
P69C 
S70C 
V71C 
I72C 
S73C 
R74C 
Q75C 
L76C 
R77C 
V78C 
S79C 
H80C 
Mutagenic primer (5'-3') 
GGCCGAGTCAACTGTCTCGGAGGAGTA 
CGAGTCAACCAGTGCGGAGGAGTATTT 
ATCCGCCACAAGTGTGTGGAGATGGCC 
CGCCACAAGATATGTGAGATGGCCCAC 
CACAAGATAGTGTGTATGGCCCACCAT 
AAGATAGTGGAGTGTGCCCACCATGGC 
ATAGTGGAGATGTGCCACCATGGCATT 
GTGGAGATGGCCTGCCATGGCATTCGG 
GAGATGGCCCACTGTGGCATTCGGCCG 
ATGGCCCACCATTGCATTCGGCGGAGC 
GCCCACCATGGCTGTCGGCCGAGCGTC 
CACCATGGCATTTGTCCGAGCGTCATT 
CATGGCATTCGGTGTAGCGTCATTTCT 
GGCATTCGGCCGTGCGTCATTTCTCGC 
ATTCGGCCGAGCTGCATTTCTCGCCAG 
CGGCCGAGCGTCTGTTCTCGCCAGCTT 
CCGAGCGTCATTTGTCGCCAGCTTCGC 
AGCGTCATTTCTTGCCAGCTTCGCGTG 
GTCATTTCTCGCTGTCTTCGCGTGTCC 
ATTTCTCGCCAGTGTCGCGTGTCCCAT 
TCTCGCCAGCTTTGCGTGTCCCATGGA 
CGCCAGCTTCGCTGTTCCCATGGATCC 
CAGCITCGCGTGTGCCATGGATCCGTC 
CTTCGCGTGTCCTGTGGATCCGTCTCT 
NllcleotÎ<!e substitutions leading to amino acid changes are illdicated in bold 
followed by electrotransfer onto nitrocellulose membranes and immunoblotting. 
Immunodetection was performed with mouse monoclonal anti-HA antibody (BabCO, 
Berkeley, CA) at a dilution of 1:1000 and visualized by enhanced chemiluminescence using a 
sheep anti-mouse horseradish peroxidase conjugated secondary antibody (Amersham 
Biosciences). Following anti-HA probing the membranes were submerged in stripping buffer 
(100 mM 2-mercaptoethanol, 2% SDS, 62.5 mM Tris-HCl, pH 6.7) and incubated at 50 ., C 
for 30 min. The membranes were then washed with TBST buffer (l0 mM Tris-HCI, pH 8, 150 
mM NaCI, 0.1 % Tween 20) at room temperature. Following blocking, the membranes were 
probed with mouse monoclonal anti-Myc antibody (BabCO) at a dilution of 1:1000 and 
visualized by enhanced chemiluminescence using a sheep anti-mouse horseradish peroxidase 
conjugated secondary antibody (Amersham Biosciences). 
Electrophoretic Mobility Shift Assays. Electrophoretic mobility shift assays (EMSA) 
were performed as previously described (Underhill et al., 1995). Each protein:DNA binding 
reaction was carried out using approximately 8 Jlg of total cell extracts from transiently 
transfected COS-7 monkey cells and 10 fmol (0.06 JlCi) of radioactively labeled double 
stranded oligonucleotides containing either PD or HD recognition sites or both. The final 
concentration of labeled oligonucleotide in the binding reaction is 0.0005 JlM. Whole cell 
extracts were incubated with 32P-Iabeled PD or composite PD and HD specifie probes in a 
volume of20 JlL containing 10 mM Tris-HCI (pH 7.5),50 mM KCI, 1 mM DTT, 2 mM 
spermidine, 2 mg/mL BSA, and 10% glycerol. To reduce nonspecific binding, 1 Jlg of 
poly(dI-dC)poly(dI-dC) was included in binding studies with PD-specifie probes and 
composite probes with both PD and HD sites, white 2 Jlg ofheat-inactivated salmon sperm 
DNA was added to binding reactions involving HD specifie probes. Following a 30 min 
incubation at room temperature, samples were electrophoresed at 12 V/cm in 6% 
acrylamide:bis-acrylamide (29:1) gels containing 0.25 or 0.5X TBE (lX TBE is 0.18 ~ Tris-
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HCI, 0.18 M borie acid, 4 mM EDTA, pH 8.3). Gels were dried under vacuum and exposed to 
Kodak BMS film with an intensifying screen. PD-specifie sequences P6CON (5')-
TGGAA TTCAGGAAAAA TTTTCACGCTTGAGTT -CACAGCTCGAGTA-(3') (Epstein et 
al., 1994) and P30PT (5')-TGGTGGTCACGCCTCATTGAATATTA-(3') (Chalepakis et al., 
1995), HO-specifie sequence P2 (5')-GATCCTGAGTCTAATTGATIACTGTACAGG-(3') 
(Xu et al., 1999), and the composite PD and HO specifie sequence PHO (5')-
GA TTTCTTCCAA TT AGTCACGCTTGAGTG-(3') (Jun et al., 1996) were synthesized as 
complementary oligonucleotide pairs and were designed in order to have recessed 3' ends for 
end labeling with [:x._32p] dATP (3000 Ci/mmol; NEN) using the Klenow fragment ofDNA 
polymerase. The thiol-specific reagent N-ethylmaleimide (NEM) from Pierce was prepared as 
a 32 mM stock in water. NEM was added as a 0.5 ilL aliquot to a 4 !!L volume ofwhole cell 
extract (final concentration ofNEM was 3.55 mM), followed by a 30 min incubation at room 
temperature prior to the addition of the e2p]-labeled probe and EMSA. 
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Results 
To study proximity relationships between the PD and the HO ofPax3, we used 
cysteine scanning mutagenesis to independently mutate Q40 and L41 (~-hairpin), as weil as 
each position of helix 2 and flanking positions within the PAl subdomain of the PD (Pax3 
positions 59-80) (see Figure 1). Mutants were constructed by PCR-based mutagenesis, 
expressed in COS-7 monkey cells, and tested for their DNA binding properties for HO or PD 
targets with or without prior site-specifie modification with NEM. 
Protein Expression and DNA Binding Properties of Pax3 Single Cysteine Mutants. To 
facilitate detection ofthe wild-type (WT), Cys-Iess (CL), and ail single cysteine mutants 
(SCM), c-Myc and hemagglutinin (HA) epitope tags were inserted in-frame at the N-terminus 
and C-terminus of ail constructs, respectively. Ali constructs were made using the pMT2 
expression vector followed by transient transfection into COS-7 monkey cells. 
Immunoblotting ofwhole cell extracts with either anti-HA or anti-c-Myc monoclonal 
antibodies indicates comparable levels of expression for the WT, CL, and of ail the SCMs 
(Figure 2). This suggests that none of the mutations introduced affect prote in stability in COS-
7 cells. The effect of single cysteine insertions in the ~-hairpin and in helix 2 on the DNA 
binding properties of the PD and HO was examined in each mutant by electrophoretic 
mobility shi ft assays (EMSAs). The DNA binding of the PD SCMs was examined using 
oligonucleotide probes P30PT and P6CON previously shown to reveal binding determinants 
present in both the amino (PAl) and carboxyl (RED) subdomains ofthe PD. Most of the 
SCMs retained PD DNA binding activity similar to the CL prote in used as control, with the 
possible exception ofCLIL41C and CLII72C which showed reduced binding to P30PT 
(Figure 3). Ali SCMs showed similar binding properties for either PD probe, P30PT or 
P6CON, with the notable exception of CLIH80C that shows little P30PT binding activity yet 
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Figure 1 
Site-directed mutagenesis of the PD ofPax3. (A) The amino acid sequence for positions 34-
162 ofPax-3 is shown, inc1uding a schematic representation of the N-terminal (PAl) and C-
terminal (RED) subdomains of the PD, together with structural features based on the three-
dimensional structure ofthe PD of the Pax6 protein (13, l3-strand; T, l3-tum; a, a-helix) (Xu et 
al., 1999). Invariant residues among ail known PDs are identified below the schematic 
representation. The type of predicted DNA contacts made by these residues (p, phosphate; m, 
minor groove; M, major groove) is shown. The positions and nature of the mutations 
introduced in Pax-3 to create the Cys-less (CL) mutant are indicated. Boxed residues show 
areas targeted when generating single cysteine mutants. (B) Schematic representation of the 
Pax3 HO, including the presence and position of predicted structural features, invariant amino 
acid residues, number and types ofDNA contacts (as for panel A). The position of the c-Myc 
and hemagglutinin (HA) epitope tags inserted in-frame at the amino and carboxyl termini of 
Pax3, respectively, is shown. 
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1 1 1 1 1 r 1 1 1 1 1 1 1 
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Invariant ----~~G-F-NGRPLP---R- ~ ~ ~~ r ~ t ~S GCVSKIL-R---TG---P--IGGSK------P-----I----------F-WEI---L-----------PS-S-I-R--R---
DNA Contact -------------mm------------------------------MMMM-MM---------------mmmm--m--------------------------------------------M---M--M---
-----pp----p-ppppp----p-----------ppp---p---pp--p-pp---p--------ppss-ss-pppp-------------------ppp------------------p--p-pp--p---
CL ------------------------------------S-----------S-----G------------------------------------------------------S-------------------
HD 
B a3 Hf--i HA 
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1 1 1 1 1 1 1 
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Invariant --R-RT-F---Q---LE--F-RT-YPD---RE-LA----L-EAR-QVWFSNRRA--R---
DNA Contact --m-m-----------------------------------------M--MM---------
-----p------------------p-----p------------p----p---p-p-p---
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Figure 2 
Expression of Pax3 mutants in COS-7 monkey cells. COS-7 cells were transiently transfected 
with wild-type (wt) Pax3, or with a Pax3 mutant devoid of cysteine residues (Cys-Iess; CL) or 
with a number of independent Pax3 mutants. The "mock" labeled lane refers to whole cell 
extracts from untransfected COS7 cells. Pax3 cONAs were cloned into pMT2 expression 
plasmid, and total cell extracts from transiently transfected COS-7 monkey cells were 
separated by SOS-PAGE (10% acrylamide) and transferred to nitrocellulose membranes. 
Immunodetection ofPax3 was carried out with mouse anti-HA (A) and anti-c-Myc (H) 
monoclonal antibodies and a horseradish peroxidase-conjugated secondary antibody. 
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Figure 3 
DNA binding properties ofPax3 mutants analyzed by electrophoretic mobility shift assays. 
Who\e cell extracts from control nontransfected cells (mock) and from cells expressing 
individua\ Pax3 mutants were used in electrophoretic mobility shi ft assays to evaluate the 
ONA binding properties of Pax3 single cysteine mutants against PD (P6CON and P30PT) 
and HO binding sites (P2), and against a probe with both PD and HD binding sites (PHO). 
Protein-ONA complexes were formed using total COS-7 cell extracts and were resolved on 
6% acrylamide nondenaturing gels, as described under Materials and Methods. The free probe 
is shown for the EMSA performed with the PHO probe only. 
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CLIH80C 
retains wild-type P6CON binding activity. The molecular basis for the unique differential 
binding of CLIH80C to P30PT and P6CON is addressed in the Discussion. The effect of 
cysteine substitutions on DNA binding properties of the HD was evaluated using a target 
sequence (P2), which contains the sequence T AA T(N2)A TT A previously shown to support 
cooperative dimerization ofPax3 (Wilson et al., 1993; Schafer et al., 1994). Most SCM 
retained near wild-type binding activity toward P2 with the exception of CLlQ40C, CLIL41 C, 
CL/M62C, CLlH65C, CLlG66C, CLIP69C, and CLII72C that showed decreased binding. 
These results indicate that sorne of the mutations in the PD affect DNA binding by the HO, in 
agreement with previously published results (Underhill et al., 1995; Fortin et al., 1997). 
Finally, ail mutants bound the PD-HO composite site present in the PHO probe, suggesting 
that the decreased binding to either PD or HD targets seen for sorne ofthe mutants did not 
impair their ability to bind to the composite site. 
Effeet ofThiol Specifie Reagents on DNA Binding by Single Cysteine Pax3 Mutants. 
The thiol-reactive compound N-ethyl maleimide (NEM) can form covalent adducts with Cys 
residues and was used for site-specifie modification of SCMs. The effect ofNEM on DNA 
binding by the PD and HD of WT, CL, and SCMs was tested in EMSA. Whole cell extracts 
from COS-7 cells expressing individual mutants were preincubated with 3.55 mM N-ethyl 
maleimide (NEM), and the ability of each mutant to bind via their PD (with P30PT and 
P6CON) or HO (with P2) or both simultaneously (with PHO) was monitored by EMSA. The 
ability of WT Pax3 to bind to either PD or HO probes or the composite PHO site is completely 
abrogated by prior incubation with NEM. On the other hand, the CL-Pax3 mutant is 
insensitive to the effect ofNEM, and retains DNA binding to aIl probes (Figure 4). 
175 
Figure 4 
Effect of site-specifie modification on DNA binding properties ofPax3 mutants. Effects of N-
ethyl maleimide (NEM) treatment on the PD and HD DNA binding properties ofwild-type 
(WT), Cys-less (CL), and single cysteine mutants in the PD. Whole cell extracts from COS7 
monkey cells (mock) or from cells expressing different Pax3 proteins were incubated with 0 (-
) or 3.55 mM (+) NEM prior to electrophoretic mobility shift assays. The DNA binding 
properties of the PD were evaluated with target sites P30PT and P6CON, while the HD was 
tested using the P2 probe. The ability to bind the composite sequence PHO was also assessed. 
Filled arrowheads indicate SCMs with PD and HD NEM sensitive DNA binding domains, 
and empty arrowheads indicate SCMs with only HD NEM sensitive DNA binding. 
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NEM-sensitivity studies showed three types ofresponses in the SCMs. The first was 
that NEM had no effect for any of the probes analyzed, similar to that seen for the CL control. 
This group included SCM at positions 61,62,65,66,67,68, 71, 74, 75, and 77. The absence 
ofNEM effect in this group can reflect either inaccessibility of the corresponding Cys to 
NEM or that modification at that site is without consequence on the PD or HD ability to bind 
the target sequences. The second group was characterized by a loss or reduction ofDNA 
binding by both PD and HD and included SCM at positions 40, 59, 60, 69, 70, 72, 73, 76, 78, 
and 79 (Figure 4). The third and most intriguing group corresponded to SCM in which NEM 
had no apparent effect on ONA binding by the PD, but caused a modest (position 41) or 
severe loss (positions 63 and 64) ofDNA binding by the HD. Ofnote, NEM did not affect the 
ability of SC Ms to bind the composite PHO site, except for SCMs CLIP69C, CLlS73C, 
CLN78C, and CLlS79C, which show partial NEM sensitivity, and CLII59C and CLII72C, 
which display complete NEM sensitivity. Finally, CLIH80C showed a unique behavior in that 
NEM impaired ONA binding by this mutant to one PD probe (P30PT) but not the other 
(P6CON), while having no effect on HD DNA binding (Figure 4). 
The positions of PO residues (PAl subdomain) that show NEM sensitivity for DNA 
binding are shown (Figure 5) in a 3-dimensional ONA-bound PD model which is based on the 
high-resolution crystal structure of PAX6 (Xu et al., 1999). Residues colored red identify 
positions at which NEM modification of a Cys reduces DNA binding by both the PD and HO, 
while those colored yellow show positions at which NEM modification of a cysteine impairs 
ONA binding only by the HO. This analysis shows that NEM sensitive SCMs are not 
randomly distributed but that they appear to cluster together in the 3-D structure of the DNA-
bound PO. The NEM sensitive regions of the PD include portions of ~-tum (pst: 40, 41) 
within the ~-hairpin and segments of al (pst: 59, 60, 63, 64) and a2 (pst: 69, 70, 72, 73, 76) as 
weIl the a2-a3 loop (pst: 78, 79). These positions appear to be solvent exposed and map to the 
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Figure 5 
Structure of the DNA-bound PD. The PD is shown as a green ribbon drawn through the oc 
carbon backbone. The DNA strands are shown as gray ribbons through the sugar-phosphate 
backbone, and bases are shown as protrusions from the ribbons. The PD positions targeted for 
cysteine substitution and at which NEM modification causes a decrease in PD and HD DNA 
binding activities are indicated in red, while those leading to a reduction in HO DNA binding 
activity only are indicated in yellow. Panel A shows the DNA-bound PD with the PAl and 
RED subdomains indicated. Aiso labeled are the a-he lices of the PAl subdomain only along 
with the p-hairpin structure. Panels B, C, and 0 show the PAl subdomain from three different 
viewpoints. Panel E shows the DNA-facing side of the PAl subdomain with the DNA strands 
removed. The three helices and the p-hairpin position numbers of residues that are NEM 
sensitive when substituted with cysteine are shown. 
179 

opposite plane of the DNA binding determinants of helix 3 (Figure 5). It is important to note 
that 8 of 13 NEM sensitive SCMs are loeated at positions that hold a hydrophobie side ehain 
(L4l, 159, V60, A63, P69, 172, L76, and V78), suggesting that the subdomain identified forms 
a three-dimensional hydrophobie poeket where the RD may doek during DNA binding. 
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Discussion 
Examining NEM sensitive PD SCMs in the 3-D model of the DNA-bound PAl 
subdomain structure (Figure 5) indicates that these informative SCMs cluster together. This 
clustering of portions of the ~-tum ofthe ~-hairpin and portions of al, a2, and the a2-a3 loop 
suggests that these regions, that are not adjacent to one another in the primary sequence, may 
come into close proximity in the tertiary structure of the PD to form a RD binding pocket. 
The docking of HD segments to this PD hydrophobie pocket may provide the physical contact 
underlying the functional interdependence ofthe PD and RD for DNA binding noted in many 
mutant Pax3 variants (Baldwin et al., 1995; Glaser et al., 1992; Lalwani et al., 1995; Underhill 
et al., 1995; Fortin et al., 1997). 
We have chosen to use site-specifie modification of single cysteine mutants (Apuzzo 
et al., 2002; Frill ingos et al., 1998; Loo et al., 2000) to probe functional interactions between 
the two DNA binding domains ofPax-3. Although this technique has been extensively used to 
decipher structure:function relationships in a number of soluble and membrane proteins 
(Apuzzo et al., 2002; Frillingos et al., 1998; Loo et al., 2000), one ofthe limitations is that 
positions that do not show NEM sensitivity are not informative in the analysis. Indeed, for 
such single cysteine insertions one cannot distinguish inaccessibility of the mutant to the 
alkylator from successful modification being without consequence for protein function. 
Although we did not take into account mutants that lacked NEM sensitivity to DNA binding, 
we believe that most of the positions studied herein are indeed accessible to NEM at the 
concentration and temperature conditions used. Circular dichroism (CD) studies ofPax5 (Tell 
et al., 1998) and Pax8 (Tell et al., 1998) reveal that the PD is largely unstructured in solution, 
adopting a more structured conformation with a larger a-helical content upon DNA binding. 
This is in agreement with our own protease sensitivity studies ofPax3 in solution and DNA-
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bound, that show a more compact less-accessible PD and RD upon DNA binding (Apuzzo et 
al.,2004). 
NEM modification of several SCMs (red regions in Figure 5) affected DNA binding 
by both the PD and the RD. This behavior is common for many Pax3 mutants bearing 
independent mutations in different portions of the PD that we have previously analyzed. In 
general, they may reflect an NEM mediated structural change in the PAl region of the PD that 
disrupts directly or indirectly conformation of the critical DNA binding a3 helix. Disruption 
of HD DNA binding in these mutants may be due to a direct structural change in the RD 
"docking" site identified here, or may suggest that docking of the RD onto the PD can happen 
only when the PD is in a DNA-bound state. Those SCM positions at which NEM 
modification only impaired DNA binding by the RD, while leaving intact the DNA binding 
properties of the PD (yellow regions, Figure 5), were of particular interest. Indeed, these 
mutants demonstrate directly that several residues in the identified "docking" site can 
modulate HD function without altering the DNA binding properties of the neighboring DNA 
binding determinants of the PAl subdomain, including the critical helix 3. Such mutants 
provide an important internai control for specificity of the site-specific modification strategy 
we have chosen to use. Overall, we favor an interpretation where NEM modification a~ aIl 
sensitive positions in the PD identified here causes a steric hindrance that reduces the ability 
of the HD to dock onto the RD binding pocket in the PD. Therefore RD docking onto the PD 
may be absolutely required for RD DNA binding, including dimerization on P2-type target 
sequences. 
The location of a HD docking pocket at the "head" portion of the PAl subdomain is 
consistent with the hypothetical model proposed by Desplan (Jun et al., 1996) for the 
interaction of the PD and RD domains ofPrd when bound to the chimeric probe PRO. Our 
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results analyzed in the light ofthis model suggest that the RD can dock between he lices 1 and 
2 of the PAl subdomain and the DNA template. This situation is very similar to the interaction 
reported between the PD ofPax5 and another DNA-binding module, the Ets domain of Ets-l 
(Garvie et al., 2001). Ets proteins bind poorly to suboptimal Pax5IEts binding sites, but 
affinity drastically increases when Pax5 is present through cooperative interactions between 
the 2 proteins (Garvie et al., 2001). Residues of the ~-turn in the ~-hairpin as weil as a portion 
of a2 of the DNA-bound Pax5 PD have been shown to be responsible for the recruitment of 
the Ets domain. The equivalent of the NEM sensitive residue Q40C in the Pax5 PD (Q22) is 
known to participate in hydrogen bonding and van der Waals contacts with Q336 and Y395 of 
the Ets domain. The equivalent of the NEM sensitive Pax3 residue L41C (L23 in Pax5) 
associates with the hydrocarbon portion of the side chain ofresidue K399 ofthe Ets domain 
ofEtsl via hydrophobic coupling. Finally the equivalent of the Pax3 residue R74, located in 
a2 of the PAl subdomain, in Pax5 (R56) contacts residue D398 and K399 of the Ets domain 
(Garvie et al., 2001). The CLIR74C mutant did not show PD or RD NEM sensitivity, ~ut 
residues flanking this position in a2 (pst: 72, 73 and 76, 78, 79) were found to be NEM 
sensitive. Taken together, the analysis ofPD:RD interactions in SCM Pax3 mutants reported 
here, and structural studies of the interface ofPax5-Ets proteins interaction in the DNA-bound 
state, strongly suggest that the ~-turn of the ~-hairpin and parts of a2 of the PD perform 
critical protein-protein interaction functions. 
Cysteine substitution at position 80 created a mutant (CLIH80C) that retains PD 
binding activity to P6CON but abrogates PD binding activity to P30PT. Initially this was 
counterintuitive since one would suspect that a cysteine substitution wou Id more likely. disrupt 
binding to a DNA sequence optimized for the Pax3 PD (P30PT) than to a DNA sequence 
corresponding to the consensus sequence for the PD ofPax6 (P6CON). Position 80 is the tirst 
residue in the DNA binding recognition helix a3 of the PAl subdomain, and it plays a critical 
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role in DNA binding specificity (XU et al., 1995; Xu et al., 1999). PD proteins, such as Pax3 
and Drosophila Prd, have a histidine residue at the first position of a3 and have a preference 
for the 5'-GTCACGC-3' DNA sequence (Xu et al., 1995; Xu et al., 1999). Other PDs, such as 
the Pax6 PD, show an asparagine at the first position of PAl a3 and have a preference for the 
5'-TTCACGC-3' DNA sequence (Xu et al., 1995; Xu et al., 1999). A histidine residue at 
position 1 of the PAl a3 hydrogen bonds the first guanine ofthe 5'-GTCACGC-3'. Instead of 
making hydrogen bonds with adenine in an AT base pair, the Asn at this position interacts 
with the thymine in the AT base pair via hydrophobie coupling (Xu et al., 1995; Xu et al., 
1999). The methylene group (-CH2-) p-carbon of the side chain participates in hydrophobie 
interactions with the methyl moiety offirst thymine of the 5'-TTCACGC-3' sequence. This 
contact is stabilized by a water-mediated interaction between the amide group of the Asn si de 
chain and the sugar phosphate backbone ofDNA (Xu et al., 1995; Xu et al., 1999). The 
substitution of a cysteine at position 80 ofPax3 essentially converts the specificity of the PD 
from Prd-Iike to Pax6-like. This can be accounted for since the hydrophobie cysteine side 
chain is more likely able to participate in hydrophobie interaction with a methyI group of a 
thymine than participate in hydrogen bonding to a guanine ofDNA. This wou Id account for 
the unusual behavior ofthis mutant toward different PD targets. 
Eight out of thirteen NEM sensitive positions in the PAl subdomain consist of residues 
with hydrophobie side chains. This suggests that interaction of the HD onto this putative PD 
docking site most likely involves hydrophobie interactions, and corresponding hydrophobie 
residues in the HO. The identity of these residues remains unknown at present, although 
several observations in chimeric and mutant proteins (Fortin et al., 1998) point to the N-
terminal arm immediately upstream ofhelix 1 of the HD as a good candidate for such 
interactions. However, the identification of a subset of PD positions at which NEM 
modification impairs DNA binding by the HD and PD provides anchor points for the 
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systematic search of potential interacting residues in the HD by a similar cysteine scanning 
mutagenesis approach. In this approach, a bifunctional sulfhydryl cross-linker (e.g. copper 
phenanthroline) could be used to look for cross-links between individual PD anchor cysteines, 
and a series of additional single cys mutants in discrete portions of the HD (Frillingos et al., 
1998; Loo et al., 2000). In this scheme, successful cross-links can manifest themselves as 
species of higher molecular mass on SDS-PAGE and can be further validated using inserted 
factor Xa cleavage sites with immunoblotting against epitope tags inserted at the NH2 and 
COOH-terminus of the proteins. 
Together, results of site-specifie modification experiments agree with the proposition 
that the PD and HD do not function as independent DNA binding modules in Pax3, but 
instead the PD and HD may physically and functionally interact, in the full length Pax3 
protein, so that one domain can modulate the DNA binding properties of the other domain. 
These interactions may be important for target site selection by the Pax3 prote in in vivo. The 
results ofthis study also explain the loss of PD and HD activity seen in the G42R sl mutant 
variant ofPax3. G42R maps within the boundaries of the proposed hydrophobic HD docking 
pocket, and independent mutations at that site behave as complete loss-of-function (Underhill 
et al., 1997). The introduction of a bulkier and charged si de chain at position 42 may prevent 
HD docking via steric hindrance, loss ofhydrophobic interface, or both. 
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The identification of a putative HD binding site in the PD supports our model that PD: 
HD intramolecular physical interaction may be responsible for the functional interdependence 
between the two domains ofPax3. AIso, the identification and characterization of the 
mechanism of this functional interdependence may constitute an essential step towards' 
understanding how proteins holding homologous domains with similar DNA binding 
activities, such as Pax proteins, achieve functional diversity. This might be especially true for 
Pax proteins with a PD and a full-length HD, such as Pax3 and Pax6. 
The next logical step to be undertaken is to identify residues or portions ofthe HD that 
are actually docking onto and physically interacting with residues in the PD. The area of the 
HD that we suspect may interact with the PD is the N-terminal arm. Our suspicion is partly 
based on the model of the Pax3 homolog, Prd, bound to the PHO DNA sequence, which 
contains both PD and HD recognition sites. This model proposes that when the PD and HD of 
Prd is bound to the composite PHO DNA sequence helix 2 ofthe PD cornes into close 
proximity, and possibly interacts with, the N-terminal arm of the HD (Jun and Desplan., 
1996). Also, protease sensitivity studies ofPax3 mutants presented in chapter 3 reveals that a 
conformational change can be detected in an area ofPax3 that lies immediately upstream of 
the HO N-terminal arm when the PD is ONA bound (Apuzzo et al., 2004). To assess whether 
the N-terminal arm of the HO docks onto the putative HD binding pocket in the PD a cysteine 
scanning mutagenesis approach was used. This involved the use of Pax3 double cysteine 
mutants as weil as bifunctional thiol specifie reagents that can crosslink two cysteines that lie 
in close proximity to one another. 
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Chapter 5 
Cooperative Interactions between the two DNA Binding Domains ofPax3: Helix 2 of the 
Paired domain is in close proximity of the amino terminus of the Homeodomain 
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Abstract 
Pax3 is a transcription factor that plays an important role during neurogenesis and 
myogenesis, and Pax3 mutant animais display neural tube defects and lack limb muscles. 
Pax3 harbors two DNA binding domains, the Paired domain (PD) and a paired-type 
Homeodomain (HD). Genetic and biochemical data have (i) identified strong cooperative 
interactions between the PD and HD domains for DNA binding in the intact Pax3 protein, and 
(ii) suggested an important role for the amino terminal portions of both domains in such 
cooperativity. We have studied proximity relationships between the PD and HD ofPax3. For 
this, we have used a cross-linking strategy with the bi-functional thiol reagent bis-
maleimidoethane (BMOE) in 21 mutants bearing pairs of cysteine residues (DCM) inserted in 
strategic locations of a functional Pax3 protein otherwise devoid of endogenous cysteine 
residues. Ali 21 DCMs were characterized for protein stability, for DNA binding by the PD 
and HD, and for the effect ofBMOE on prote in binding to PD, HD or PDIHD combined DNA 
targets. BMOE-induced cross-links in DCMs were detected as slower migrating species on 
immunoblots. Mutants bearing double cysteine insertions I59C/ S222C, S73C/ Q219C and 
V78C/ K218C showed the most robust cross-linking upon BMOE exposure. These cross-
linking studies suggests that portions ofhelixl (159), helix 2 (S73) and the loop between helix 
2 and 3 (V78) ofthe PD are in close proximity to the N-terminal segment of the HD (K218, 
Q219 and S222) in the tertiary structure ofPax3. These results are compatible with a model in 
which the PD and HD are organized in an everted arrangement, with the N-terminal portion of 
the PD being in close proximity to the N-terminus of the HD. This arrangement may be 
important for the noted PDIHD cooperativity in DNA binding. 
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Introduction 
Pax3 is a member of the Pax family, a group of transcription factors that play critical 
roles during mammalian development (Bopp et al., 1986; Stuart et al., 1994; Balling et al., 
1988; Dahl et al., 1997; Glaser et al., 1992; Hill et al., 1991; Jordan et al., 1992; Macchia., 
1998; Mansouri et al., 1998; Sanyanusin et al., 1995; Sosa-Pineda et al., 1997; Torres et al., 
1995). Pax3 is expressed in a number of embryonic structures (somites, the neural tube, 
several neural crest cell derived lineages) and is essential for the normal process of 
myogenesis and neurogenesis (Bober et al., 1994; Goulding et al., 1991). A mutation in the 
mouse Pax3 gene causes severe neural tube defects (spina bifida, exencephaly) and absence 
oflimb musculature; likewise, in humans, mutations inPAX3 cause Waardenburg syndrome 
(WS), a condition associated with sensorineural deafness, cranio-facial abnormalities and 
pigmentary disturbances (Goulding et al., 1991; Auerbach et al., 1954; Baldwin et al., 1992; 
Baldwin et al., 1995; Beechey et al., 1986; Franz et al., 1989; Franz et al., 1990; Goulding et 
al., 1994). Pax3 appears to orchestrate the expression of a number of target genes during 
normal development, but aberrant P AX3 activity causes alveolar rhabdomyosarcoma (Barr et 
al., 1993; Galili et al., 1993). Structurally, Pax proteins are defined by the presence of a 
unique DNA binding domain called the PD. In addition, Pax3 and several other Pax proteins 
contain a second DNA binding domain, a paired-type HD (Stuart et al., 1994; Noll et aJ., 
1993). Other structural domains of Pax proteins include a conserved octapeptide (OP) in the 
segment linking the PD and HD and proline/serine/threonine-rich (PST) transactivation 
domain at the carboxyl terminus. 
High resolution three-dimensional structures (Xu et al., 1995; Xu et al., 1999) show 
that the PD is formed by N-terminal (PAl) and C-terminai (RED) subdomains, each 
consisting of a three helical foid that includes a helix-tum-helix (HTH) motif, with the C-
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terminal helix of each HTH making base-specific contacts in the major groove ofDNA (Xu et 
al., 1995; Xu et al., 1999). The linker joining the PAl and RED subdomains also makes base-
specific contacts in the minor groove of DNA. In addition to the HTH motif, the PAl 
subdomain harbors a p-turn structure at its amino terminus that also makes critical contacts in 
the minor groove ofDNA (Xu et al., 1995; Xu et al., 1999). The DNA sequences recognized 
by the PD can be bound by both subdomains (Class 1 sequences) or only by the PAI 
subdomain (Class II sequences) (Czerny et al., 1993; Epstein et al., 1994). The structure ofthe 
DNA-bound Prd paired-type HD shows 3 a helices, the last 2 forming a HTH motif (Kappen 
et al., 1993; Treisman et al., 1989; Wilson et al., 1993; Wilson et al., 1995). The C-terminal 
helix of the HTH makes base specific contacts in the major groove ofDNA and is responsible 
for DNA binding specificity. The N-terminal segment preceding the HTH motifmakes 
additional contacts in the minor groove ofDNA. A unique feature ofpt-HDs is their ability to 
dimerize on palindromic sequences of the type TAAT(N2_3)ATTA (Treisman et al., 1989; 
Wilson et al., 1993; Wilson et al., 1995). 
Although the PD and HD can bind to cognate DNA sequences when expressed 
individually, a large body of genetic and biochemical data indicate that the two domains are 
functionally interdependent in intact Pax3. For instance, the G42R mutation in the PD ofPax3 
from the Splotch-delayed (Spd) mouse mutant abrogates DNA binding by the PD but also 
impairs DNA binding by the HD. Interestingly, deleting helix 2 of the PAl subdomain in the 
context ofthe G42R mutation (Spd) restores DNA binding by the HD suggesting that this 
helix is invo\ved in cooperative interaction between the PD and HD ofPax3 (Underhill et al., 
1995). Studies in chimeric Pax3 proteins have shown that the PD can modulate both DNA 
binding specificity and dimerization potential ofheterologous HDs (Fortin et al., 1998). 
Conversely, studies ofthe HD mutation R53G found in a Waardenburg patient shows that it 
impairs DNA binding by both the HD and the PD (Fortin et al., 1997). Site-specific 
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modification of single cysteine Pax3 mutants with thiol reagents have shown that independent 
modification of position 82 in the PD and position 263 in the HD (V263C) abrogate DNA 
binding by both the PD and HD (Apuzzo et al., 2002). Finally, protease sensitivity studies in 
Pax3 mutants bearing engineered Factor Xa sites either in the linker separating the PAl and 
RED motif (position 100), or upstream the HD (position 216), revealed that DNA binding by 
either the PD or the HD causes a structural change in the other DNA binding domain (Apuzzo 
et al., 2004), providing a structural basis for the observed interdependence in DNA binding. 
Additional studies with single cysteine mutants independently introduced in the second a 
helix (a2, positions 59-80) and in the (3-hairpin (positions 40-41) at the amino terminus of the 
PD identified a number of positions (Q40, 159, V60, P69, S70, 172, S73, L76, V78, S79C) at 
which NEM modification abrogated DNA binding by the PD and HD (Apuzzo et al., 2006). 
Three dimensional modeling revealed that these residues are not randomly distributed, but 
rather that they c1uster in a hydrophobie pocket, representing a possible docking site for the 
HO during ONA binding by the intact prote in (Apuzzo et al., 2006). 
The objective ofthe present study was to characterize further the structural basis of the 
HOIPO functional interaction in Pax3, and possibly identify individual residues ofthe HD 
that may come in close proximity to the PD during DNA binding. Proximity relationships 
were investigated in Pax3 mutants bearing pairs of single Cysteines inserted at different 
positions of the amino terminus of the PD and of the HD respectively (double cysteine. 
mutants, DCMs), followed by cross-linking with the thiol-specific bi-functional reagent 
BMOE. For this, we created 21 Pax3 mutants bearing pairs of cysteine between positions 59, 
73, and 78 in the amino terminus of the PD on the one hand, and 7 positions (215-218, 219, 
222,225) in the amino terminus of the HD on the other hand. The ability ofBMOE to induce 
cross-Iinking of cys pairs in Pax3 mutants bound to different DNA targets recognized by 
either the PD (P30PT), the HD (P2) or both (PHO) was evaluated. These cross-linking studies 
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suggest that portions ofthe PD al (159), a2 (S73) and the loop joining a2 and a3 (V78) are in 
close proximity to the N-terminus of the RD (K218, Q219 and S222) in the tertiary structure 
ofPax3. 
Material and Methods 
Mutagenesis. The construction ofthe pMT2 expression plasmid containing the entire 
coding region ofwild type (WT) Pax3 cDNA has been described (Underhill et al., 1995; 
Apuzzo et al., 2002). Pax3 was modified by the in-frame addition of c-Myc and HA epitopes 
at the N and C-termini respectively, thereby generating the pMTI/Myc-Pax3-HA WT 
construct (Apuzzo et al., 2004). The construction and functional characterization of a Pax3 
mutant lacking cysteines (cys-Iess, CL) has been described (Apuzzo et al., 2002), and this CL 
Pax3 was similarly modified by insertion of epitopes to create pMTI/ Myc-Pax3-HA CL. The 
generation of the 3 PD (CLlI59C, CLlS73C, CLN78C) single cysteine mutants used in this 
study was previously described (Apuzzo et al., 2006). The 7 other single cysteine mutants 
have cysteines introduced in N-terminal arm and upstream Iinker of the RD (CLIL215C, 
CLlK216C, CLIR217C, CLIK218C, CLlQ219C, CLlS222C and CL1T225C) by PCR 
mutagenesis using the pMTI/ Myc-Pax3-RA CL as a template and with primers listed in 
Table 1. Pax3 contains a KpnI cassette defined by two endogenous KpnI restriction sites at 
positions 563 and 1500. Swapping of KpnI cassettes of Iinker/RD SCM constructs into the 3 
PD SCM constructs permitted the generation of the following 21 double cysteine mutants: 
159C1L215C, 1591K216C, 159C1R217C, 159C1K218C, I59C/Q219C, 159C/S222C, 
159C/T225C, S73C1L215C, S73C1K216C, S73C1R217C, S73C1K218C, S73C/Q219C, 
S73C/S222C, S73C1T225C, V78C1L215C, V78C1K216C, V78C1R217C, V78C1K218C, 
V78C/Q219C, V78C/S222C and V78C1T225C. Each mutation was verified by nucleotide 
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Table l.Oligonucleotides used for Pax3 mutagenesis 
Substitution 
SCM 
159C 
S73C 
V78C 
L215C 
K216C 
R217C 
K218C 
Q219C 
S222C 
T225C 
Mutagenic primer (5'-3') 
ATCCGCCACAAGTGTGTGGAGATGGCC 
CCGAGCGTCATTTGTCGCCAGCTTCGC 
CGCCAGCTTCGCTGTTCCCATGGATCC 
CCTGATTTACCGTGTAAGAGGAAGCAGCGCÇGATCGAGAACCACCTTC 
GATTTACCGCTGTGTAGGAAGCAGCGCAGGTCTAGAACCACCTTC 
GACTCTGAACCAGATÇTACCGCTGAAGTG TAAGCAGCGCAGGTCGCGAACCACCTTC 
CCGCTGAAGAGGTGTCAGCGCAGGTCGCGAACCACCTTC 
GATGAAGGATCCGATATTGACTCTGAACCTGATTTACCGCTGAAGAGGAAGTGTCGCAGGAGC 
CAGCGCAGGTGCÇGIACQACCTTCACG 
GAGCAGAACCTGCTTCACGGCAGAGCAGCTGGAGGAACTGGAGCGCGCGTTCGAGAG 
Nucleotide substitutions leading to amino acid changes are in bold and 
italicized and those that introduce silent restriction sites are underlined. 
sequencing, and accessibility of restriction sites for cloning was verified by endonuclease 
fragmentation. 
Expression and Detection of Pax3Mutants. The expression plasmids were used to 
transiently transfect COS-7 monkey cells. One million cells were plated in Dulbecco's 
modified Eagle medium containing 10% fetal bovine serum and were transfected by the 
calcium phosphate co-precipitation method using 15 Jlgofplasmid DNA doubly purified by 
ultracentrifugation on cesium chloride density gradients. Calcium-DNA precipitates were 
placed onto the cells for 5 h and then treated with HBS (0.14 M NaCl, 5 mM KCl, 0.75 mM 
Na2HP04, 6 mM dextrose, 25 mM HEPES, pH 7.05) containing 15% glycerol for 1 mi~. The 
cells were then washed and placed in complete Dulbecco's modified Eagle medium. Whole 
cell extracts were prepared 24 h following glycerol shock by sonication in a buffer containing 
20 mM HEPES (pH 7.6), 0.15 M NaCl, 0.5 mM DIT, 0.2 mM EDTA, 0.2 mM EGTA, and a 
mixture of protease inhibitors: aprotinin, pepstatin, and leupeptin used at 1 mg/ml and 
phenylmethysulfonyl fluoride used at 1 mM. These extracts were stored frozen at -70 oC until 
use. To assess Pax3 mutant protein expression and stability, aliquots of whole cell extracts 
were analyzed by electrophoresis on acrylamide-containing SDS gels (SDS-PAGE), followed 
by electrotransfer onto nitrocellulose membranes and immunoblotting. Immunodetection was 
performed with mouse monoclonal anti-HA antibody (BabCO, Berkeley, CA) at a dilution of 
1: 1 000 and visualized by enhanced chemiluminescence using a sheep anti-mouse horseradish 
peroxidase conjugated secondary antibody (Amersham Biosciences). Subsequently, the 
immunoblots were submerged in stripping buffer (100 mM 2-mercaptoethanool, 2% SDS, 
62.5 mM Tris-HCl, pH 6.7,30 min at 50 oC), and washed with TBST buffer(lO mM Tris-
HCl, pH 8, 150 mM NaCI, 0.1 % Tween 20, 20 oC) at room temperature. The membranes were 
then probed with mouse monoclonal anti-Myc antibody (BabCO) at a dilution of 1: 1000 and 
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visualized by enhanced chemiluminescence using a sheep anti-mouse horseradish peroxidase 
conjugated secondary antibody (Amersham Biosciences). 
Electrophoretic Mobility Shift Assays. Electrophoretic mobility shift assays (EMSA) 
were performed as previously described (Apuzzo et al., 2002). Each protein:DNA binding 
reaction was carried out using approximately 8 IJ.g of total cell extracts from transiently 
transfected COS-7 monkey cells and 1 Of mol (0.06IJ.Ci) ofradioactively labeled double 
stranded oligonucleotides corresponding to different Pax3 target sequences. The final 
concentration oflabeled oligonucleotide in the binding reaction is 0.5nM. Whole cell extracts 
were incubated with 32P-labeled probes in a volume of20 IJ.L containing 10 mM Tris-HCI (pH 
7.5),50 mM KCI, 1 mM DTT, 2 mM spermidine, 2 mg/ml BSA, and 10% glycerol. To reduce 
nonspecific binding, 1 j.lg ofpoly(dI-dC)poly(dI-dC) was included in binding studies with 
PD-specifie probes and composite probes with both PD and HD sites, while 2 j.lg ofheat-
inaetivated salmon sperm DNA was added to binding reactions involving HD specifie probes. 
Following a 30 min incubation at room temperature, samples were eleetrophoresed at 12V/cm 
in 6% acrylamide:bis-acrylamide (29:1) gels containing 0.25 or 0.5X TBE (IX TBE is 0.18 M 
Tris-HCl, 0.18 M borie acid, 4 mM EDTA, pH 8.3). Gels were dried under vacuum and 
exposed to Kodak BMS film with an intensifying screen. PD-specifie sequences P6CON (5')-
TGGAA TTCAGGAAAAA TTTTCACGCTTGAGTTCACAGCTCGAGTA-(3') (Epstein et 
al., 1994) and P30PT (5')-TGGTGGTCACGCCTCA TTGAATA TT A-(3 ') (Chalepakis et al., 
1995; Epstein et al., 1995), HD-specific sequence P2 (5')-
GATCCTGAGTCTAATTGATTACTGTACAGG-(3') (Wilson et al., 1993) and the 
composite PDIHD binding site PHO (5 ')-GATTTCTTCCAATTAGTCACGCTTGAGTG-(3') 
(Jun et al., 1996) were synthesized as complementary oligonucleotide pairs with recessed 3' 
ends for end labeling with [a}2p] dA TP (3000 Ci/mmol; NEN) using the Klenow fragment of 
DNA polymerase. The thiol-specific reagent N-ethylmaleimide (NEM, Pierce) was 
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prepared as a 32 mM stock in water. Bis-Maleimidoethane (BMOE), a sulfhydryl-to-
sulfhydryl cross-linking reagent (Molecular Probes) was prepared as a 32mM stock in 100% 
dimethyl sulfoxide. To assess the effect ofNEM or BMOE on DNA binding they were added 
as a 0.5 I..IL aliquot to a 4 ~L volume ofwhole cell extract (final concentration of3.55mM), 
followed by a 30 min incubation at room temperature prior to the addition ofthe e2p]-labeled 
probe and EMSA. Western blotting was carried out with whole cell extracts treated with non-
radiolabeled DNA prior to BMOE treatment to assess the extent of cross-linking in double 
cysteine mutants. When BMOE-treated whole cell extracts were destined for Western 
blotting, they were treated with NEM (3.55 mM, 30 minutes at 20 oC) prior to SDS-PAGE to 
block any remaining un-modified cysteines and to prevent non-specifie cross-Iinking. Films 
generated from Western blotting were used to perform densitometry studies to quantifY the 
amount of chemiluminescence using a Fuji LAS-I 000, as we have previously described 
(Apuzzo et al., 2002; Apuzzo et al., 2004). 
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Results 
Construction of Pax3 Mutants Bearing Single or Double Cysteine Insertions. 
A large body of biochemical and genetic data indicates that DNA binding by Pax3 
involves cooperative interactions between the PD and the HD. Indeed, point mutations (Fortin 
et al., 1997) or site-specifie modifications of single cysteines in either PD or HD abrogate 
DNA binding by both domains (Apuzzo et al., 2002), and DNA binding by either PD or HD 
causes a structural change in the other domain (Apuzzo et al., 2004). In addition, a number of 
studies have suggested that this functional cooperation may involve physical interactions 
between the two domains. The goal of the present study was to investigate proximity 
relationships between the PD and HD, including the identification of specifie residues 
mapping at the interface of such interactions. We targeted the amino terminal portions ofboth 
the PD and the HD as two sites that are most likely to physically interact in intact Pax3. This 
was based on the following published data. DNA binding studies with the Drosophila Prd 
protein using hybrid DNA sequences (PHO) optimized for combined PD and HO binding 
show that the two domains are everted (Jun et al., 1996). Additional modeling studies suggest 
that the N-terminus of the PAl subdomain is closely apposed to the N terminus of the HD 
when bound to the combined PHO site (lun et al., 1996), with helix 2 of the PAl domain in 
very close proximity of the N-terminal extension ofthe HD. A critical role ofthe PAl 
subdomain helix 2 in interaction with the HD is supported by functional studies showing that 
deletion ofhelix 2 in the context ofthe Spd mutant allele ofPax3 (G42R) restores DNA 
binding by the HD in the context ofthe mutant prote in (Fortin et al., 1998). Finally, studies in 
Pax3IPhox chimeras suggest that the C-terminal portion of the linker domain separating the 
PD and HD contributes to functional interactions between the 2 domains in DNA bindi.ng 
(Fortin et al., 1998). 
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Here, we investigated proximity relationships in the Pax3 protein by cross-linking. For 
this, we used a Pax3 mutant that is devoid of cysteine (Cys-Iess, CL) residues but that retains 
wild type DNA binding properties towards PD or HO target sequences (Apuzzo et al., 2002; 
Apuzzo et al., 2006). We created double cysteine mutants (DCM) bearing 1 cysteine in 
individual positions of each the PD and the HD; proximity of the 2 cysteines was assessed by 
the ability of a bi-functional, thiol-specific cross-linking agent (BMOE) to make a covalent 
adduct between the two targeted positions. The effect ofDNA binding by the PD and the HO 
on the formation of such adducts was also investigated. The implementation of this strategy 
requires that both inserted Cys residues be at exposed positions accessible to the sulfhydryl 
reagent. For this, we selected positions at which Cys insertion do not affect DNA binding, but 
yet confer N-ethyl maleimide (NEM) modification sensitivity ofDNA binding in the context 
of a single Cys mutant. Such single Cys mutants were then systematically reconstructed as 
DCM and functionally analyzed. 
Previous cysteine scanning mutagenesis identified a hydrophobie pocket in the N-
terminal segment of the PAl subdomain at which insertion of single Cys confer NEM 
sensitivity to DNA binding by the PD and HO in the intact protein (Apuzzo et al., 2006). In 
this proposed docking site for the HD, positions 159 (a helix 1), S73 (a helix 2) and V78 (a2-
a3 linker) of the PAl subdomain (Figure 1) were most sensitive to NEM treatment and were 
selected for potential PD candidates for the CUITent cross-linking studies. In the HD the N-
terminal arm (first 9 residues) was targeted for study. In preliminary experiments, substitution 
ofeach of the se 9 residues to cysteine in SCM showed that only 3 positions (Q219, S222, 
T225) could tolerate this replacement without loss ofDNA binding by the HD (data not 
shown). These together with 4 adjacent residues from the linker domain (L215, K216, R217, 
K218) were selected for potential HD candidates for cross-linking studies (Figure 1). 
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Figure 1 
Site-directed Mutagenesis of the Paired Domain of Pax3. The amino acid sequence for 
positions 34-278 ofPax-3 is shown, including a schematic representation of the N-terminal 
(PAl) and C-terminal (RED) subdomains of the PD, together with structural features based on 
the three-dimensional structure of the PD of the Pax6 prote in (~, ~-strand; 't, ~-tum; u, u-
helix) (Xu et al., 1999). Invariant residues amongst aIl known PDs are identified below the 
schematic representation. The type of predicted DNA contacts made by these residues (p, 
phosphate; m, minor groove; M, major groove) is shown. The positions and nature of the 
mutations introduced in Pax-3 to create the Cys-Iess (CL) mutant are indicated. Residues 
targeted when generating single cysteine mutants are indicated with filled arrowheads. The 
figure also includes a schematic representation of the Pax3 linker and homeodomain (HD), 
including the presence and position of predicted structural features, invariant amino acid 
residues, number and types ofDNA contacts (as for the PD). The position of the c-Myc and 
hemagglutinin (HA) epitope tags inserted in-frame at the amino and carboxyl termini ofPax3, 
respectively, is shown. 
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The following single cysteine mutants (SCM) were created in the PD (CLII59C, CLlS73C and 
CLN78C), and in the N-terminal part of the HD (CLIL215C, CLIK216C, CLIR217C, 
CL1K218C, CLlQ219C, CLlS222C and CLfT225C) using the Pax3 CL backbone as a 
template. In addition, double cysteine mutants (DCM) were created by combining each of the 
3 PD mutations with each of the 7 HD mutations in a group of 21 DCMs. 
Protein Expression and DNA Binding Properties of Pax3 Single and Double Cysteine 
Mutants. 
To facilitate detection ofwild type (WT), Cys-less (CL) and ail single (SCM) and 
double (DCM) eysteine mutants, cMyc and hemagglutinin (HA) epitope tags were inserted in-
frame at the N-terminus and C-terminus of ail constructs, respeetively. AlI constructs Were 
made using the pMT2 expression plasmid and were used to transiently transfect COS-7 
monkey eeUs. Immunoblotting ofwhole cell extracts with either anti-HA or anti-c-Myc 
monoclonal antibodies show that ail SCMs and DCMs can be expressed at similar levels in 
COS-7 eeUs (Figure 2). This indicates that none of the mutations had a major effect on prote in 
expression or stability in COS-7 cells. The effects of single and double cysteine substitutions 
on DNA binding properties ofthe PD and the HD ofPax3 were assessed in each mutant by 
eleetrophoretic mobility shift assays (EMSAs). The DNA binding activity of the PD was 
measured using the PD specific probes P30PT (Chalepakis et al., 1995; Epstein et al., 1.995) 
and P6CON (Epstein et al., 1994) which have been shown to contain binding determinants for 
both the PAl and RED subdomains of the PD. The DNA binding activity ofthe HD was 
determined using the P2 target sequence, which contains the T AA T(N2)-A TT A sequence 
previously shown to support cooperative dimerization ofPax3. Finally, ail mutants were 
assessed for DNA binding activity to the PD-HD composite site present in the PHO probe. Ail 
SCMs, and DCMs retained PD DNA binding activity for both the P30PT and P6CON probes 
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which was similar to that displayed by the WT or CL Pax3 protein (Figure 3). Most mutants 
retained DNA binding by the HD and showed dimerization on the P2 probe, with the possible 
exception ofSCM CL/L215C and the DCMs S73C/ R217C and V78C/ S222C that showed 
decreased binding to this target. However, ail mutants showed wild type binding activity for 
the composite probe PHO (Figure 3). These results indicate that most of the mutations either 
alone or in combination have no effect on DNA binding by Pax3, and none appear to alter the 
ability of the protein to bind a PDIHD composite site. 
Effeet of Thiol specifie reagents on DNA Binding by Single and Double Cysteine Mutants. 
Both N-ethyl maleimide (NEM) and bis-maleimidoethane (BMOE) can covalently 
modify and alkylate cysteine residues and were used for site-specific modification of SCMs 
and DCMs. BMOE contains two maleimide functional groups, as opposed to one with NEM, 
and thus can create covalent adducts (cross-links) between cysteines showing spatial 
proximity in an otherwise intact protein. The effect ofmono-functional NEM (Supplementary 
figure SI) and bi-functional BMOE (Figure 4) on DNA binding properties ofWT, CL and of 
single and double Cys mutants was evaluated by EMSA, using PD (P30PT), HO (P2) and 
combined PD-HD (PHO) target sequences. Whole cell extracts from COS-7 cells expressing, 
CL or SCMs or DCMs were incubated with either 3.55mM NEM or 3.55mM BMOE prior to 
testing DNA binding properties by EMSA. For control WT Pax3, treatment with either NEM 
or BMOE abrogates DNA binding by the PD and HD for both individual and combined target 
sequence. On the other hand, DNA binding by the Pax3-CL control protein to ail probes 
tested was completely insensitive to NEM and BMOE treatment (Supplementary Figure SI; 
Figure 4). 
The effect ofNEM (Supplementary Figure SI) or BMOE treatment (Figure 4) on the 
DNA binding properties of SCMs and DCMs was identical for each mutant, and only results 
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Figure 2 
Expression olPax3 Mutants in COS-7 Monlœy cel/s. Wildtype, Cys-less, SCMs and DCMs 
were cloned into pMT2 expression plasmid, and total cell extracts from transiently transfected 
COS-7 monkey cells were separated by SDS-PAGE (12% acrylamide) and transferred to 
nitrocellulose membranes. Immunodetection ofPax3 was done with mou se anti-c-Myc 
(MYC) and anti-HA (HA) monoclonal antibodies and a horseradish peroxidase-conjugated 
secondary antibody. The "mock" labeled lane refers to who le cell extracts from untransfected 
COS7 cells. 
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Figure 3 
Paired domain and homeodomain DNA binding properties of wild-type, Pax3CL, SCMs and 
DCMs. Electrophoretic mobility shift assays were used to measure the DNA binding 
properties ofPax3 (WT), Cys-less (CL), single (SCM) and double cysteine Pax3 mutants 
(DCMs) against paired domain (P30PT, P6CON), homeodomain (P2) and a paired 
domain/homeodomain composite site (PHO). Protein-DNA complexes were formed using 
total cell extracts from transiently transfected COS-7 cells, and were resolved on 6% 
acrylamide non-denaturing gels, as described in Materials and Methods. 
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Figure 4 
Effect of site-specifie Modification on DNA binding properties of Pax3 Mutants. Effects of 
bis-maleimidoethane (BMOE) treatment on the paired domain and homeodomain DNA 
binding properties ofwild type (WT), Cys-Iess (CL), single (SCM) and double (DCM) 
cysteine mutants. Whole cell extracts from COS7 monkey cells (mock) or from cells 
expressing different Pax3 mutants were incubated with 0 (-) or 3.55mM (+) BMOE prior to 
electrophoretic mobility shift assays. The DNA binding properties of the different Pax3 
proteins were tested against paired domain (P30PT, P6CON), homeodomain (P2) and a 
paired domainlhomeodomain composite site (PHO). 
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Supplementary Figure 1 
Effect of site-specific modification on DNA binding properties of Pax3 mutants. Effects ofN-
ethyl maleimide (NEM) treatment on the paired domain and homeodomain DNA binding 
properties ofwild type (WT), Cys-Iess (CL), single cysteine mutants and double cysteine 
mutants was determined. Whole cell extracts from COS7 monkey cells (mock) or from cells 
expressing different Pax3 proteins were incubated with 0 (-) or 3.55mM (+) NEM prior to 
electrophoretic mobility shift assays. The DNA binding properties of the PD were evaluated 
with target sites P30PT and P6CON, while the RD was tested using the P2 probe. The ability 
to bind the composite sequence PHO was also assessed. 
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obtained with BMOE will be reviewed. As we have previously reported for NEM (Apuzzo et 
al., 2006), alkylation of PD positions 59 (l59C), 73 (S73C), and 78 (V78C) by the BMOE 
reagent abrogated DNA binding by the PD and RD in the corresponding SCM (Figure 4). 
This formally verifies that sulfbydryl groups introduced at these positions are accessible to the 
bi-functional BMOE reagent. Modification of single cysteines inserted at either ofthe seven 
positions of the N-terminal portion ofthe RD was without consequences on DNA binding of 
corresponding SCMs to the P30PT probe. On the other hand, BMOE modification of the 
L215C, R217C, Q219C and S222C SCM mutants had sorne effect on DNA binding by the 
HO to the P2 probe. Nevertheless, BMOE treatment had no effect on binding to the PD-RD 
composite site in any of the 7 HD SCMs tested (Figure 4). 
As expected from the observed BMOE-sensitivity ofDNA binding by the single 
mutants I59C, S73C, and V78C, aIl DCMs showed BMOE sensitivity for aIl probes tested. 
OCMs V78CIL215C and V78CIK216C were notable exceptions: although both showed 
BMOE sensitive ONA binding to PD and PD-RD probes, they showed partial (V78CIL215C) 
or complete (V78CIK216C) insensitivity for binding to the P2 probe. 
Cross-Lin king Studies in Single and Double Cysteine Mutants. 
Proximity relationships between pairs of cysteines were studied by cross-linking in 
OCMs. In these experiments, WT, CL as weIl as aIl SCMs and DCMs were treated with 
BMOE and cross-linked species were detected by SDS-PAGE and immunoblotting with 
monoclonal anti-RA (Figure 5) or anti-cMyc antibody (data not shown). In these experiments, 
cross-linked Pax3 proteins are detected as higher molecular mass species of slower 
electrophoretic mobility on denaturing, detergent-containing (SDS) polyacrylamide gels (Loo 
et al., 2001). Exposure of WT Pax3 to BMOE followed by SDS-PAGE and immunoblotting 
results in the appearance of cross-linked Pax3 species of slower mobility that are absent from 
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Figure 5 
Detection and Quantification of Cross-linking Species of Pax3 mutants. Fifteen micrograms 
ofwhole cell extracts from COS-7 cells transfected with either wild type (WT), Cys-less 
(CL), or with the different single cysteine mutants (SCMs) (Panel A) or with double cysteine 
mutants (panel B) were incubated with 3.55mM BMOE and were analyzed by SOS-PAGE on 
12% acrylamide gels and by immunoblotting with anti-HA antibody. Cross-linked species are 
visible as higher molecular mass bands. (C) The immunoblots ofONA unbound, BMOE 
exposed double cysteine mutants probed with anti-HA antibody were scanned by 
densitometry and the % cross-linked protein was determined. (0) The immunoblots ofBMOE 
exposed wildtype Pax3 and selected OCMs probed with anti-HA antibody were scanned by 
densitometry and the % cross-Iinked prote in was determined with and without prior 
incubation of a PD specifie probe (P30PT), HO specifie probe (P2) and a composite POIHD 
probe (PHO). 
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the control untreated sample (Figure 5A). Such cross-links probably arise from the reaction of 
BMOE with 2 or more of the 7 endogenous cysteines present in the WT prote in. In agreement 
with this proposai, no such cross-links are detected when the CL mutant is similarly treated 
with BMOE. These results additionaIly show that under our experimental conditions, the 
BMOE reagent can induce the formation of cysteine-specific cross-links. Treatment of aIl 10 
SCMs with BMOE does not result in the formation of slow migrating cross-links. This 
absence of cross-links in BMOE-treated SCMs together with the demonstrated accessibility of 
at least single Cys insertions at positions 59, 73 and 78 of the PD (Figure 4) strongly suggest 
that BMOE does not induce the formation of intermolecular cross-links in these SCMs. 
Exposure of DCMs to BMOE resulted in the appearance of cross-links for sorne ofthe 
combinations tested (Figure 5B and 5C). This, together with the absence of such cross-links in 
aIl 10 similarly treated SCMs (Figure 5B and C) strongly suggest that these BMOE-induced 
cross-links in DCMs are specific for the individual cysteine pairs and occur in an intra-
molecular fashion. 
Studies in DCMs with a PD cysteine at position 59, indicated that this residue could 
react with aIl N-terminal HD positions with the exception ofK216C and Q219C, with the 
most robust cross-link formed between 159C and S222C (Figure 5B and 5C). To confirm that 
the detected cross-links were indeed intramolecular (as opposed to intermolecular) SCMs 
159C and S222C were mixed together, treated with BMOE and analyzed by SDS-PAGE and 
immunoblotting. No cross-links were observed under such conditions, confirming that the 
noted reactivity between 159C and S222C was indeed intramolecular (data not shown). A 
cysteine at position 73 of the PD (S73C) could react with 5 of the 7 N-terminal HD cysteine 
insertion, with the strongest reactivity detected for the Q219C. Finally, V78C cross-linked 
primarily with L215C and particularly K218C, but showed little if any reactivity with any of 
the other positions. 
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In summary, ofthe 7 cysteines inserted in the N-terminal position ofthe RD, only 
L215C and K218C form cross-linked species with all three targeted positions in the PD. AIso, 
only K216C fails to significantly cross-link with any ofthe PD cysteines tested. R217C 
appears to react only with PD position 59 (I59C) and 78 (V78C), while Q219C reacts only 
with position 73 (S73C). Finally, RD cysteines S222C and T225C both only cross-link PD 
cysteines 159C and S73C (Figure 5B and 5C). 
Effect of DNA Binding on BMOE-Induced Cross-Linking in Double Cysteine Mutants 
The effect of DNA binding by the PD and RD on proximity relationships in the Pax3 
prote in was further investigated by allowing DCMs to bind PD (P30PT), RD (P2) or 
combined PD-RD targets (PRO) prior to treatment with BMOE and resolution of cross-linked 
products by SDS-PAGE and immunoblotting (Figure 5D and Supplementary figure S2). For 
these studies, the am ou nt of cross-linked species following BMOE treatment ofWT and 
DCMs (in the absence ofDNA) was first quantified by densitometry analysis ofthe 
immunoblots and is expressed as a percentage ofthe total detectable protein on the blot. The 
effect ofDNA binding on the formation of cross-links in WT and DCMs was similarly 
quantified for each probe. We focused these studies on the 4 DCMs that show the strongest 
BMOE-induced cross-linking between cysteines inserted in the PD and RD, namely 
159C1R217C, 159C/S222C, S73C/Q219C, V78CIK218C (Figure 5D). Incubation of WT and 
DCM Pax3 variants with the combined PRO sequence considerably reduced the degree of 
cross-linking induced by BMOE. Because the effect was seen with all proteins, we suspect 
that it may reflect a change in overall accessibility of cysteine residues to the BMOE agent in 
the PRO bound form of the protein. On the other hand, binding to PD or RD-specific probes 
had both similar and distinct effects on BMOE-induced cross-linking in individual mutants. 
For example, in the 159C/S222C mutant, there was no effect ofbinding to P30PT or P2 
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probes on BMOE-induced cross-links, while in the S73C/Q219C and V78CIK218C DCMs, 
binding to both probes caused a reduction in cross-link formation. On the other hand, the 
I59CIR217C mutant had a distinct behavior, with significant inhibition of cross-linking when 
the PD engages in DNA binding and no effect when the protein binds DNA through the HO. 
These results demonstrate that DNA binding can induce local conformational changes in Pax3 
that can be detected by quantitative changes in BMOE-induced cross-linking between 
individual cysteine pairs of unique DCM variants. In this case, such alterations most likely 
reflect DNA-induced changes in the distance or orientation ofthe 2 cysteines, as opposed to 
overall change of accessibility to the BMOE reagent. Differences in BMOE cross-linking 
upon DNA-binding would suggest distinct conformations present in the bound and free 
protein, which differ further depending on the nature ofthe oligonucleotide bound. 
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Discussion 
We studied proximity relationships in the Pax3 protein by a cross-linking approach 
based on the use of a bi-functional suthydryl cross-linker (BMOE) in Pax3 mutants bearing 
pairs of engineered cysteines. For this, discrete portions of the PD and RD previously shown 
to play a key role in cooperative interactions ofthe 2 domains for DNA binding were selected 
for cysteine insertion. In this approach, and to ascertain that cysteine mutagenesis did not 
affect overall structure or function ofthe Pax3 protein, we purposely limited our study to 
positions at which replacement of the endogenous residue by cysteine was without 
consequences for DNA binding by the protein. Accessibility of individual Cys substitution to 
alkylating agents was not determined directly but was inferred from the ability ofNEM and 
BMOE to interfere with DNA binding by the targeted domain. In such an experimental 
scheme, BMOE-insensitive Cys mutations may retlect a) lack of effect of alkylation on DNA 
binding, or b) inaccessibility ofmutated position to BMOE. The ability ofBMOE to induce 
cross-links in a specific pair of double cysteine mutants was also used as evidence that the 2 
positions were accessible to reagent. 
The three positions in the PD targeted for Cys mutagenesis (159, S73, V78) ail showed 
BMOE sensitivity ofDNA binding by the PD and the HD, confirming the accessibility of 
these three positions. The solvent accessibility ofthese 3 residues is in agreement with 
previous NEM sensitivity studies (Apuzzo et al., 2006) and the noted capacity of cysteines at 
aU 3 positions to form cross-links with a sub-set of Cysteines introduced in the HD (Figure 5). 
On the other hand, none of the Cys mutations introduced in the N-terminal part of the HD 
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showed BMOE sensitivity for DNA binding, except for smaU effects on RD DNA binding 
se en in mutants R217C, Q219C, S222C, and L215C. Therefore, it is likely BMOE sensitivity 
ofDNA binding seen in aU DCMs is caused in large part by the BMOE reactivity of Cys at 
the PD positions in these double mutants. On the other hand, the ability of aU N-terminal HD 
Cys substitutions to form cross-links with one or several of the PD Cys insertions indicate that 
the HD cysteines were indeed accessible to the BMOE cross-linker. One exception is K216C, 
which failed to generate, upon BMOE exposure, robust cross-links with any of the 3 PD 
cysteines. In summary, DNA binding and cross-linking studies suggest that all PD and RD 
cysteines introduced in Pax3, with the possible exception ofK216C, were accessible to 
BMOE and therefore may be solvent-exposed. 
The BMOE-induced cross-links detected in WT Pax3 must arise from reaction of any 
two endogenous cysteines with the bi-functional cross-linker. The endogenous cysteines most 
likely to be BMOE-reactive are cysteines C70 in the PAl helix 2, C82 in the PAl helix 3 and 
C 143 in the RED subdomain in the loop joining helix 5 and 6 (Tell et al., 1998). Indeed, mass 
spectroscopy experiments as well as mutagenesis studies have shown that under oxidative 
conditions a disulfide bridge is formed between Cys70 and 82 as well as Cys 82 and Cys 143 
thereby abrogating DNA binding via the PD. Lack of cross-links in Pax3-CL is indicative of 
the specificity of the BMOE reagent for cysteines and the absence of cross-links in SCMs 
shows that any cross-links formed in DCMs are more likely the result of intramolecular 
cysteine cross-Iinking and not intermolecular cross-linking. In the DCMs analyzed, the most 
robust cross-links appeared to be formed between 159C and R217C, I59C and S222C, S73C 
and Q219C and between V78C and K218C. An obvious interpretation ofthese results is that 
these pairs of cysteines, and corresponding positions in the wild type prote in, are in closest 
proximity amongst all pairs tested. 
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The amount ofBMOE-induced protein cross-links in WT and mutants was estimated 
by densitometry and the effect of DNA binding by the PD and HD on the production of such 
cross-links was measured. Binding to the composite site sequence PHO caused a dramatic 
decrease in the overall amount ofBMOE-induced cross-linking in aIl proteins tested. One 
likely explanation ofthis observation is that DNA-binding to PHO increases the compactness 
and inflexibility of the protein and reduces accessibility of cysteines to BMOE, hence 
decreasing the number of cross-links formed. This interpretation is in agreement with circular 
dichroism spectroscopy studies with the PD ofPaxS and S showing that the PD adopts a more 
ordered structure with more helical content upon DNA exposure (Tell et al., 1995). AIso, X-
ray crystallography and NMR studies of HD proteins have revealed an increased order of the 
HTH motif, including the N-terminal arm and the recognition helix, of the DNA-bound form 
of Pbx (Sprules et al., 2003; Sprules et al., 2000; Jabet et al., 1999; Piper et al., 1999), 
Antennapedia (Qian et al., 1994), engrailed (Clarke et al., 1994) and Oct-l (Cox et al., 1995) 
proteins. Also, previous studies have shown that engineered protease sites in the PAl 
subdomain and N-terminal arm of the HD in Pax3 become less accessible to c1eavage upon 
DNA exposure indicating a more compact conformation of the DNA-bound form (Apuzzo et 
al., 2004). 
It has been established that for BMOE to induce cross-links, the two sulfhydryl side 
chains must be located 6-1O.sA apart (average SA) (Green et al., 2001). Therefore, one can 
conc1ude that the maximum intermolecular distances separating the above-mentioned pairs of 
residues must be within the range of 6-1 o.sA. The pairs of cysteines showing the most robust 
BMOE-induced cross-links (lS9CIR217C, IS9C/S222C, S73C/Q219C and V7SCIK21SC) 
have been positioned on the three-dimensional structure of the DNA bound models of the PD 
from Pax6 (Xu et al., 1999) and of the HD from Drosophila Prd (Wilson et al., 1995) 
proteins. From this modeling, an everted positioning of the PD and HD for DNA binding to a 
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combined site appears required to account for cross-linking results obtained here in DCMs 
variants. Such a model is in agreement with that previously proposed by Jun and Desplan for 
combined PD and HD binding ofthe Drosophila Prd protein to chimeric target sequences 
(Jun et al., 1 996).The model suggests that the N-terminus of the PAl domain is closely 
apposed to the N-terminus of the HD when bound to the combined site. Their model suggests 
that PD and HD bind opposite sides ofDNA helix with the N-terminal arm of the HD in very 
close proximity to helix 2 of the PAl subdomain. The PD/HD physical interaction suggested 
in this model may be responsible for the interdependence of DNA binding observed in Pax3 
and may also be used to explain the interaction of the PD ofPax3 with the N-terminal arm of 
Msx 1 (Bendall et al., 1999). The model shown in Figure 6 indicates only the most extensive 
cross-linking patterns observed. The most N-terminal 159 residue is closest to the most.C-
terminal residue of the N-terminal arm ofthe HD, S222C. While the most C-terminal PD 
residue V78 forms the most cross-links with and is closest to the most N-terminal HD residue 
K218. This is in accordance with the head-to-head orientation of the PD and HD when they 
are physically interacting. The cross-linking studies and the model proposed in figure 6 
support our previous study that implicates the role ofresidues 159, S73 and V78 in forming a 
hydrophobie pocket in the PD whereby the HD can dock and participate in the physical 
interaction responsible for DNA binding functional interdependence (Apuzzo et al., 2006). 
These cross-Iinking studies provide, for the first time, an indication that residues in the 
PAl subdomain are in close proximity to residues in the N-terminal portion ofthe HD. The 
PD and HD residues in close proximity may be the residues responsible for the PDIHD 
physical interaction that accounts for the functional interdependence of the two DNA binding 
domains. 
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Figure 6 
Structure of the DNA-bound Paired domain and Homeodomain. (A) The PAl and RED 
subdomains of the PD are indicated on a 3D DNA-bound structure. The 3 a-he lices and the p-
hairpin ofthe PAl subdomain are indicated. (B) and (E) show different close-up views of the 
PAl subdomain. (C) View of the ONA-facing PAl subdomain with the DNA structure 
removed for c1arity. (0) The ONA-bound 3D HO structure. The PD and HD are shown as a 
green ribbon drawn through the a carbon backbone. The ONA strands are shown as blue (A) 
or gray (B-E) ribbons through the sugar-phosphate backbone, and bases are shown as 
protrusions from the ribbons. The positions targeted for cysteine substitution and at which 
BMOE modification causes cross-linking are indicated in red. Turquoise lines that link 
cysteine substitutions in figure C and 0 indicate cysteines that undergo extensive cross-links 
when paired in a OCM and exposed to BMOE. (F) A model of the "head-to-head" orientation 
of the PD and HO that facilitates POIHO physical interaction responsible for the 
interdependence of ONA binding. The black line indicates the linker that joins the PD and 
HO. 
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Supplementary Figure 2 
Detection ofCross-linking Species of Pax3 mutants that were incubated with DNA prior to 
BMGE exposure. Fifteen micrograms ofwhole celI extracts from COS-7 monkey celIs 
transfected with either wild type (W1), Cys-Iess (CL), a SCM or a DCM Pax3 mutant were 
incubated with 3.55mM BMOE and were analyzed by SDS-PAGE on 12% acrylamide gels 
and by immunoblotting with anti-HA antibody. Cross-linked species are visible as higher 
molecular mass bands. Cross-linked species were detected in mutants exposed to BMOE with 
or without prior incubation of a PD specific probe (P30PT), HD specific probe (P2) and a 
composite PDIHD probe (PHO). The proteins were incubated with no DNA and no BMOE 
(a), no DNA and BMOE (b) or BMOE with DNA probes specific for the PD (P30PT) (d), the 
HD (P2) (e) or both the PD and HD (PHO) (c). 
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Chapter 6 
Conclusion and Summary 
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Like many other Pax proteins, Pax3 contains conserved DNA binding domains yet can play 
different regulatory roles and functions in several diverse processes in embyrogenesis. How 
can Pax3 be involved in such different diverse processes as neurogenesis, myogenesis and 
melanogenesis and yet carry only a few conserved DNA binding motifs? Why doesn 't . 
redundancy in recognition result in redundancy in function? One possible solution to this 
question is that Pax proteins use mechanisms involving intra and intermolecular interactions 
between DNA binding domains to attain functional diversity. The studies described in the 
previous chapters shed light on what we consider an important set of interactions in Pax3 that 
mediate DNA recognition: intramolecular PDIHD cooperative interactions. This chapter is to 
position the work ofthis thesis in the context ofwhat is already known about Pax protein 
biochemistry and to assess its impact on Pax research. 
Intramolecular Mechanisms for creating Functional Diversity in Pax Proteins 
Functional diversity is typical of multiple modular domain transcription factors such 
as Zinc finger domain proteins. Zinc finger domains interact with DNA as weIl as one another 
(intramolecular interaction) to modify specifie DNA recognition (Rebar and Pabo., 1994). 
Like multiple modular domains in Zinc finger transcription factors, proteins with multiple 
helix-tum-helix (HTH) motifs may interact intramolecularly and in different combinat ions to 
permit binding to DNA with different modes thereby allowing for the recognition of a series 
of different DNA sequences and generating different specificities. 
Many Pax proteins contain two DNA binding domains (PD and HD) and consequently 
hold three distinct DNA binding HTH motifs. Pax proteins are able to recognize different 
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types ofbinding sites with the use of different combinations oftheir HTH motifs. To reinforce 
this point, what follows are a series ofDNA binding modes that Pax proteins and related 
proteins have been shown to adopt when they bind DNA. Pax3 recognizes the c1ass 1 DNA 
sequence P30PT with the use ofboth the PAl and RED subdomains (Vogan et al., 1997). 
Similarly, Pax6 is able to bind the P6CON class 1 probe with both subdomains in the PD as 
weil (Epstein et al., 1994). Pax3 and other Pax related proteins are also able to bind class II 
DNA sequences, which requires only the use of the PAl subdomain (Epstein et al., 1994; 
Czerny et al., 1993). Alternatively spliced isoforms of Pax6 and Pax8 introduce insertions into 
the PAl subdomain rendering the subdomain nonfunctional (Epstein et al., 1994; Kozmik et 
al., 1997). These isoforms are able to bind a different set of DNA sequences solely through 
the use of the RED subdomain (Epstein et al., 1994; Kozmik et al., 1997). It has been shown 
that the Pax Drosophila homo log Prd interacts with the PHO DNA probe with the cooperative 
use of the PAl subdomain and the HD (Jun and Desplan., 1996). Along with other Pax and 
Pax related proteins, Pax3 can bind to HD specific DNA sites as a monomer (on the P1I2 
probe) (Apuzzo et al., 2002) or dimer (on the P2 probe) (Apuzzo et al., 2002). The most 
recently discovered DNA binding mode that may also be used by Pax proteins requires the 
interaction of the RED subdomain and the HD on DNA. This mode is the major mode of 
DNA binding used by the product of the Drosophila eye gone gene (eyg) known as the Lune 
Pax-like protein which lacks a PAl subdomain (Jun and Desplan., 1998). AIso, recent studies 
with Pax6 have shown that basic residues in the N-terminal arm and recognition helix <;>fthe 
paired-type HD form an interaction surface. This surface can associate with acidic side chains 
of residues in helices 1 and 2 ofthe RED subdomain in the presence and absence of DNA 
(Bruun et al., 2005). 
Therefore, each HTH motif ofPax3, and other related proteins, can bind DNA alone or 
may associate with another motif as a strategy to generate different specificities. The mode 
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that we chose to study extensively involves cooperative interactions between the PAl and HD 
RTR motifs. We believe these interactions exists in Pax3 when the protein is in the DNA 
unbound state as weIl as PD DNA bound (P30PT and P6CON probes), RD DNA (P1I2 and 
P2 probes) bound and PD and RD DNA bound (pRO probe) states. 
Intermolecular Mechanisms for creating Functional Diversity in Pax Proteins 
Another innovative solution implemented by Pax proteins to remedy the requirement 
of generating functional diversity using only conserved DNA binding domains is throu~h 
interactions with other proteins on DNA. Pax3 and related proteins can participate in 
intermolecular interactions with other DNA binding proteins and this may lead to modulation 
ofDNA specificity of Pax proteins. Many proteins are known or suspected to bind Pax 
proteins and most were mentioned in the previous chapters. Of particular interest are the 
cooperative complexes that Pax5 can form with members of the Ets family of transcription 
factors. One extensively studied example of the se complexes is formed between Pax5 and c-
Ets-l on the promoter of the mb-l gene (Fitzsimmons et al., 1996; Wheat et al., 1999; 
Hagman et al., 2000). A Pax5 recognition site lies adjacent to a sub-optimal Ets binding site in 
the promoter of mb-l. Pax5 is able to bind the promoter on its own but Ets proteins associate 
with the sub-optimal recognition site only when they may form a complex with Pax5 to form 
a ternary complex. Both the Pax5 and Ets DNA binding sites are required on DNA. The 
formation ofthis ternary complex is required for optimal expression of the mb-l gene 
(Fitzsimmons et al., 1996). Pax5/Ets ternary complex formation on the composite site of mb-l 
requires portions of the p-hairpin and helix 2 of the PAl subdomain ofPax5 (Wheat et al., 
1999; Garvie et al., 2001). This study and others suggests that these structures in the PD of 
Pax proteins (p-hairpin and helix 2) can participate in protein-protein intra and intermolecular 
interaction that permit modulation ofDNA specificities. 
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Studies ofPax3 and Msxl proteins, on the activity of the MyoD promoter, is yet 
another example ofhow Pax proteins can use intermolecular interactions as a means to 
generate functional diversity. Pax3 can bind the MyoD promoter with the PD to induce MyoD 
expression. Yet, when complexed with the Msxl prote in, Pax3 no longer retains the same 
affinity for the MyoD promoter and reduced MyoD expression results (Bendall et al., 1999). 
ln vitro assays indicate that the N-terminal arm of the HD ofMsxl is the element involved in 
intermolecular interactions with the PD ofPax3 and modulation ofPax3 DNA binding 
activity (Bendall et al., 1999). 
These as weIl as many other studies of Pax proteins indicate that prote in: protein 
interactions that modulate Pax DNA affinity and specificity may involve the prote in segments 
in or close to the ~-hairpin and helix 2 of the PAl subdomain as weIl as the N-terminal arm of 
a HO. Studies show that these segments are required for cooperative binding ofthe PD and 
HO. The importance of the PDIHD cooperative mode ofDNA binding is accentuated by the 
observation that the rescue of the Prd Drosophila mutant only requires a functional PAl 
domain and HD in the same molecule (Bertuccioli et al., 1999). These observations suggest 
that, at least for the Prd prote in, PD and HD containing proteins may principally act by 
binding through a combination of its PAl domain and HD. We propose that the cooperative 
interactions between the PAl subdomain of the PD and the HD of Pax3 are strong enough to 
influence PD DNA binding activity, HD DNA binding activity as well as binding to 
composite PDIHD DNA sequences. The methods we chose to explore the se PDIHD 
cooperative interactions are cysteine scanning mutagenesis and protease sensitivity assays, 
which are weIl known for their use in protein structure: function studies. 
Waardenburg syndrome Missense Mutations and the Cooperative Intramolecular 
interactions between Pax3 PD and HD 
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To date over fifty Waardenburg syndrome mutations have been reported. A subset of 
the se mutations are truncating mutations that are located almost anywhere in the P AX3 gene 
and result in the deletion of either the proline-serine-threonine rich transactivation domain, the 
HD and the rest of the residues C-terminal to the HD, or the whole gene (Baldwin et al., 
1995). Missense mutations cluster to the PAl subdomain and the HD (Baldwin et al., 1995) 
thereby suggesting a critical role of these prote in segments for PAX3 function. These 
missense mutations cause very similar phenotypes to the truncating mutations previously 
described and are therefore considered loss of function PAX3 mutant alleles. Therefore, 
studying the biochemistry ofthese mutants can give information about the possible roles these 
protein segments play during DNA binding and transcriptional activity by Pax3. 
Most Waardenburg syndrome PAX3 mutant aIle les that encode for proteins with 
missense mutations in the PD change the amino acid identity at conserved positions (Fortin et 
al., 1997; Xu et al., 1995). The determination of the structural basis ofthese missense 
mutations is possible with the use ofthe PDIDNA co-crystal structures of Pax6 and Prd (Xu et 
al., 1999; Xu et al., 1995). More than a third of the residues affected in Waardenburg 
syndrome missense mutations map to invariant areas of the PD that are involved in DNA 
contacts. Only a few of these missense mutations affect base-specific DNA contacts, most 
actually map to residues that non-specifically associate with the sugar-phosphate backbone. 
Mutations at conserved positions required for specific and non-specific DNA contacts 
compromise DNA binding by the PAX3 protein (Fortin et al., 1997). According to the 
published Pax6 and Prd crystal structures, sorne Waardenburg syndrome deleterious missense 
mutations map to positions that don't associate with DNA. These missense mutations inc1ude 
159F, V60M and S73L and were previously only thought to disrupt the stability of the helices 
in which they lie (Fortin et al., 1997; Xu et al., 1999; Xu et al., 1995). Invariant residues 159, 
and V60 are in the C-terminal half ofhelix 1 and the weil conserved residue S73 lies in the 
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middle of the second helix of the PAl subdomain. The study described in the chapters 4 and 5 
suggests that these three residues play critical roles in the formation of a hydrophobie binding 
pocket in the PD that is formed from segments of the PAl subdomain helix 1 and 2, the loop 
between helix 2 and 3 as weIl as portions ofthe ~-tum in the ~-hairpin (Apuzzo et al., 2006). 
When the se three positions are substituted with cysteine and alkylated by a thiol specifie 
reagent, such as N-ethylmaleimide, both PD and RD DNA binding activities are abrogated 
(Apuzzo et al., 2006). In light ofthis new discovery, we propose that the Waardenburg 
syndrome missense mutations I59F, V60M and S73L, which replace the naturally occurring 
side chain with longer and larger side chain s, results in the inability for the PD to properly 
form the HO hydrophobie binding pocket. Consequently, the PDIRD physical interaction and 
functional cooperativity is severely affected. This PDIRD physical interaction is required for 
proper ONA binding of both the PD and RD and therefore its disruption results in impaired 
PO and HO DNA binding activities (Apuzzo et al., 2006). Another possible interpretation is 
that the modification ofthese three positions, via cysteine substitution and site-specifie 
modification or substitution by bulkier amino acids, does not disrupt the formation of the RD 
binding hydrophobie pocket but prevents the docking of the RD onto the PD via steric 
hindrance. In either case, PD/HD physical interaction and cooperativity required by both the 
PO and HO to bind DNA is disrupted. 
In conclusion, the structural and functional characterization of naturally occurring 
Pax3 mutations have played a role towards our improved understanding of the mechanisms 
that account for the interdependence ofDNA binding of the PD and RD ofPax3. 
Hence, ongoing and future investigations of other Pax3 biochemical activities or functions 
cou Id greatly benefit from the molecular characterization of naturally occurring mutati~ns. 
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The Possible Role of the Type 1 p-turn, a2 and the a2 - a3loop of the PAl subdomain in 
the Cooperative Intramolecular interactions between Pax3 PD and HD 
Several findings are consistent with a model in which the PD and RD of Pax3 
physically interact. For example, the functional interaction between the PD and RD is 
uncoupled by deletion of the second helix of the PAl subdomain (Fortin et al., 1998). The Prd 
PD ONA bound structure reveals that this helix is solvent exposed and a therefore a good 
candidate for being involved in protein: prote in interaction (Xu et al., 1995). Also, modeling 
of the HO and PD crystal structures on the cooperatively bound composite PDIHD PRO site 
shows that helix 2 is in a favorable location to physically interact with the N-terminus of the 
HD (Jun and Oesplan, 1996). However, until now, a direct physical interaction between the 
HO and PD remained to be supported by experimental data. 
The Prd ONA bound PD structure reveals that PAl subdomain residues that form the 
Type 1 ~-tum in the ~-hairpin (positions 39 to 43 in Pax3) interacts with residues in 0.2 
(position 73 in Pax3) and the 0.2 - 0.3 loop (positions 77 and 78 in Pax3) (Xu et al., 1995). The 
schematic representation of the PD in figure 1 in chapter 4 reveals that the identity of the 
Type 1 ~-tum ('Cl) residues in Pax3 are N39, Q40, L41, 042 and 043 and that the 0.2 position 
73 residue is a serine and the 0.2 - 0.3 loop residues at position 77 and 78 are arginine and 
valine, respectively. Figure 4 in chapter one clearly shows how the Type 1 ~-tum and portions 
of 0.2 and the 0.2 - 0.3 loop come in close proximity when the PD is ONA bound. We propose 
that the Type 1 ~-tum, 0.2 and 0.2 - 0.3 loop together form a protein-protein interaction surface 
that is required for intra and intermolecular interactions. More specifically, we postulate that 
these secondary structures come together in the tertiary structure of the PO of Pax3 to form 
the hydrophobie HO binding pocket described in chapter 4. AIso, we believe that disruption 
of the ability of these segments in the PO to associate will prevent the formation of this HO 
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binding pocket and consequently preventing PD:HD physical interaction and cooperativity. 
This would result in the weakening of both PD and HD mediated DNA binding activities, in 
accordance with the interdependent model ofDNA binding of the PD and HD ofPax3. 
The mutation G42R in the Type 1 p-turn in the PD ofPax3, found in the splotch-
delayed mou se mutant (Spd), not only shows reduced DNA binding to PD oligos, but also 
causes reduced DNA binding to HD-specific oligos (Underhill et al., 1995; Fortin et al., 
1998). We believe that the replacement ofthe glycine side chain with the larger and bulkier 
side chain of arginine must sterically prevent the Type 1 p-turn structure from interacting with 
residues in a2 and the a2 - a3 loop. Consequently, the hydrophobic HD binding pocket in the 
PD cannot form properly thereby preventing the PD:HD physical interaction required for 
PD/HD interdependence of DNA binding. The inability of the Pax3 HD and PD to interact in 
the G42R mutant compromises both PD and HD mediated DNA binding activities. Deletion 
ofhelix 2 of the PAl subdomain in the context of the Spd mutation (Pax3 G42M(2) has been 
shown to restore HD DNA binding (Underhill et al., 1995). We propose that for Pax3, and 
other Pax proteins with a PD and a HD covalently linked within the same polypeptide chain, 
the HD requires a2 to pack tightly against the Type 1 p-turn for the PD to modulate HD DNA 
binding activity. Removal of a2 in the Pax3 G42R mutant uncouples PD dependent HD DNA 
binding activity. 
Another indication that the Type 1 p-turn structure may play an important role in 
PD:HD physical interaction and functional interdependence is the fact that each and every 
residue in this structure is completely conserved among ail members of the Pax family as weil 
as among Pax homologs from various other organisms. Another important fact to note is that 
the multiple sequence alignment ofthe PD from various genes also indicate that the a2 S73 
and the a2 - a3 loop V78 residues are also invariant (see figure 1 of chapter 4). 
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The involvement of the PAl subdomain Type 1 ~-tum and a2 structures in forming a 
protein: protein interaction surface is further supported by structural studies of the temary 
complex formed between the PD ofPax5 and the Ets domains ofEts-1 on DNA. Pax5 Type 1 
~-tum residues Q22 (Pax3 equivalent residue is Q40) and L23 (Pax3 equivalent residue L41), 
as weIl as residue R56 in helix 2 (Pax3 equivalent residue is R74), make contacts with the Ets 
domain when both proteins are DNA bound (Garvie et al., 2001). The Pax5-Ets structure has 
led us to believe that NEM modification ofNEM sensitive single cysteine mutants Q40C and 
L41 C may mimic the splotch G42R deleterious effect on PD:RD physical interaction. More 
specifically, we postulate that the side chain replacement ofany of the residues in the Type 1 
p-turn with larger or bulkier groups sterically prevents the approach of helix 2 and 
consequently the formation ofthe protein: protein interaction site (the hydrophobie HD 
binding pocket) in the PAl subdomain. 
The helix 2 R74C Pax3 single cysteine mutant did not show PD or RD NEM 
sensitivity, but residues flanking this position (pst: 72, 73 and 76, 78, 79) were found to be 
NEM sensitive (Apuzzo., 2006). Alkylations at the se flanking positions with bulky groups 
must sterically prevent the approach of the Type 1 ~-turn and, like alkylation of residues in the 
Type 1 ~-turn, lead to prevention of the prote in: protein interaction surface on the PAl 
subdomain. 
Therefore, the analysis ofPD:HD interactions in SCM Pax3 mutants, structural studies 
of the interface ofPax5-Ets proteins interaction in the DNA-bound state, the Prd PD DNA 
bound structure, and the characterization of the Pax3 G42R splotch mutant protein strongly 
suggest that the Type 1 ~-turn, a2 and the a2 - a3 loop ofthe PD interact to form a proÙ~in: 
protein interaction surface. We believe that this surface is used by the PD to associate with the 
HD (intramolecular interaction) as weIl as with other transcriptions factors like members of 
the Ets family of proteins (intermolecular interaction) . 
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As mentioned previously, the Prd PD DNA bound structure indicates that the Pax3 
residues that associate with the Type 1 ~-turn structure include S73 in a2 and V78 in the a2 -
a3 loop (Xu et al., 1995). The role ofthese residues in Type 1 ~-turn interaction and formation 
of the hydrophobie RD binding pocket is further accentuated by the fact that the alkylation by 
NEM of single cysteine mutants S73C and V78C abrogate both PD and HD mediated DNA 
binding activities (Apuzzo et al., 2006). We propose that when unmodified with thiol specifie 
reagents single cysteine mutants S73C and V78C are still able to form similar van der Waals 
to residues in the Type 1 ~-turn. We believe this since the side chains of valine and cysteine 
are known to both be able to participate in hydrophobie coupling interactions with the side 
chains of other hydrophobie amino acids. Also, serine and cysteine share many physico-
chemical properties and therefore it is likely that they participate in the very similar van der 
Waal forces with the side chains of other amino acids. We believe that alkylation of single 
cysteine mutants S73C and V78C with larger and bulkier groups not only destroy interactions 
with the Type 1 p-turn but also sterically prevent the approach of the p-turn to both a2 and the 
a2 - a3 loop. This would prevent HD binding pocket formation and PD:HD physical and 
functional interaction. One way to further confirm the association of S73 and V78 with 
residues in Type 1 p-turn is to create double cysteine mutants with a cysteine in a2 or in the a2 
- a3 loop and another in the Type 1 p-turn and attempt to cross-link them with a bifunctional 
thiol specific reagent. 
Cooperative Intramolecular interactions between the PD and HD: a comparison of the 
Pax6 and Pax3 models. 
Functional interaction between the PD and HD has also been demonstrated with the 
Pax6 protein (Sheng et al., 1997; Singh et al., 2000), but the mechanism employed seems to 
be different from that ofPax3. For Pax3 the RED subdomain seems to play no significant role 
in the PDIHD physical and functional interaction, this is not the case with Pax6. A naturally 
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occurring missense mutation in the RED subdomain, I87F, abrogates both PD and RD DNA 
binding activities, while no missense mutation in the RED subdomain ofPax3 has ever been 
detected that abrogates HO DNA binding activity. This indicates that a functional (and 
possibly physical) association may exist between the HO and the RED subdomain of the PD 
(Singh et al., 2000). 
Also, the naturally occurring missense mutation in the PAl subdomain R26G a~d the 
alternative splicing isofonn Pax6(5a), with a 14 amino acid insertion in the PAl subdomain, 
both abrogate the DNA binding activity of the PAl subdomain (Singh et al., 2000). PAl 
subdomain inactivating Waardenburg missense mutations in Pax3 abrogate HO DNA binding 
activity yet the Pax6 PAl subdomain inactivation mutations indicated above actually increase 
the DNA binding activity of the HO at both the monomer and dimer level on both P2 and P3 
probes (Singh et al., 2000). Two non-exclusive interpretations may account for these 
observations. PAl subdomain inactivation may uncover a positive interaction between the 
RED subdomain and the HO or the PAl subdomain inactivation relieves any PAI-mediated 
negative regulation of the HO DNA binding activity. One must not rule out the possibility that 
the other potential explanation for these differences between Pax3 and Pax6 may involve 
sequences outside of the paired domain and homeodomain. 
Recent findings confirm that the HO and the RED subdomain ofPax6 physically 
interact and that this interaction is independent ofDNA (Bruun et al., 2005). No such 
interaction has been observed in Pax3 to date. MutagenesislEMSA studies, GST pull-down 
assays, Yeast two-hybrid assays and FRET were used to study and generate a model of the 
REDIHD physical interaction in Pax6 (Bruun et al., 2005). This physical interaction is 
mediated by basic residues in the recognition helix (a3) in the HO and acidic residues in the 
RED subdomain. More specifically, the basic residues that lie entirely on one side of the HO 
recognition helix (R57 and R58) and basic residues in the RD N-tenninal ann (R3 and R5) 
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fonn salt bridges with acidic residues in the RED subdomain helix 4 (El12) and helix 5 (E120 
and E128) (Bruun et al., 2005). Most helix 3 RD residues that interact with the RED 
subdomain are conserved and are not involved in making DNA contacts, therefore they 
presumably solely serve the purpose of mediating RED subdomain interaction which 
presumably serves to increase the DNA specificity ofthe Pax6 protein. Contrastingly, the RD 
N-tenninal ann residues R3 and R5 that make contacts with the RED subdomain in the Pax6 
prote in both make base specifie contacts in the minor groove ofDNA (Wilson et al., 1995). 
There are two striking similarities and two differences between the models of the 
PAIIHD physical interaction ofPax3 with that of the REDIHD interaction ofPax6. In both 
models the solvent exposed portions of the two most N-tenninal he lices of the three helical 
folds of the PAl and RED subdomains act as surfaces in the PD that interact with the HO. 
Also, in both models the N-tenninal ann ofthe HO plays a role in the physical interaction. 
The Pax6 HD N-tenninal ann residue R3 is equivalent to residue R221 in Pax3 and the R5 
residue is equivalent to residue R223 in Pax3. The involvement ofR221 and R223 in the 
PAIIHD interaction model ofPax3 was not assessed by the cysteine scanning 
mutagenesis/site-modification approach used in sorne of our studies. This was unfortunately 
the case since the single cysteine mutants R221 C and R223C do not retain PD and HO DNA 
binding activities comparable to the wild type protein and therefore any site-specifie 
modification with thiol specifie reagents would have been uninfonnative (Apuzzo et al., 
unpublished, Chapter 5). This is most probably due to the loss of the base specifie contacts 
these arginines make with the minor groove ofDNA when they are substituted to cysteines. 
An important observation to note though is that when flanking residues Q219, S222 and T225 
were substituted to cysteine they were able to fonn cross-links with cysteines placed in or 
near helix 2 ofthe PAl subdomain (Apuzzo et al., unpublished, Chapter 5). The most obvious 
difference between the two models is that one involves the use of the HO recognition helix 
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while the other does not. AIso, the REOIHO contacts in Pax6 consists primarily of salt bridges 
while those in the PAIIHO model ofPax3 is assumed to be mostly mediated by hydrophobic 
coupling (Bruun et at., 2005; Apuzzo et al., 2006). 
AIso, the differences in the mechanisms that Pax3 and Pax6 use to mediate PD and 
HO interactions is further suggested by the observation that Pax6 cooperatively dimerizes on 
P3 sequences (Singh et al., 2000) regardless of the presence or absence of the PD, yet the 
Pax3 HO dimerizes on P2 only when present with the Pax3 PD in the same polypeptide but in 
vitro generated Pax3 HO dimerizes on P3 only (Fortin et al., 1998). 
In conclusion, although Pax proteins have highly homologous DNA binding domains 
that can bind similar ONA sites, the se proteins can obtain higher levels of specificity and 
functional diversity via the distinctive use or combination ofONA binding modules. As of 
now, functional interactions have been shown for each possible type ofpairing ofthese 
modules, suggesting that their combined use has more than additive consequences on the 
ONA binding specificity and activity of Pax proteins. Characterization ofthese interactions is 
therefore essential for the proper understanding of specific target gene recognition and 
regulation by individual Pax proteins. FinaIly, it is essential to realize that the identification of 
functional associations between each of the PD subdomains and the RD emphasizes the 
necessity to use full-Iength proteins in functional studies to obtain results applicable to the 
native prote in. While the effects of intramolecular interactions on Pax prote in DNA binding 
function are starting to be characterized, the biological relevance, regulation and mechanism 
of action is stilliargely unexplored. However, prior to these higher levels of functional 
complexity being assessed, the biochemical mechanisms responsible for these interactions 
must be the primary focus for ongoing research. Surely, the complete understanding of the 
mechanisms that underlie these functional interactions shall promote the elucidation of the 
roles Pax genes play in molecular pathways as weIl as in embryogenesis. 
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